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CHAPTER 1  
Aim and Outline of the Thesis 
 
1.1 Introduction 
 
 What is a virus? 
Viruses are infectious agents that replicate only within living cells. Viruses are not 
“alive” because they need resources from a host cell to be able to reproduce. They can 
be classified depending on the host that they infect, which can be plants, bacteria (the 
virus is then called a bacteriophage), fungi, or animals. After entering the host cells, 
viruses are able to control the transcription/translation machinery of the cell, which is 
then employed for the production of the virus constituents that assemble again to form 
new virus particles (Figure 1.1).  
 
Figure 1.1 A diagrammatic representation of the six phases common to all virus 
multiplication cycles. 
 
A complete virus particle, also known as virion, consist of two or three parts: the 
genetic material, which can be DNA or RNA; the protein capsid that protects this 
genetic material by assembling around it; and some viruses (termed “enveloped” 
viruses) additionally have a lipidic membrane that surrounds the protein capsid (Figure 
1.2). Although we used to relate viruses with disease-causing agents, since the 
pioneering work of Douglas and Young,[1] viruses are seen as new biomaterials that are 
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attractive for different fields, such as materials science and nanotechnology. Most of 
such studies involve viruses without enveloping membranes. 
 
a) 
 
b) 
 
c) 
 
d) 
 
 
   
 
Figure 1.2 Image reconstructions or models, and cryo–electron micrographs of 
different kind of viruses. a) The rod-shaped virus tobacco mosaic virus. b) An example 
of an adenovirus. c) The human immunodeficiency virus (HIV). d) The T4 
bacteriophage. 
 
 Bionanotechnology 
At the interfaces of chemistry, biology, physics, medicine, engineering, and materials 
science exists the field of bionanoscience. This multidisciplinary field involves the 
exploitation of biomaterials, devices, or methodologies on the nanoscale. There is an 
increasing interest in the production of nanosized materials for different fields and 
applications. For example, in the field of electronics there are strong commercial 
incentives to produce increasingly miniaturized microelectronic devices and in the field 
of medicine there is great interest in the development of new nanoscale systems for drug 
delivery and imaging.  
There are two different approaches for the production of these nanosystems: top-down 
and bottom-up. The top-down approach involves the construction of increasingly 
smaller structures down to the nanoscale often by using masks and light or the 
embedding of nano-features into macroscopic materials, whereas the bottom-up 
approach uses the techniques of component assembly and/or supramolecular chemistry 
to make small molecules bigger. A number of groups are rapidly expanding the 
repertoire of biological scaffolds for nanochemistry and several investigations have 
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recognized virus capsids as versatile building blocks for the production of nanomaterials 
by using the bottom-up approach.  
In recent years an increasing number of reviews have appeared describing new 
approaches that use biological molecules as building blocks in nanoscience. Many 
detailed reviews[2-7] of using protein cages and viruses in nanotechnology have followed 
the initial ones from Niemeyer,[8] Douglas and Young,[9] Belcher et al.,[10] and Vriezema 
et al.[11] An essential feature of all viruses is their ability to infect a host cell, replicate, 
package the nucleic acid, and exit the cell. During this process, viruses have evolved to 
move through a broad range of chemical environments. The intrinsic properties obtained 
during evolution, together with the properties that can nowadays be realized with the 
help of modern genetic and/or chemical techniques, can impart new functions to protein 
cage architectures, which is important for the development of multifunctional 
nanoplatforms.[4,7]  
 
 Why viruses? 
Viruses are interesting particles for use in nanotechnology for the following 
reasons:[6,12] 
(i) Viruses can be found in a variety of distinct shapes (most commonly icosahedrons, 
spheres, tubes, and helices) and their sizes range from approximately 10 to 500 nm for 
icosahedral structures to more than a micron for filamentous or rod-shaped viruses 
(Figure 1.3). 
 
 
Figure 1.3 Cryo–electron micrograph and image reconstructions of a library of viral 
capsids, including both icosahedral and helical viruses. a) Paramecium bursaria 
Chlorella virus type 1, 170 nm in diameter. b) Murine polyoma virus, 51 nm in 
diameter. c) Cowpea mosaic virus, 31 nm in diameter. d) Cowpea chlorotic mottle 
virus, 28 nm in diameter. e) Satellite tobacco necrosis virus, 18 nm in diameter. f) A 
small section of the rod-shaped tobacco mosaic virus, which measures 18 by 300 nm. 
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g) Sulfolobus turreted icosahedral virus isolated from a boiling, acid environment in 
Yellowstone National Park.[4] 
 
(ii) Viral capsids are typically assembled from repeating protein subunits to form highly 
symmetrical and polyvalent architectures. The coat proteins of several viruses have been 
characterized at atomic resolution,[13,14] providing essential knowledge required for 
making modifications to the capsid to impart new synthetic functions by design. 
(iii) Unlike other materials in this size range, viruses are often perfectly monodisperse in 
size and composition. Only in rare cases does a particular virus exist in more than one 
size or shape. On the other hand, species such as colloids, dendrimers, and polymers of 
comparable dimensions (200–800 Å in diameter), which are made in the laboratory, are 
all polymorphous.  
(iv) Viruses offer three different interfaces that can be exploited: the exterior, the 
interior, and the interface between the protein subunits (see next section).  
(v) The protein subunits that comprise the building blocks of the virus structures can be 
modified both chemically and genetically to introduce designed functionality to 
different surfaces of the cage. It should be noted, however, that these changes can affect 
the assembly of the particle; therefore, it is important to leave those regions of the 
protein surface that are responsible for the intermolecular interactions, which guide and 
stabilize assembly, undisturbed. 
(vi) Many viruses can be obtained in large quantities. They can be isolated from their 
natural host cell masses in a few hours and substantial yields (often in the range of 0.1–
1% by weight). 
(vii) Viruses are more stable toward variations in pH, temperature, and solvent than 
standard proteins, thereby providing a wider range of conditions for their isolation, 
storage, and use. This stability can be in some cases enhanced by chemical or genetic 
modification of the viral capsid.  
 
 Virus exploitable surfaces 
As mentioned at point (iv) above, when we look at viruses as molecular containers there 
are three important interfaces that can be exploited (Figure 1.4).[4] All viruses encode, 
package, and transport viral nucleic acid. However, many will assemble in vitro (either 
naturally or through genetic manipulation) into noninfectious containers, called capsids 
or virus-like particles (VLPs), devoid of genetic material. These protein capsids have an 
inner cavity accessible to small molecules and impermeable to big ones, which allows 
one to use the interior space of viral capsids as nanotemplates and nanoreactors.  
Furthermore, the viral container interacts with its environment through its external 
surface which can be genetically or chemically modified in order to obtain specific 
interactions with biological or nonbiological surfaces. The exterior surface of many 
Aim and Outline of the Thesis 
 
 13
viruses has emerged as a robust platform for chemical and genetic modification, 
allowing multivalent ligand display.  
The subunit interface in the viral architecture is crucial for assembly and provides a tool 
for the manipulation of the cage architecture and stability. Many viral capsids exhibit 
pleomorphism, which is the ability to assemble into a range of different architectures, 
either naturally or through genetic and chemical manipulation. In this way it is possible 
to have control over the kind of assembly and the stability of the structure.[3,4] 
 
 
Figure 1.4 Scheme of the three important interfaces available for chemical and genetic 
manipulation in an assembled viral protein cage architecture.[4] The interior surface, 
the exterior surface, and the interface between the subunits have all been used for the 
construction of multivalent or multifunctional viral-cage-based materials. 
 
 
1.2 Aim and outline of this thesis 
 
The research described in this thesis aims to construct a virus nanoreactor by the 
encapsulation of enzymes within the cowpea chlorotic mottle virus (CCMV) protein 
capsid. In the Nolte group there has been much interest in the construction of 
supramolecular assemblies using both synthetic and biological building blocks. Many of 
these assemblies were prepared starting from catalytically active building blocks, the 
goal being to mimic the efficiency of enzymes, mainly based on molecular recognition 
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processes.[11] Furthermore, these assemblies were also designed to resemble the 
constrained environment of a cell, in which multienzymatic processes occur with high 
efficiencies. Enzyme assemblies obtained through the synthesis of giant amphiphiles[15-
17] or the formation of enzyme-encapsulating polymersomes[18,19] are examples of 
supramolecular assemblies designed for this purpose (Figure 1.5).  
 
 
 
 
Figure 1.5 Top: Nanoreactors based on polymersomes of polystyrene–
polyisocyanopeptide with pendant thiophenes (PS-PIAT), encapsulating CAL B lipase 
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enzymes. a) Structural formula and schematic representation of PS-PIAT. b) Scanning 
electron micrograph of PS-PIAT polymersomes. c) Schematic representation of the 
nanoreactor.[18] Bottom: Vesicles formed in water by a horseradish peroxidase (HRP)–
polystyrene biohybrid amphiphile. d) Structural formula of the modified heme cofactor. 
e) Computer-generated model of the HRP–polystyrene biohybrid. f) Transmission 
electron micrograph of the formed polymersomes (scale bars represent 200 nm). 
 
The studies reported in this thesis describe the first fundamental steps in the 
construction of a nanoreactor by encapsulating enzymes in the viral protein capsid. We 
have chosen CCMV for this goal because of its remarkable assembly properties. This 
thesis not only describes the investigations, in which CCMV is used as a platform for 
nanotechnology, but also reports in detail the procedures to purify the virus and basic 
studies of its properties, which are needed to carry out such investigations.  
Chapter 2 of this thesis is a literature survey discussing a selection of the work that has 
been carried out with viruses in the field of nanotechnology and materials science. 
Studies with the protein cage ferritin, similar protein cages, and the tobacco and cowpea 
mosaic viruses are described. Since the number of studies reported in the literature 
regarding this topic is rather large, only three of the most used particles are described in 
detail to exemplify the approaches that are being followed with different kinds of 
protein cages and viruses. The last section of the chapter focuses on the virus used in 
this thesis, namely CCMV.  
In order to be able to work with CCMV it was first necessary to obtain the virus in 
sufficient quantities and to establish the optimal purification. In Chapter 3 a detailed 
protocol for the purification of CCMV is described, following the procedure of 
Verduin,[20,21] based on the first reports from Bancroft et al.[22] Once purified the self-
assembly properties of the virus were investigated to find the optimum conditions to 
exploit the virus as a nanoreactor. Chapter 4 describes how, based on established 
methods, the RNA could be removed from the virus and how the different forms of 
assembly of the isolated coat protein were characterized. The chapter aims to guide the 
reader through the different techniques that are available for the characterization of the 
CCMV assemblies, which is thought to be useful for the proper understanding and 
evaluation of the studies described in subsequent chapters. 
Chapter 5 reports on investigations that provide additional information about the 
CCMV assembly properties in solution and about the structure of the viral capsid when 
it is used as a host for the inclusion of an ionic organic polymer. Small-angle neutron 
scattering (SANS), performed at the ISIS facility in the UK, and dynamic light 
scattering (DLS) are the two non-destructive techniques used for this study.  
After the assembly properties of the virus and the capsid structure had been defined, 
attention was focused on studies in which CCMV was used as a host for proteins. The 
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encapsulation of three different model proteins, namely myoglobin, dronpa, and 
streptavidin, is described in Chapter 6. The results show that the CCMV capsid indeed 
is a suitable system for the encapsulation of proteins. Chapter 7 is a follow-up of 
Chapter 6. In this chapter the encapsulation of an enzyme, that is HRP, in the CCMV 
capsid is described. After encapsulation, single-molecule fluorescence spectroscopy 
experiments were performed to study the catalytic activity of the enzyme at the single-
capsid level. 
As outlined in Section 1.1, the outer surfaces of viruses are ideal platforms for chemical 
modifications. Chapter 8 reports on studies in which the outer surface of CCMV is 
modified with polyethylene glycol (PEG) tails. By combining the PEG-functionalized 
viral coat protein with the assembly properties of a polystyrene sulfonate polymer 
described by Sikkema et al.,[23] the controlled integration of two different synthetic 
polymers into a viral capsid was obtained for the first time.  
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CHAPTER 2  
Protein Cages as Multifunctional Nanoplatforms 
 
2.1 Introduction 
  
This chapter is a short literature survey of the research carried out over the last two 
decades in which viruses have served as building blocks in nanoscience and 
nanotechnology. In recent years an increasing number of reviews have appeared in this 
topic[1-10]  and the current interest stems from the fact that viruses display a high degree 
of organization, are often easy to modify, and occur in well-defined self-assembly 
motifs.[11]  
Research on what may be called ‘chemical virology’ has expanded enormously over the 
last 10 years, with an increasing number of publications in different fields, such as 
medicine, materials science, and nanotechnology. This chapter does not review all work 
reported about viruses, instead only a few examples that are relevant for this thesis to 
demonstrate the vast potential virus particles offer as platforms in nanotechnology are 
chosen. The use of viruses as building blocks was inspired by protein cages, such as 
ferritin. The first section of this chapter is therefore focused on the protein cages Dps 
(DNA-binding protein from starved cells) ferritin, horse spleen ferritin, small heat shock 
protein, and lumazine synthase (Figure 2.1). In the next section relevant studies on 
tobacco mosaic virus (TMV) and cowpea mosaic virus (CPMV) are highlighted. These 
two viruses have a very different shape (rod-shaped vs. icosahedral, Figure 2.1) and are 
much used in bio-nanotechnology research nowadays. The last section gives a detailed 
overview of CCMV because it is the virus that we have used for the studies presented in 
this thesis (Figure 2.1). It is important to note that throughout this chapter the terms 
“protein cage”, “capsid”, and “virus-like particle” (VLP) are often used 
interchangeably; they refer to the protein shell derived from the dissociated protein 
subunits or virus.  
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Dps ferritin 
9 nm 
 
Horse spleen Ferritin 
12 nm 
 
Small heat shock protein (sHsp) 
12 nm 
 
 
Lumazine synthase 
15 nm 
 
 
Cowpea chlorotic mottle 
virus (CCMV) 
28 nm 
 
Cowpea mosaic virus (CPMV) 
30 nm 
 
Tobacco mosaic virus (TMV) 
300 nm × 18 nm 
Figure 2.1 Protein cages and viruses mentioned in this chapter, ordered by average 
diameter. The images are colored to distinguish the symmetry-related subunits and are 
taken from the VIPER database (http://viperdb.scripps.edu)[12,13] and the Protein Data 
Bank (www.rcsb.org/pdb/). 
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2.2 Protein Cages 
 
Nature has developed a variety of proteins that function as carriers or storage devices 
for metal ions and minerals. The iron storage protein ferritin is probably the most 
intensively studied and best understood example. In this protein the mineral is 
sequestered within one single compartiment, which has a shell of well-defined size and 
form. Since the early 1990s the use of ferritin and other storage proteins as nanometer-
sized reaction vessels has been explored.[7] The use of protein cages in nanotechnology 
has been reviewed in several recent publications.[2,14,15]  
  
 Ferritin 
Ferritins are found throughout the animal, plant, and microbial kingdoms.[16] They 
consist of a central core of hydrated iron(III) oxide encapsulated within a multi-subunit 
protein shell. Ferritins are robust proteins that can withstand high temperatures (85 °C) 
and high pH (8.5−9) for an appreciable period of time without significant disruption of 
their quaternary structure. Iron-free ferritin molecules (apoferritin) are composed of 24 
polypeptide subunits that assemble into a hollow sphere of approximately 500 KDa. The 
outer diameter of the protein is 12 nm, while the inner diameter is 8 nm (Figure 2.1). 
The ferritin protein shell has several functions: it acquires iron(II), catalyzes its 
oxidation, and induces mineralization within the cavity. Up to 4500 iron atoms can be 
housed within the protein cavity. Such a high iron-to-protein ratio is made possible by 
sequestering the iron as a compact mineral, which has a structure similar to that of the 
mineral ferrihydrite (5Fe2O3·9H2O). Hydrophilic and hydrophobic channels are 
incorporated into the shell, and as a result, iron atoms can be removed from the cage by 
reductive dissolution. In vitro reconstitution of iron(III) oxide cores can be readily 
achieved by room-temperature incubation of intact empty protein (apoferritin) with FeII 
solutions at moderate pH.[17]  
In 1991, Mann and co-workers began to explore the use of ferritin as a nanometer-sized 
bioreactor for producing monodisperse metal particles from metal ions other than the 
natural hydrated iron(III) oxide.[17] They showed, for the first time, that supramolecular 
protein cages have the potential to act as constrained reaction environments in the 
synthesis of inorganic materials of nanometer dimensions. Horse spleen apoferritin 
(HSFn) was used as a nanocontainer to generate iron sulfide particles, manganese oxide, 
and uranyl oxohydroxide crystals.[17-19] In Figure 2.2 the three different approaches 
followed by Mann and co-workers are schematically depicted. For example, incubation 
of the empty protein cages with MnCl2 at pH 9 resulted in specific manganese ion 
uptake, oxidation, and precipitation. Depending on the original concentrations of protein 
and MnII, discrete manganese oxide cores up to 7 nm in diameter were formed, as 
shown by transmission electron microscopy (TEM) and electron dispersive X-ray 
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analysis (EDXA) spectroscopy. Other inorganic nanoparticles have been synthesized 
within apoferritin by using similar biomimetic strategies. Thus, iron sulfide,[20] 
manganese oxide, manganese oxyhydroxide,[21,22] cobalt oxide,[23] cobalt 
oxyhydroxide,[24] chromium hydroxide, nickel hydroxide,[25] indium oxide,[26] cadmium 
sulfide,[27] cadmium selenide,[28] and zinc selenide[29] have been prepared within the 
nanosized cavity of horse spleen ferritin. Oxyhydroxide nanoparticles of high-oxidation-
state transition metals (Eu and Ti) have also been synthesized in the iron storage protein 
ferritin by using a new synthetic approach consisting of photoinduced mineralization.[30] 
 
Figure 2.2 Schematic representation of the use of ferritin in the synthesis of nanophase 
materials. a) Iron sulfide formation by in situ reaction of native iron oxide cores. 
b) Manganese oxide reconstitution by redox-driven reactions within apoferritin. 
c) Uranyl oxyhydroxide deposition by ion binding and hydrolytic polymerization.[18] 
 
Other work consisted of synthesizing the ferromagnetic nanocrystals of magnetite 
(Fe2O4),[31,32] and magnetite/maghemite (Fe3O4/γ-Fe2O3),[33] within the ferritin cavity to 
construct a magnetic protein, “magnetoferritin”; this could be performed under 
conditions of elevated temperatures and pH. As a result of the restricted space within 
the nanoreactors, crystalline inorganic particles with diameters of approximately 
6−7 nm were formed, as determined by TEM. The magnetite/maghemite particles were 
generated by trimethylamino-N-oxide oxidation of apoferritin, which was loaded with 
various amounts of iron(II) ions. The temperature-dependent magnetic properties of 
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magnetoferritins with different iron loadings were investigated. Recently, the 
preparation of mixed Co/Fe oxide materials in the inner cavity of ferritin was reported. 
A two- to fourfold increase in the ferromagnetic blocking temperature, with respect to 
undoped magnetoferritin, was observed by controlled addition of Co to the reaction 
mixture.[34] 
A new approach in the use of ferritin was introduced by Douglas et al., who studied the 
protein-constrained iron oxide core of ferritin as a catalyst for photoreduction 
reactions.[35] They demonstrated that the iron oxide nanoparticle encapsulated within the 
protein cage of ferritin could act as a semiconductor photocatalyst for the reduction of 
CrVI to CrIII. Furthermore, the same system was shown to be capable of photoreducing 
CuII to form a colloidal dispersion of Cu0 with a fairly narrow size distribution.[36] 
Examination of the photolysis products by TEM revealed electron-dense spheroid 
particles. It was found that the molar ratio of CuII/ferritin was the major factor in 
determining the particle size. A similar approach was followed by Ueno and co-workers 
when they constructed a size-selective hydrogenation biocatalyst.[37] They encapsulated 
a Pd nanocluster in the apoferritin cavity by in situ chemical reduction of PdII ions. 
Subsequently, the catalytic hydrogenation of olefins by the Pd−apoferritin hybrid was 
evaluated in aqueous media. It was shown that the catalytic system discriminates with 
respect to size of the substrates through the threefold channels that cross the protein 
cage (Figure 2.3). Similarly, Ag nanoparticles were synthesized by combining the 
protein-cage encapsulation approach and selective nucleation by specific phage-display 
peptides.[38] Furthermore, the formation of a ferritin encapsulating up to ten Gd 
complexes resulted in a complex that exhibited high relaxivity of water protons with 
potential applications in magnetic resonance imaging (MRI).[39] A recombinant human 
ferritin (rHFn)–iron oxide nanocomposite has also been investigated as an MRI contrast 
agent for the imaging of macrophages that play an important role in inflammatory 
diseases.[40]  
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Figure 2.3 Top: Scheme showing the preparation of Pd–apoferritin. Bottom: TEM 
images of the Pd–apoferritin: a) an ice-embedded unstained sample (inset: 
magnification 4×), b) a sample negatively stained with uranyl acetate. Scale bars 
represent 50 nm.[37] 
 
Modification of the outer surface of ferritin has been investigated by Mann and co-
workers.[33,41] Alkylated derivatives of ferritin were prepared by carbodiimide-activated 
coupling of long-chain primary amines to carboxylic acid residues on the protein 
surface. As a consequence of this surface modification, the proteins become soluble in 
several organic solvents as intact, nonaggregated biomolecules. The long-term goal of 
this approach is to exploit alkylated ferritins as nanoreactors for condensation reactions 
involving metal alkoxides and related organometallic compounds, which is only 
possible in nonaqueous systems. Another surface modification involved the preparation 
of biotinylated ferritin.[42] In this case, the outer protein surface was derivatized with 
approximately 70 biotinylated ligands, which were available to interact with 
streptavidin to form a cross-linked network of biomacromolecules. Such ferritin-based 
arrays could have important applications in magnetic storage and nanoelectronic 
devices. In another example, titanium-binding peptides were introduced to the N-
terminus of the ferritin subunit, so that the resultant modified ferritin displayed specific 
affinity for titanium metals. The N-terminal extension was genetically engineered so 
that it was uniquely present on the exterior surface of the ferritin cage.[43,44] Following a 
similar approach, a tumor-binding peptide was genetically introduced onto the exterior 
surface of a magnetite-containing ferritin as an N-terminal fusion.[45] The complex 
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bound to melanoma cells in vitro due to the specific interaction of the peptide. These 
results demonstrate the capability of a genetically modified protein-cage architecture to 
serve as a multifunctional nanoscale container for simultaneous iron oxide loading and 
cell-specific targeting. 
 Dps ferritin 
Dps ferritin is a protein-cage member from the ferritin family. The Dps ferritin from the 
bacterium Listeria inocua prevents oxidative damage of DNA by accumulating iron 
atoms within the central cavity to produce an iron oxide core similar to that of 
ferritins.[46,47] This protein cage was also utilized as a size- and shape-constrained 
reaction environment, as previously described for ferritin. Dps ferritin differs from other 
known ferritins in that the protein shell is assembled from 12 instead of 24 identical 
subunits; it can accumulate only 500 iron atoms within its 5 nm diameter central cavity 
(Figure 2.1).[48] Ferrimagnetic iron oxide,[49] cobalt oxide,[50] cadmium sulfide,[51] and 
platinum[52] nanoparticles were synthesized within the Dps protein cage. The formation 
of these particles has been recently monitored for the first time by using mass 
spectrometry.[52,53] The combination of electrospray ionization (ESI) and time-of-flight 
(TOF) mass analysis makes it possible to measure the mass of intact noncovalently 
associated macromolecular complexes without disturbing the structures, as well as the 
masses of individual protein components.[54] This has allowed one to precisely follow 
the transition from metal binding to nucleation and subsequently to nanocluster 
formation within a protein cage at the molecular level. Moreover, Dps protein cages 
have been synthesized with a hydrophobic interior surface to enhance the formation of 
metal nanoparticles.[55]  
 
 Other protein cages 
The investigations on ferritin as a size- and shape-constrained reaction vessel have 
paved the way for other groups to use different biomolecular systems for the same 
purpose leading to the development of a general class of self-assembled bioinorganic 
hybrid materials with designed functionality and biocompatibility. Aside from ferritin, 
the following proteins have been used as bionanoreactors.  
 Lumazine synthase 
Lumazine synthase is a hollow icosahedral bacterial enzyme with a molecular weight of 
1 MDa, which is formed by the self-assembly of 60 subunits (Figure 2.1).[56] The self-
assembled structure of this protein is very similar to the structures of the protein cages 
described above. Following the same concept as published for the protein ferritin, 
lumazine synthase was shown to be a suitable mineralization template for the 
fabrication of nanocrystalline iron oxide.[57] 
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 The small heat shock protein 
The small heat shock protein (sHsp) cage from Methanococcus jannaschii consists of 24 
subunits that self-assemble into a cage with octahedral symmetry (Figure 2.1).[58,59] The 
main difference between sHsp and ferritin are the large pores (3 nm in diameter) that the 
former compound presents on its surface, which allow easy access from the interior to 
the exterior environments of the cage.[60] The protein has an exterior diameter of 12 nm, 
is stable in the pH range 5−11, and can withstand temperatures up to 70 °C. The 
possibility to functionalize this template with organic and inorganic groups was first 
studied by Douglas and co-workers.[61] Thiol groups, which were engineered by genetic 
manipulation of the protein, and endogenous amine groups on both the exterior and the 
interior surfaces were used for the attachment of different molecules and the templation 
of reactions. By analogy to ferritin, sHsp was studied for its ability to act as a size-
constrained reaction environment for mineralization.[61,62] A novel route for nanoparticle 
synthesis with an engineered crystal phase was developed by genetically engineering 
peptide sequences (specific for particular inorganic materials) in the sHsp inner 
cavity.[63,64] This allowed for the selective design of the properties of the material and 
helped nanoparticle synthesis to be performed under milder conditions. 
The thiol groups engineered in the sHsp cage were also used for the chemical 
attachment of an organic drug molecule, namely doxorubicin, a chemotherapeutic 
agent.[65] The drug could be released under acidic conditions, such as those found in an 
endosome. The outer surface of sHsp has been decorated, by chemical and genetic 
manipulation, with fluorescent probes and cell-specific targeting antibodies and 
peptides, highlighting the potential of this cage as a (targeted) imaging agent and drug-
delivery vehicle.[61,65,66] 
Recently, the first example of the synthesis of a cross-linked, branched polymer network 
inside a protein cage has been reported (Figure 2.4).[67] This polymer material was 
generated by the sequential coupling of multifunctional monomers using click 
chemistry. The encapsulated polymer was found to dramatically increase the stability of 
the protein cage.  
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Figure 2.4 Rationale and strategy for the fabrication of a hybrid protein dendritic cage 
structure. a) Scheme of a protein cage filled with a branched polymer; addressable sites 
on the polymer can be used to load drugs, imaging agents, or functional components of 
a solid-state device. b) A cutaway view of the HspG41C genetic construct. c) Scheme for 
sequential synthesis of the dendritic structure. Generation numbers are indicated at the 
bottom.[67] 
 
 
2.3 Viruses 
 
Virus particles typically consist of several hundred to thousands of protein molecules, 
which self-assemble to form a hollow scaffold that holds the viral nucleic acid. In the 
past decade there has been growing interest in the use of virus particles as templates for 
nanosized materials. Viral capsids (the self-assembled protein-cage structures) offer 
robust and monodisperse structures and exist in a large variety of sizes and shapes. 
Moreover, the protein surface can be used as a synthetic platform for chemical 
modification. Because certain types of viruses can be obtained in large quantities and 
manipulated at the genetic level, they afford a unique opportunity for chemists to 
expand the repertoire of natural starting materials for synthetic and catalytic 
applications. 
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 Rod-shaped virus: tobacco mosaic virus (TMV) 
The tobacco mosaic virus (TMV) is the most comprehensively understood system of 
biological self-assembly to date.[68,69] TMV is a stable virion that can withstand 
temperatures of up to 90 °C, pH values as low as 2 and as high as 10, and solvents such 
as ethanol and DMSO. TMV can be obtained in large quantities from infected plants 
and it is made up of 2130 identical protein building blocks (of molecular weight 
17.5 kDa) arranged in a helical motif around the viral RNA to form a hollow tube 
300 × 18 nm in size with a central channel that has a diameter of 4 nm (Figure 2.1).[6,7]  
The TMV assembly process results in a template that has an inherent asymmetry and 
chirality, which is distinct from that of the spherical viral capsids. This allows for 
chemical and genetic modifications at one end or the other of the helical rod. TMV can 
form three different kind of assemblies, depending on the solution conditions, as 
depicted in Figure 2.5.[70] Furthermore, mutations in which aspartic acid or glutamic 
acid are transformed into asparagine or glutamine, respectively, showed that assembly 
of the virion is possible without RNA.[71] 
 
 
Figure 2.5 The three possible assembly forms of the TMV coat protein. 1) The 4S/A-
protein dimers and trimers, 2) the 20S disks and short helices, and 3) the extended 
helical rod.[70]  
 Template mineralization of TMV: formation of nanotubes and nanowires 
The internal and external surfaces of the TMV protein capsid consist of repeat patterns 
of charged amino acid residues, such as glutamate, aspartate, arginine, and lysine. These 
functionalities were first used by Mann and co-workers as nucleation sites for surface-
controlled biomineralization.[72] Taking advantage of the surface chemistry of TMV, 
and the high stability of the protein assembly, they could mineralize a variety of 
inorganic solids on the virus outer surface with the concomitant formation of nanotubes 
(Figure 2.6a).  
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The electrochemical modification of the TMV inner and outer surface was performed by 
Knez et al., by electroless deposition of different metals such as nickel and silver.[73,74] 
Depending on the metallization conditions, they could selectively target the outer or 
inner surface of the tubelike TMV, as shown by TEM (Figure 2.6b). Furthermore, the 
same group used TMV for the synthesis of metal nanowires.[75] The central channel of 
the virus was used as a template to synthesize nickel and cobalt wires only a few atoms 
in diameter and lengths up to the micrometer range. More recently, bimetallic alloys of 
CoPt, CoPt3, and FePt3 nanowires have been synthesized in the TMV capsid channel.[76] 
Dujardin et al. also investigated the use of cylindrical particles of TMV as templates for 
the in situ formation of anisotropic assemblies of spherical Pt, Au, or Ag 
nanoparticles.[77] 
 
a) 
 
b) 
Figure 2.6 a) Routes for the synthesis of nanotube composites by using TMV templates. 
Clockwise from top right: sol−gel condensation (silica); coprecipitation (PbS and CdS 
nanocrystals); oxidative hydrolysis (iron oxide).[72] b) TEM image of a TMV virion 
containg a nickel wire inside the central channel of the capsid.[74] 
 
More recently other examples of TMV surface modification have been described. 
Royston et al., for example, have attached TMV1cys-based nanotemplates onto a solid 
surface to produce functional high-surface-area nanomaterials (Figure 2.7).[78] First, 
TMV templates were engineered to encode unique cysteine residues (TMV1cys). In a 
second step these templates were assembled onto a gold patterned surface. Because the 
engineered cysteine residues at the 3’ terminus are more exposed than those embedded 
in the helix, the particles assembled in a vertically oriented fashion. Subsequently, 
electroless deposition of ionic metals onto the surface-assembled virus templates was 
performed, producing uniform metal coatings up to 40 nm thick. Organic molecules 
such as poly(ethylene glycol)[79] and carbon nanotubes[80] were also attached to the 
exterior surface of TMV. 
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a) 
 
c) 
 
b) 
 
Figure 2.7 a) Computer-generated model depicting the position of the 1cys mutations 
on the outer rod surface (above) and at the 3’ end of TMV (below). b) Diagram showing 
the construction of nickel- and cobalt-coated TMV1cys molecules onto a gold surface. 
c) Field emission electron microscopy (FESEM) images showing a nickel-coated gold 
surface with 1 mg mL-1 TMV1cys particles.[78] 
 
 TMV as a self-assembling, multichromophoric system 
The development of synthetic self-assembling, multichromophoric systems to create 
tunable light-harvesting architectures is an important goal in the fields of materials 
science and nanotechnology. The Francis group has used the in vitro assembly of TMV 
capsids to create such systems.[81] Three different fluorescent chromophores were 
separately attached to genetically introduced cysteine residues on the surface of the 
TMV coat protein. When placed under the appropriate assembly conditions, these 
conjugates could be assembled into stacks of disks or extended rods that reached 
Protein Cages as Multifunctional Nanoplatforms 
 
 31
hundreds of nanometers in length (Figure 2.8). Photophysical studies demonstrated that 
efficient energy transfer is possible in these rods through direct donor–acceptor 
interactions. In a similar approach, Endo et al. showed that TMV coat-protein subunits 
could be chemically modified with either Zn-coordinated porphyrin or free-base 
porphyrin.[82] When assembled in vitro, these materials also displayed energy-transfer 
and light-harvesting properties.  
 
Figure 2.8 Synthetic of light-harvesting structures. Mixtures of modified TMV coat 
protein monomers labeled with dye 1 and dye 3 were assembled into rods,[81]that 
display energy transfer and light-harvesting properties. 
 
 Patterning and arrays 
The formation of ordered aggregates of TMV in the presence of divalent metal ions has 
been studied in concentrated solutions of the virus.[83] Some divalent metal ions were 
found to promote the precipitation of TMV and it was shown that the precipitates 
possessed nematic liquid-crystalline behavior. Nematic liquid crystals of TMV have 
also been used to prepare silica nano- and mesostructures with parallel or radial arrays 
of linear channels.[84] Tubular structures based on TMV as a template have been 
obtained by Fujikawa and Kunitake.[85] They assembled TMV on a surface and then 
covered it with ultrathin titania films in a sol−gel process. Another example is the work 
of Yi et al., who assembled TMV onto glass substrates patterned with specifically 
captured DNAs.[86,87] This approach provides a reliable, selective, and controllable 
approach to assemble multiple TMV molecules. Furthermore, a paper has been 
published in which the adsorption and surface behavior of TMV on different surfaces 
was studied by noncontact atomic force microscopy (AFM).[88] 
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 Cage-structured virus: cowpea mosaic virus (CPMV) 
The cowpea mosaic virus (CPMV) is a plant virus that belongs to the family of 
Comoviridae. It infects black-eyed pea plants (Vigna unguiculata) and it can be 
obtained in good yields; gram quantities of virus particles can be isolated from a 
kilogram of infected leaf tissue.[89]  
The virus possesses a structure that is known at atomic resolution[90] and it is 
remarkably stable; its particles maintain their integrity at 60 °C (pH 7) for at least 1 h 
and at room temperature and pH values from 3.5 to 9 for almost indefinite periods of 
time.[91,92] The virus, therefore, is of potential use as a building block in bio-
nanotechnology. The CPMV capsid is formed by 60 copies of an asymmetric unit that is 
composed of two protein subunits: a small one, the A domain, and a large one, the B+C 
domain (Figure 2.9a). These 60 asymmetric units self-assemble around a single-
stranded RNA genome to form the virus particle. The virus displays icosahedral 
symmetry, the outer diameter of which is approximately 30 nm (Figure 2.1). In addition 
to the small percentage of capsids devoid of RNA which are produced during 
infection,[93] it is possible to generate empty CPMV capsids by hydrolyzing the RNA.[94] 
Infectious clones of the virus RNAs are available and allow site-directed mutations or 
peptide insertions in the capsid proteins.[95] When plants are infected with the mutated 
RNAs, the sequence is genetically stable through multiple rounds of infection, 
harvesting, and reinoculation.[96,97] 
 
 
a) 
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b)                                         c)                                                  d) 
Figure 2.9  Structure of CPMV and cysteine-added mutant of CPMV. a) Left: schematic 
representation of CPMV, showing the distribution of the protein subunits that comprise 
the asymmetric unit. Right: the folds of the two subunits, A and B+C.[91] b) The atomic 
structure of the CPMV coat protein, with the sites of mutational insertion βB-βC loop 
and βE-βF loop. c) Amino acid sequences corresponding to native and mutant CPMVs 
1–4. d) A model of the entire particle showing the addition of a five amino acid residue 
insert (GGCGG) at the two positions of interest in the wild-type CPMV structure. The 
resulting mutant viruses correspond to 1 and 3. The BC loop resides further “up” on 
the protruding cap than the EF loop at each fivefold axis of the icosahedral 
structure.[98] 
 
 Traditional bioconjugation strategies 
Both wild-type (wt) and genetic variants of CPMV have been used as scaffolds for 
chemical derivatization. Early investigations of the chemical reactivity of wt CPMV,[99] 
and mutant CPMV,[98] which aimed at lysine- and cysteine-selective derivatives, 
revealed that CPMV can be easily modified. Finn and co-workers showed that activated 
fluorophores in the form of N-hydroxysuccinimide (NHS) esters can react with 
endogenous lysines (K) and be linked to the virus surface.[99] Unique reactivity was 
achieved through the introduction of cysteine residues on the virus outer surface, which 
could be modified with either maleimide-functionalized fluorophores or gold 
nanoparticles (see below), by means of genetic manipulation (Figure 2.9b–d).[91,98] The 
functionalization of cysteine and lysine residues with biotin derivatives resulted in 
virions decorated with biotin molecules, which were shown to assemble by cross-
linking with avidin or streptavidin (Figure 2.10).[98-100] These types of experiments 
provide information as to whether the reactive thiol and amine groups are situated on 
the inner or outer surface of the virus particle. 
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a) b)
 
Figure 2.10 Electron microscopy images of virus–biotin–avidin aggregates. a) CPMV–
(biotin)20 (0.1 mg mL-1). b) CPMV–(biotin)20 (1.5 mg mL-1) plus avidin (0.5 mg mL-1); 
the mixture was diluted by a factor of 10 before observation by means of TEM.  
 
Once the reactivity of the different endogenous and engineered functional groups on the 
inner and outer surface of the CPMV had been determined, different types of 
modifications of the virus could be performed, for example, the construction of hybrid 
CPMV virus−polymer particles by derivatizing the outer surface of the virus with 
poly(ethylene glycol) (PEG).[101-103] The resulting hybrids had physical and 
immunogenic properties that were markedly different from those of the native virus, 
which opens possibilities for biomedical applications. In addition to PEG, other 
compounds have been covalently attached to surface-exposed amino acids, for example 
redox-active compounds,[104,105] antibodies,[106] small proteins,[107] oligonucleotides,[108] 
quantum dots (QD),[109-111] and carbohydrates.[112,113] Furthermore, different mutants of 
CPMV have been used as scaffolds to bind gold nanoparticles through gold−sulfur bond 
formation.[114,115] Unstained TEM images showed patterns that were in line with the 
locations of the cysteine functions on the capsid (Figure 2.11). Such experiments in 
which the CPMV capsid acts as a template, to create complex 3D assemblies, have great 
potential for the design of nanodevices such as sensors or electronic circuits.[114,116] 
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Figure 2.11 TEM images and models of three different CPMV mutants with gold 
nanoparticles on the outside surface (scale bars are 5 nm long). a) Unstained TEM 
image of eight gold nanoparticles bound to an isolated CPMV virus mutant. The arrow 
marks a fivefold axis with two particles bound to two different cysteine residues around 
the axis. b) Model of the CPMV mutant in (a) showing the location of the eight gold 
particles (one gold particle per fivefold axis). c) Unstained TEM image of 13 gold 
nanoparticles bound to an isolated CPMV virus mutant. The arrow marks a 
nanoparticle on the other side of the virus that is out of focus. d) Model of the mutant in 
(c) showing the 13 gold particles. e) Unstained TEM image of an isolated CPMV 
mutant with 42 gold particles bound to it. The spherical shape of the virus is clearly 
visible due to the large number of gold particles that are bound to the virus. f) Model of 
the CPMV mutant shown in e).[114] 
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 Bioconjugation via the copper(I)-catalyzed azide–alkyne cycloaddition reaction 
The exterior surface of the protein cage of CPMV has also been decorated with azide 
and alkyne groups, which were treated with derivatives containing the complementary 
groups (alkyne or azide) for a copper(I)-catalyzed azide–alkyne [3+2] cycloaddition 
reaction (so-called “click” reaction).[117] The improved efficiency and selectivity of this 
bioconjugation approach has expanded the array of compounds that can be attached to 
virus scaffolds. CPMV has been modified in this way with small compounds, such as 
fluorescent dyes,[117-119] gadolinium complexes,[120] and sugars, but also with large 
compounds as polymers,[121] and even the 80 kDa protein transferrin.[119] Many of these 
constructs have important applications in biomedicine, for example, CPMV coupled to 
gadolinium-tetraazacyclododecanetetraacetic acid (Gd(DOTA)) analogues by “click 
chemistry” has been used as contrast-enhancing agent for medical diagnostics (Figure 
2.12).[120] 
 
Figure 2.12 Synthesis of Gd(DOTA)-derivatized CPMV.[120] 
 
 Fabrication of CPMV arrays 
The presence of two different subunits (A and B) in CPMV offers the possibility to 
specifically modify the viral protein capsid at different locations by genetic methods or 
chemical reactions. This allows breaking of the symmetry of CPMV and the ordering of 
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the virus into 2D and 3D structures. Different approaches have been followed to 
assemble modified CPMV particles into hierarchically ordered structures.[108,109,122,123] 
For example, complex patterns could be made by allowing droplets of concentrated 
solutions of modified CPMV to dry on mica surfaces. The resulting patterns were 
studied by AFM.[124] Furthermore, dip pen nanolithography (DPN) has been combined 
with chemoselective protein-to-surface linkers to create nanometric chemical templates 
for the fabrication of arrays of virus particles.[125,126] To this end, DPN was used to 
pattern a gold substrate with a thiol-selective linker to which a genetically modified 
Cys-CPMV was immobilized. Layer-by-layer assembly using solutions containing the 
streptavidin–biotin pair has been applied to make arrays of CPMV on a solid 
support.[100,127] All these examples highlight that CPMV offers great opportunities for 
new science in the fields of biomaterials and nanotechnology.[128] 
 
 
2.4 The Cowpea Chlorotic Mottle Virus (CCMV) 
 
In this section a detailed description of the cowpea chlorothic mottle virus (CCMV) is 
given because CCMV is the virus used for the studies described in this thesis. First the 
structure and properties of the virus will be discussed as well as its assembly pathways. 
Subsequently, the potential use of CCMV as a reaction vessel, as a scaffold for chemical 
derivatization, and as a building block in hierarchical assemblies will be highlighted. 
 
 Structure 
CCMV is a member of the bromovirus group of the Bromoviridae family of plant 
viruses.[129] It is formed by the assembly of 180 identical coat protein subunits around 
the genetic material, which is RNA. The CCMV genome consists of four single-
stranded, positive-sense RNA molecules, which are encapsidated into three structurally 
similar virions.[130,131] The protein subunits are arranged as 20 hexamers and 12 
pentamers altogether forming an icosahedral shell 28 nm in diameter with T = 3 quasi-
symmetry (see Appendix, Figure 2.13). Every coat protein contains 190 amino acids 
with the N terminus located on the inside of the virus capsid (Figure 2.13a and b). The 
residues on the N terminus (amino acids 1–25) are predominantly basic and are 
responsible for interaction with the negatively charged RNA. The residues are not 
ordered according to icosahedral symmetry and therefore not seen in the crystal 
structure of the virus (Figure 2.13c). The C terminus, namely, amino acids 186–190 (for 
the complete amino acid sequence see Figure 2.13d), of a subunit reciprocally deeply 
invades an adjacent subunit and results in the formation of a noncovalent coat-protein 
dimer (Figure 2.13c). This explains the existence of subunit dimers in solution when the 
virus is completely disassembled.[129,132]  
Chapter 2  
 38
                                   a) 
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 c) 
 
d) 
 
 
Figure 2.13 The CCMV particle. a) The crystal structure of the T = 3 CCMV capsid 
with the pentameric and hexameric faces drawn on the cage structure. The symmetry 
axes are highlighted with two-, three-, five-, and sixfold symbols, open symbols indicate 
quasi-symmetry and filled symbols icosahedral symmetry. Each asymmetric unit 
contains three subunits, A in blue, B in red, and C in green (for colors see Figure 2.16 
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and the Schematic Overview on page 187). There are two types of dimers in the capsid: 
the A–B dimer and the C–C dimer. b) Ribbon diagram showing the tertiary structure of 
the protein subunit of CCMV. Selected residues and secondary structure elements are 
labeled together with the functions of the highlighted regions. c) A close-up view of the 
A–B dimer interaction showing the interdigitated C-terminal peptides that produce a 
strong dimer. The crystal structure of the A subunit (blue) starts at amino acid residue 
42, whereas the B subunit (red) has a more ordered N-terminus and starts at residue 
27.[129,132,133] d) Amino acid sequence of the CCMV coat protein. 
 
 Properties 
Dynamic structural transitions occur in many viruses, often induced by specific 
chemical signals. One interesting feature of CCMV is its sensitivity to pH and ionic 
strength.[132] CCMV undergoes a reversible pH-dependent swelling, which results in a 
10% increase in virus dimension. Structural analysis has revealed that CCMV swelling 
leads to the formation of 60 separate openings (2 nm in diameter) at the quasi-threefold 
axes (Figure 2.14).[129] Furthermore, depending on the pH and ionic strength, CCMV 
particles can be rapidly disassembled in vitro into dimers and RNA, and then 
reassembled again. Empty capsids (capsids devoid of viral RNA) are not found in 
natural infections. In contrast, in vitro assembly using purified coat protein or 
expression of the CCMV coat protein in heterologous expression systems (e.g., bacteria) 
can result in capsids devoid of viral RNA.[131,134-136] The cavity is 18 nm in diameter; 
approximately twice the diameter of the iron storage protein ferritin. In the assembled 
empty capsid, the interior surface carries a high positive-charge density due to the 
presence of nine basic residues (arginine and lysine) in the amino-terminal region that 
project inward into the capsid interior. This interior surface, in the absence of RNA, can 
be used for directing the nucleation of mineralization to produce spatially constrained 
nanoparticles in the preformed capsid, as shown below. 
a) 
 
b) 
 
Figure 2.14 Model of the a) unswollen and b) swollen CCMV.  
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 CCMV assembly 
In the 1960s, Bancroft et al. performed the first steps towards the mechanistic 
elucidation of CCMV virus and capsid assembly in vivo and in vitro under different 
solution conditions (e.g., pH) and in the presence of different polyelectrolytes.[134,137-140] 
They observed that the virus assembly is dynamic and that different types of 
architectures (e.g., tubes, sheets, and multiple shells) can be formed by varying the 
assembly conditions. An increased understanding of the system has been obtained by a 
combination of genetic modifications of the subunits and controlling the in vitro 
assembly conditions. Based on the X-ray structure of CCMV, it was postulated in 1995 
that hexamers of dimers nucleate the assembly process.[132] This hypothesis was 
weakened when Zlotnick et al., using full-length CCMV subunits in the absence of 
RNA, demonstrated in vitro that pentamers of dimers (PODs) nucleate protein capsid 
assembly and that propagation of this process proceeds via the addition of subunit 
dimers and PODs.[141] Willits et al. corroborated this hypothesis by proving that 
hexamers with their associated β-barrel structure were not critical for proper 
assembly.[142] Johnson et al. proposed a mechanism for CCMV assembly in which the 
first step consists in the formation of a coat protein–RNA complex followed by folding 
and growth (Figure 2.15).[143,144]  
 
Figure 2.15 Proposed assembly path for CCMV. i) CP initially binds excess RNA with 
low cooperativity. ii) CP and RNA slowly fold to form the C1 nucleoprotein complex. 
This step is not required for RNA packaging. It is found that about ten CP per RNA are 
required for folding; the actual stoichiometry and structure of the C1 complex however 
is not known. iii) Addition of CP to C1 is highly cooperative and yields the complete 
virus particle. 
 
Other in vitro studies on the assembly of the CCMV coat protein have shown that a 
mutant CCMV coat protein lacking most of the N-terminal domain (3–36) or naturally 
degraded subunits (which usually lack the same N-terminal domain), assemble in vitro 
into products with high heterogeneity (polymorphism).[133] This observed behavior is 
believed to be the result of a change in the interaction between two dimers, which in 
turn depends on the increased flexibility of the structure defining the dihedral angle 
between the two protein subunits present in the dimers. Not only the expected native-
like T = 3 capsids of 90 dimers are formed, but also smaller capsids, namely, “T = 2” 
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capsids of 60 dimers and T = 1 capsids of 30 dimers (see Appendix). The results are 
consistent with the POD nucleating assembly theory, and assembly pathways were 
proposed for each of the particles (Figure 2.16). However, the outcome also shows that 
the capsid geometry is flexible and may readily adapt to new requirements as the virus 
evolves. Recently, these same mutant coat proteins have been assembled around solid 
nongenomic cores, resulting into structures that can be tuned by varying the 
nongenomic core size.[145]  
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Figure 2.16 Proposed assembly pathways for the different particle types. The assembly 
proceeds from top to bottom. 1) The assembly of each particle type starts with a POD 
for nucleation. 2) Addition of a dimer to the starting POD can direct assembly toward 
T = 1 or T =  3 particles, depending on the trajectory established by the dihedral angle 
in the dimer. The “T = 2” is formed by the addition of preformed PODs. In the case of 
T = 1 only A–B dimers are added (blue/red), while T = 3 particles can add either A–B 
or C–C (green/green) dimers. 3) More dimers have been added to T = 1 and T = 3 
particles, while “T = 2” receive more PODs. 4) The finished T = 1 particle has all 
subunits in the same conformation, depicted in blue. The “T = 2” particle contains two 
kinds of subunits (blue/red) and the T = 3 particle has three structurally unique 
subunits in its asymmetric unit (blue, red, and green). 
 
As shown above, the manipulation of the interactions between coat-protein subunits 
allows some degree of control over the final capsid shape. This has important 
consequences for applications in nanotechnology. The way the capsid architecture is 
directed by the nucleic acid has been mimicked, for example, by using carboxyl acid 
terminated PEGs to which Au nanoparticles were attached,[146] sulfonated polymers,[147-
149] TMV polynucleotides,[150] and DNA.[151] 
 
 CCMV as reaction vessel 
Inspired by ferritin, the well-defined cavity of CCMV has been used as a nanoreaction 
vessel for the reversibly gated entrapment of organic and inorganic 
compounds.[1,2,6,8,15,148] The assembly properties of CCMV provides a unique pH-
dependent gating mechanism to control the entrapment and release of different guest 
compounds. There are two different approaches for the encapsulation of material within 
the capsid interior. The guest molecules can be entrapped during the capsid assembly 
process or they can diffuse into the preassembled capsid architectures through the 
capsid pores. The host−guest relationship between the viral cage and the encapsulated 
material is primarily based on a complementary electrostatic interaction. In the native 
viral protein cage, the cationic interior of the virus interacts with the polyanionic RNA. 
This electrostatic host−guest interaction has also been used to bind other 
polyanions.[138,147,148,151] 
Douglas and Young were the first to report the encapsulation of polyoxometalate 
species (paratungstate and decavanadate) inside the CCMV cage, controlled by the pH-
dependent gating of the virion's pores.[148] To this end, empty virions were incubated 
with inorganic tungstate (WO42−) at pH 6.5, after which the solution was concentrated, 
and washed at pH 5, at which point the pores in the protein shell closed and the 
tungstate ions oligomerized to form the polyoxytungstate. The final process was a 
crystallization that yielded uniform nanocrystals with a diameter of 6.7 nm, which were 
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characterized by TEM. In a similar way, our group recently reported a fast and efficient 
route to prepare, under mild conditions, monodisperse Prussian blue (PB) nanoparticles 
(schematically depicted in Figure 2.17a) inside CCMV capsid.[152] In this case, after the 
PB precursors had diffused through the pores into the capsid, the reaction was initiated 
by UV irradiation using a 405 nm laser beam. Fast protein liquid chromatography 
(FPLC), UV/Vis spectroscopy, and TEM confirmed the formation of the PB 
nanoparticles. In Figure 2.17b, TEM micrographs of the PB-containing capsids which 
were taken with and without uranyl acetate staining are shown. The particle size 
distribution of the PB particles was 18±1.7 nm, which accurately corresponds to the 
dimensions of the inner cavity of the CCMV capsid. 
a) 
 
b) 
 
Figure 2.17 a) Schematic representation of the approach employed to prepare PB 
nanoparticles within the CCMV virus particle. b) TEM micrographs of the PB–CCMV 
nanoparticles. A) grid stained with uranyl acetate showing the complete PB–CCMV 
particles. B) unstained grid, which only shows the PB particles inside the CCMV 
capsid.[152] 
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The electrostatic properties of the interior surface of the CCMV protein cage have been 
altered by replacing nine basic residues at the N-terminus of every protein subunit with 
glutamic acid residues.[153] Also this mutant CCMV was found to assemble readily into 
a cage-like architecture similar to that of the wild-type virus. The modified CCMV 
cages were treated with FeII salts at pH 6.5, after which the particles were allowed to 
oxidize in air, yielding iron oxide cores as was shown by electron microscopy. The 
synthesis proceeded through cationic precursors that are likely to be stabilized at the 
interior surface of the engineered cage by complementary electrostatic interactions. 
 
 Functionalization of CCMV on the outer surface  
In 2002, Douglas and Young performed the first studies on the derivatization of the 
external surface of CCMV by using both endogenous functional groups and engineered 
site-specific functional groups.[154] To these groups fluorophores could be attached 
without disrupting the overall cage architecture. Coupling was achieved to surface-
exposed amines, carboxylic acids, and engineered thiol groups, and the degree of 
surface modification (and hence the number of available reactive sites) was varied 
(Table 2.1).[154] 
 
Table 2.1 Labeling of CCMV with fluorophores that react with different functional 
groups (between brackets) at the outside of the virus.[154] 
 
Fluorophore  Mol excess  
Average number of attached 
fluorophores 
FAM (lysines) 100 180/cage 
 300 380/cage 
 1000 540/cage 
F5M (sulfhydryls) 100 30/cage 
 500 60/cage 
 1000 100/cage 
Cadaverine (carboxylic acids) 100 500/cage 
 500 520/cage 
 1000 560/cage 
SAMSA (bifunctional linker to lysines) 250 45/cage 
 500 95/cage 
 1000 150/cage 
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More recently, a large variety of ligands, including fluorescent dyes,[154,155] 
organometallic photosensitizer,[156] biotin,[155,156] small peptides,[154] and even intact IgG 
antibodies,[155,156] have been effectively linked to the exterior surface of CCMV by the 
Douglas and Young groups. Furthermore, paramagnetic gadolinium atoms (Gd3+), 
commonly used as MRI contrast agents in humans, have been bound to the CCMV coat 
protein subunits.[6,155,157,158] They are located at the interface between the subunits in the 
assembled CCMV capsid, namely, at the quasi-threefold axes (Figure 2.18).[159]  
 
Figure 2.18 Ball and stick model of amino acids (E81, Q81, E148, Q149, D153) that 
make up the binding site for gadolinium ions, at the quasi-threefold axis of the 
CCMV.[2] 
 
The above results demonstrate the robust nature of CCMV offering the possibility to 
impart multiple functionalities to the same capsid by using both the endogenous groups 
and the groups that can be introduced by genetic and chemical modification. The 
combination of surface modification and the possibility to locate molecules at the 
interface and in the inner cavity of the CCMV protein cage makes this virus a very 
interesting nanoplatform for medical and biotechnological applications (Figure 
2.19).[6,155,156,160] This conclusion is supported by in vivo studies. When tested in mice, 
CCMV showed a rapid and broad distribution throughout most tissues and organs. 
Furthermore, it was  rapidly excreted, displaying no overt toxicity after a single 
injection.[161]  
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Figure 2.19 a–e) Scanning electron microscopy (SEM) images showing the 
arrangement of targeted CCMV particles containing a conjugated photosensitizer (PS) 
on a pathogenic bacterium wall.: a) cell exposed to a CCMV mutant (S102C/K42R) 
with no targeting groups; b) cell targeted with a CCMV mutant (S102C/K42R-PS). 
Binding of the virus occurs through electrostatic interactions; c) cells targeted with a 
CCMV mutant (S130C/K42R-PS). Binding occurs via complementary biological 
interactions; d) magnification of the region indicated in (b); e) magnification of the 
region indicated in (c). The scale bars are: a,b) 200 nm; c) 100 nm; d,e) 28 nm (the 
diameter of CCMV).[156] f) TEM images of a thin section showing a high-density 
coverage of CCMV on S. aureus cells. Binding occurs through specific protein–ligand 
interactions. g) Magnification presented in (f). Insert shows a TEM image at the same 
scale as the thin slice of CCMV particles adsorbed on Formvar. The scale bars in (f) 
and (g) are 200 and 100 nm, respectively.[155] 
 
 Assembly of CCMV capsids into higher-order structures 
The higher order assembly of viruses into well defined 2D and 3D architectures, all the 
way from the nanoscale to the macroscopic scale, is one of the major challenges in the 
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field of bionanotechnology.[2,6,128] The construction of such high-order assemblies will 
need asymmetric building blocks and hence will be difficult with a particle like CCMV, 
which is symmetrical. Two different approaches have been reported to break the 
symmetry of CCMV by using either the exterior surface[162] of the virus or by 
manipulating its in vitro assembly pathway (Figure 2.20).[163] The first approach 
involved the synthesis of a CCMV capsid with a reactive thiol group present on only 
one single face, which was used to direct a 2D monolayer of capsids onto a gold surface 
(Figure 2.20b).[162] The second approach consisted of mixing two populations of coat 
proteins, each labeled with a different ligand, which resulted in capsids with a 
controlled stoichiometry of ligand display (Figure 2.20a).[163] Suci et al. have 
investigated the higher order 2D and 3D assembly of CCMV capsids by making use of 
electrostatic interactions. Different surfaces were tested and the assemblies were studied 
with AFM and Fourier transform infrared spectroscopy (FT-IR).[164] In another report 
three different approaches were employed to form higher order 3D architectures via the 
layer-by-layer (LbL) technique. In this case capsids were incorporated into multilayer 
films.[165] 
a)                                                                   b) 
 
Figure 2.20 Two different strategies to break the symmetry of the CCMV particle. 
a) Disassembly of differently modified CCMV followed by mixing and reassembly of the 
subunits.[163] b) Symmetry breaking by synthesizing a CCMV mutant whose alanine was 
replaced by a cysteine residue at position 163 on one of the subunits (A163C): 1) The 
viral cage is bound to resin containing activated thiol groups; 2) passivation of the 
remaining cysteine residues of the virus with iodoacetic acid; 3) removal of the virus by 
reduction, which leads to a unique SH group on the virus surface.[162] 
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2.5 Conclusion 
 
The use of protein cages and viruses as multifunctional nanoplatforms and as building 
blocks for nanotechnology provides unique advantages. Protein cages are biological in 
origin and, as such, highly monodisperse and amenable to genetic manipulation and 
large-scale production. As exemplified in this chapter, nature has provided a wide 
variety of protein capsids that vary in size, stability, and functionality. These capsids 
can be modified by using either chemical or genetic approaches to impart specific 
designed functionalities. The ability to utilize the interior and exterior surfaces of the 
viral capsids, as well as the interface between the subunits, allows for a degree of 
control that spans the full range of possibilities offered by these particles. All these 
features will allow many of the capsid systems described in this chapter to be 
engineered for specific applications in materials science. This research is ongoing and 
can be expected to have an increasing impact on the field in the future.  
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CHAPTER 3  
CCMV Isolation and Purification 
 
3.1 Introduction 
 
 Plant virus purification 
Purified virus samples are essential to obtain information about chemical, physical, 
biochemical, and biological properties of viruses.[1] Purification, with its usual aims of 
high quality and quantity, is often a major stumbling block in such studies.[2] The 
tobacco mosaic virus (TMV) was the first plant virus to be purified, which resulted in 
Stanley being awarded the Nobel Prize for Chemistry in 1946.[3-5] In 1936, he published 
the successful isolation of TMV in apparently a pure crystalline state and he also 
reported the protein nature of the virus. The virus was isolated after several extractions 
and precipitation steps. One year later Bawden and Pirie discovered the RNA content of 
TMV particles.[6] TMV was also the first virus that was reassembled from its 
constituents (RNA and capsid protein), which will be further discussed in the next 
chapter.[7]  
Following the purification of TMV, other plant viruses, including spherical ones, were 
also purified as well with essentially the same extraction and precipitation technology, 
for example, potato virus X (PVX) and tomato bushy stunt virus (TBSV). The choice of 
extraction buffer and additives can greatly influence the outcome of purification 
attempts and it is based on the physical and chemical properties of the virus. Acidic 
buffers of about pH 5 are useful for the extraction of some icosahedral viruses because 
their host proteins are precipitated at low pH. For cases in which pH-induced 
purification may result in low virus yields, the use of organic solvents or detergents may 
be required to remove the contaminating plant material.[2] A more recent method for 
further purification is the specific precipitation of the virus, for example, by the so-
called polyethylene glycol (PEG) precipitation.[8] Since the late 1940s, isolation and 
purification were facilitated by the fact that preparative ultracentrifugation became 
available. This technique separates viruses on the basis of size, shape, and density of a 
virus.[9] In 1951, Brakke developed the density gradient centrifugation to purify 
viruses.[10] The final purification of viruses that are contaminated by host materials, is 
often carried out by centrifugation in density gradients, either by so-called rate-zonal 
centrifugation in sucrose (separation based on size, shape, and density) or by so-called 
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isopycnic sedimentation in gradients of sucrose or cesium salts (separation based on 
density only).[2]  
 
 Purification and characterization of CCMV 
The purification of CCMV was described for the first time by Kuhn.[11] Leaves of 
cowpea plants were mechanically inoculated with virus particles and after further 
growth of the plant and harvesting of the leaves, isolation was carried out by extraction 
with chloroform and n-butanol. The resulting material was characterized by electron 
microscopy and UV/Vis spectroscopy. The nucleic acid content of the isolated virus 
was determined by phosphorous analysis and amounted to approximately 22% (w/w).  
Bancroft et al. in their studies on the assembly properties of CCMV (see Chapter 4) 
used a modified procedure to isolate and purify the virus particles. The virus was grown 
in cowpea plants (Vigna unguiculata), which were harvested about 10–15 days after 
inoculation.[12] The leaves were blended in sodium acetate buffer of pH 5 and the sap 
was expressed through cheesecloth and stored overnight at T = 4 °C. The virus was 
subsequently subjected to differential ultracentrifugation. The resulting solution, when 
analyzed by TEM, contained spherical particles approximately 28 nm in diameter 
(Figure 3.1). The yield varied between 20 and 40 mg of virus per 100 g of leaf tissue, 
depending on the growing conditions. 
a) 
 
b) 
 
 
Figure 3.1 Electron micrographs of CCMV stained with uranyl acetate.[12] a) Typical 
view. b) A magnification showing stain accumulation in the center in the particle. 
 
The purification of CCMV was further optimized by other groups,[8,13-16] for example 
Verduin,[17,18] and the virus was structurally studied by a variety of techniques. The 
quaternary structure of CCMV was described in 1993 by Speir et al. as determined from 
X-ray studies on crystalline virus (Figure 3.2).[19,20] An improved purification strategy 
was needed to provide crystalline material suitable for the high-resolution (3.1 Å ) X-
ray structure determination.  
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a) b) 
Figure 3.2 CCMV models obtained from X-ray electron density data [20] a) View of the 
CCMV capsid at pH 4.5. b) Ribbon diagram showing the tertiary structure of the 
CCMV protein subunit. 
 
A small scale (1 g tissue) purification method for brome mosaic virus (BMV) and 
CCMV without the application of density gradient centrifugation was reported by 
Bujarski which however required a much longer procedure.[21] A virus yield of 0.5–
5 mg per g of infected leaf tissue was obtained and it was claimed that the virus would 
preserve its biological activity for years when stored in storage buffer at −70 °C. In 
2004, Michel et al. described a new technique for the last step of CCMV purification by 
applying ultrafiltration through polyethersulfone membranes, instead of 
ultracentrifugation. The purification protocol was thoroughly explained and both the 
ultrafiltration and ultracentrifugation methods were compared. CCMV purified by 
ultrafiltration was shown to provide material of similar quality as CCMV purified by 
CsCl ultracentrifugation.[22] The advantage of their ultrafiltration method was that 
expensive equipment and materials such as ultracentrifuges and rotors, and toxic CsCl 
chemical waste could be avoided. Recently, a new procedure was published for the 
rapid and efficient purification of CCMV, namely, by sucrose-cushion 
ultracentrifugation. A five-step protocol was developed to allow the purification of 
CCMV in approximately 4 h.[1] However, the coat protein obtained showed a low 
molecular weight by SDS-PAGE electrophoresis, probably due to degradation of the 
protein, which makes the method inconvenient. 
Apart from plant extraction, the CCMV virions can also be obtained from bacteria, 
namely, by using a molecular biology approach. Zhao et al. reported on a CCMV in 
vitro assembly system that uses coat protein expression in Escherichia coli (E.coli) and 
viral RNAs transcribed from full-length cDNA clones in vitro.[23] According to electron 
microscopy, particles assembled from coat protein expressed in E. coli were virtually 
identical to virus particles purified from infected plants. This approach opened the way 
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to study CCMV assembly by constructing different mutants of this virus by using tools 
from molecular biology. 
CCMV yields (mg of CCMV per gram plant leaf) depend not only on the purification 
procedure, but also on the strength of the inoculation solution, the type of the light 
source, the duration of light exposure, the health of the plant, and so forth.[22] Virus 
purity is routinely determined with the help of denaturating SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) of the protein and by UV/Vis spectrophotometry 
(A260nm(1 mg mL−1) = 5.87; A260/A280 = 1.5–1.7).[19] 
Purification of the CCMV virions is still in the process of being further developed and 
new technology often leads to an improvement of the established protocols (see above). 
In the next paragraph the protocol for the purification of CCMV as developed and used 
in our laboratory will be described. It is based on the approach published by 
Verduin.[17,18] Furthermore, the different characterization techniques used to identify the 
virus and determine its purity will be discussed.  
 
 
3.2 Results and Discussion 
 
 Purification protocol1 
 Planting of the Cowpea plants 
1) Pots (40 to 60) were filled with soil and the Cowpea seeds (Figure 3.3a) were planted 
2 cm deep in the soil (4 seeds per pot). 
2) The plants were allowed to grow for ten days in a greenhouse or in a growth room 
(with two lamps hanging approximately 1.5 m above the plants). The plants were 
watered every two to three days by adding water to the saucers. 
(NOTE: Although the virus can only be mechanically transmitted, plants were brought 
to a growth room before inoculation, to avoid the infection of other plants in the 
greenhouse. Danger of infection was also the reason for destroying the waste material 
once the whole plant growth and infection process was finished. With the later batches, 
to avoid moving the plants from one place to another, the whole process (planting, 
growing, and inoculation of the plants) was performed in the growth room, which gave 
the same results with respect to virus yield and purity) 
                                                 
1 The reagents and equipment required for the purification are given in the Experimental Section 
(Section 3.4).  
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 Inoculation of the plants  
3) At this point primary leaves were present (Figure 3.3b). The leaves were dusted with 
carborundum (to abrase the leaves when the inoculum was applied) such that it was 
possible to see some of the powder staying on every leaf.  
(NOTE: Plants should not be left much longer than 10 days before inoculation because 
they tend to develop age resistance against the virus) 
4) The inoculation solution (inoculum) was prepared either with a purified virus 
suspension or with infected cowpea leaves. In both cases a mixture of sap from ground 
leaves, water (5–10 mL), and purified virus solution (ca. 0.5 mg virus) or infected 
leaves (3–4 leaves) was prepared by using mortle and pestle.  
5) The leaves were inoculated by smoothly rubbing them with the forefinger dipped in 
the inoculum (Figure 3.3c). The leaves were rubbed hard, but without putting too much 
pressure on the leaf to avoid leaf damage.  
6) By using a household sprayer, the plants were immediately sprayed with water after 
inoculation to prevent leaf dehydration.[21]  
7) To keep the plants upright, they were attached to wooden garden stakes with small 
pieces of wire (Figure 3.3d and e). 
(NOTE: Leaves may look bad for a day after inoculation. After a week some yellow 
spots can appear on some leaves, although not all leaves will show the effects of the 
virus. Some may present some black spots due to leaf damage, which is a consequence 
of applying too much pressure on the leafs during the inoculation process) 
 
a) 
 
b) 
 
c) 
 
d) 
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e) 
 
f) 
 
Figure 3.3 Pictures of the different stages of the process of growing and infecting 
cowpea plants. a) Bag containing cowpea seeds. b) 10-days-old cowpea plants in the 
greenhouse, ready for inoculation. c) Inoculation of the plants by hand-rubbing the 
virus inoculum on every leaf. d) A plant, three days after inoculation. e) Plants in the 
growth room, one week after inoculation. f) Plant infected with CCMV, just before 
harvesting. 
 
 Preparation of homogenate 
8) Seven to ten days after inoculation (Figure 3.3f), the plants were harvested by cutting 
the stem at soil level.  
9) The plant material (about 500 g) was cut into pieces and blended in portions in cold 
homogenization buffer (about 1 mL per gram of tissue) for approximately 3 min (Figure 
3.4).  
(NOTE: The homogenization buffer contains ascorbic acid used as antioxidant 
(reducing agent) and EDTA to avoid RNA degradation.[18])  
10) Two layers of cheesecloth (25 × 25 cm) were boiled in water containing half a 
spatula (0.3–0.5 g approximately) of EDTA and rinsed with MilliQ filtered H2O. 
11) The homogenate was pressed through a double layer of cheesecloth to remove the 
larger plant debris and collected in a 2 L erlenmeyer flask by using a funnel. 
12) The homogenate was kept at T = 4 °C for an hour to allow the plant proteins to 
precipitate.[2] 
13) The homogenate was subjected to low-speed centrifugation (10 min at 10,000 rpm, 
T = 4 °C) in a Sorvall SLA-1500 rotor to precipitate the leaf tissue.  
 
 Precipitation of CCMV with PEG[8]  
14) The pellet was discarded and the supernatant was added to 10% (w/v) solid PEG 
(MW = 6000 g/mol) through a funnel containing a small piece of glass wool to filter the 
remaining plant material.  
15) The mixture was stirred for an hour at T = 4°C to dissolve the PEG (Figure 3.4b).  
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16) The precipitate was pelleted by low-speed centrifugation with a Sorvall SLA-1500 
rotor (15 min at 10,000 rpm, T = 4°C). The supernatant was discarded and the bottles 
were drip-dried thoroughly to remove the PEG solution (Figure 3.4c). 
17) The pellet was resuspended in cold virus buffer (at least 5% of the original 
homogenization volume, used in Step 9) with the help of a glass stick with a small piece 
of wet cotton on one of the ends (a so-called policeman).  
(NOTE: The virus buffer contains sodium azide to avoid bacterial growth and again 
EDTA.) 
18) The resuspension was cleared of undissolved material by low-speed centrifugation 
with a Sorvall SS-34 rotor (10 min at 10,000 rpm, T = 4 °C).  
 
 Purification of CCMV 
19) The pellet was discarded and the supernatant was mixed with cesium chloride in 
such a way that 37.5% of the total weight was cesium chloride and the rest (62.5 weight 
%) was the supernatant.  
20) Once completely dissolved, the mixture was subjected to a density gradient 
centrifugation (density of CCMV in CsCl is ρ = 1.36 g/cm3) by using the Step Saver 
70V6 Sorvall rotor (≥ 16 h at 40,000 rpm, T = 10°C).  
21) The tubes were carefully removed from the rotor to avoid disturbing the formed 
brownish band, which contained the pure virus (Figure 3.4d). The cap was removed 
with a blade and the band was collected with a bent needle.  
22) The obtained solution was dialyzed against three volume changes of virus buffer (at 
least three hours per change) in a cold room at T = 4 °C, and then stored at T = 4 °C.  
 
 
 
 
 
 
 
 
 
Chapter 3 
 62
a) b) 
 
c) d) 
 
Figure 3.4 CCMV purification process. a) Leaves in the Waring blender. b) Virus 
solution mixed with PEG 6000. c) Pellet containing the virus precipitated by the PEG. 
d) Resulting tubes after CsCl gradient centrifugation. The brownish band contains the 
CCMV. 
 
Typical yields of CCMV were 200–300 mg per kg of cowpea tissue. Purification was 
usually performed starting from 40 to 60 pots, which resulted in 1 kg of plant material, 
which was purified in two batches to give a final virus solution of approximately 10 mL 
(10–15 mg mL−1) per 500 g of cowpea plants tissue. The virus solution was always kept 
in the fridge at T = 4 °C in virus buffer at pH 5. 
During the whole process, the virus solution was kept cold either in an ice bath or in the 
cold room (T = 4 °C). Buffers were used cold and centrifugation was always performed 
at low temperatures. 
 
 Characterization 
Many ways have been described in the literature to check the concentration, purity, and 
degree of degradation of CCMV. We have reproduced many of these analyses following 
different techniques to obtain experience in CCMV characterization. In-depth analysis 
of the virus is essential for understanding the properties of future, modified virus 
particles.  
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 UV/Vis spectroscopy 
The first analysis of the virus solution was carried out with the help of UV/Vis 
spectroscopy, which is a fast and classic way to get information about virus 
concentration and purity.[19] The CCMV UV/Vis spectrum is typically that of a virus 
solution, with a maximum absorption occurring at λ = 260 nm and a minimum at 
λ = 240 nm (Figure 3.5a). The λmax = 260 nm is the wavelength of maximum absorbance 
of the nucleic acids (RNA and DNA) due to the presence of the aromatic bases in these 
biomacromolecules, whereas λmax = 280 nm is the wavelength of characteristic 
absorption bands in proteins which are due to the presence of the aromatic amino acids 
phenylalanine, tyrosine, and tryptophane. Tryptophane also has a strong absorbance at 
λ = 292 nm, which gives a small peak in the UV/Vis spectrum of CCMV (Figure 3.5a). 
The extinction coefficients of the RNA (ε260) and the coat protein (ε280) are 
27,812,999 M−1cm−1 and 24,075 M−1cm−1, respectively.[24] Although CCMV contains 
only approximately 25% of RNA, the contribution of the nucleic acid is 25 times 
stronger than the contribution of the protein on a weight basis; therefore, the maximum 
absorbance appears at λ = 260 nm. The ratio of absorbances at λ = 260 and 280 nm 
(A260nm/A280nm) is used to determine the viral purity of the sample, and for CCMV a 
value of 1.5–1.7 means a sample of good quality.[22] 
By using the extinction coefficient of CCMV (A = 5.85 at λ = 260 nm for a 
concentration of 1 mg mL−1 and a light path of l = 1 cm), the concentration of the 
solution was calculated. CCMV purification normally starts from about 500 g of plant 
material, which, after the whole process is finished provides approximately 10 mL of 
virus solution of around 10 mg mL−1; this concentration can go up to 20–25 mg mL−1 
when the homogenization step is performed with a larger amount of plant material. 
 
 Fast protein liquid chromatography (FPLC) 
Size-exclusion FPLC using a Superose 6 column is a valuable technique for the 
characterization and the purification of the virus. The elution of material from the 
column is monitored by UV/Vis detection at two different wavelengths, λ = 260 nm for 
the RNA contribution and λ = 280 nm for the protein contribution in the sample. The 
FPLC chromatogram (Figure 3.5b) usually shows an elution peak at 1.1 mL and, in line 
with the UV/Vis spectroscopy data (Figure 3.5a), the absorbance at λ = 260 nm is higher 
than the absorbance at λ = 280 nm. The latter absorption is not only caused by the 
protein, but also contains a contribution from the RNA.  
 
 
 
 
Chapter 3 
 64
a) 
 
b) 
Figure 3.5 Analysis of CCMV by UV/Vis spectroscopy and FPLC. a) Typical UV/Vis 
spectrum of a CCMV solution (c = 0.085 mg mL−1) in acetate buffer of pH 5 at 25°C. 
b)  FPLC chromatogram of a CCMV solution (c = 8.5 mg mL−1) in acetate buffer of 
pH 5 at 25°C. 
  
 Microscopy studies2 
CCMV was routinely analyzed by electron microscopy techniques, such as SEM and 
TEM. In one case we also used cryo-SEM to characterize the virus particles. This 
technique has not been used before in the literature for CCMV (Figure 3.6a and b). The 
first studies were directed towards finding the optimal conditions for sample 
preparation. The CCMV concentration, the type of grid, the deposition time, the kind of 
staining and its concentration, and so forth were varied. Typical TEM micrographs of 
the virus are shown in Figure 3.6c and d, in which a monolayer of CCMV can be 
observed with a hexagonal pattern in some areas. Depending on the preparation 
conditions, areas with multilayers can also be formed. The best conditions for sample 
preparation are as follows: 
 
1) CCMV solution (5 μL; c ≈ 0.16 mg mL−1) was applied to a Formvar carbon-coated 
grid, previously made hydrophilic by glow discharge, and the solution was left for 1 min 
on the grid. 
2) The excess buffer was blotted away with the help of filter paper.  
3) A drop of uranyl acetate solution (0.2% in MilliQ filtered H2O ) was applied to the 
grid and the solution was left for 15 s (negative-staining step). 
4) The excess liquid was blotted away with filter paper. 
5) The samples were left to dry in air for 15 min. 
                                                 
2 Part of the work described herein has been performed by Willem van Heugten as part of his 
Master degree under the supervision of the author. 
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By following these conditions the quality of the micrographs improved considerably 
and CCMV particles randomly distributed over the grid could be observed (Figure 3.6e) 
instead of the complete black particles that are obtained when higher concentrations of 
virus and staining reagent were applied (Figure 3.6c and d).The particles now displayed 
inner cavity, as revealed by the uranyl acetate solution (dark dot in the virus).  
a) 
 
b) 
 
c) 
 
d) 
 
e) 
 
f) 
 
Figure 3.6 Microscopy studies on CCMV. a) Cryo-SEM micrograph of CCMV particles 
and b) magnification. c) First TEM micrographs of CCMV and d) magnification. 
e) TEM micrograph of CCMV particles under optimized conditions; inset 
magnification. f) TEM micrograph of CCMV particles organized in a hexagonal pattern 
(negative-staining carbon-film technique). 
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We also performed studies aimed at controlling the assembly of the virus on a surface, 
which can be very valuable for future applications of CCMV. To obtain monolayers of 
the virus organized in hexagonal patterns, the “negative-staining carbon-film technique” 
was used.[25,26] The procedure is schematically described in Figure 3.7. By following 
this protocol hexagonal arrays of CCMV particles on carbon could be successfully 
prepared (Figure 3.6f). 
 
Figure 3.7 Schematic drawing of the negative-staining carbon-film technique.  
  
 Gel electrophoresis 
The CCMV samples were also characterized by SDS-PAGE. Purified CCMV particles 
were diluted with MilliQ filtered H2O (c = 0.1 mg mL−1) and mixed with an equal 
volume of SDS-PAGE gel loading buffer (1:1 v/v), and heated for five minutes in 
boiling water to denaturate the virus. The gel (see the Experimental Section for 
preparation, loading, and running conditions) usually shows a single coat-protein band, 
with a molecular weight of approximately 20 kDa, resulting from the 180 identical 
protein subunits (Figure 3.8a). In most cases no additional bands were observed, 
indicating that no degradation of the protein had occurred and no contamination was 
present. The protein could be visualized by using Coomassie Blue staining; for solutions 
containing very low virus concentrations, silver staining is an alternative. Agarose gel 
electrophoresis was also used to characterize the whole virus particle, in which case no 
previous denaturating step was applied. In this case, only one band was observed on the 
gel, which was stained by Commassie Blue (specific for proteins) and ethidium bromide 
(specific for nucleic acid). Both stains gave a spot at the same place, showing the co-
migration of the protein and RNA on the gel. CCMV has a pI of 3.7 and contains RNA 
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that is negatively charged at neutral pH, which makes that the virus runs considerably 
on the gel from the cathodic (top) to the anodic (bottom) end. 
a) 
 
b) 
 
 
c) 
 
 
Figure 3.8 Gel electrophoresis of CCMV. a) SDS-PAGE gel of the denatured CCMV 
stained with Coomassie Blue. b) Agarose gel of CCMV stained with Coomassie Blue. 
c) The same gel as that shown in (b) stained with ethidium bromide.  
 
 Small-angle neutron scattering (SANS) 
We also performed a SANS analysis of CCMV. Details are described in Chapter 5. 
 
 
3.3 Conclusion 
 
In this chapter the purification and characterization protocols for CCMV as worked out 
in our laboratories are described. Based on the variety of experiments CCMV particles 
can be obtained in good yields and high purity; allowing them to be used in a range of 
research projects. 
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3.4 Experimental Section 
 
 Materials 
 Reagents 
Sodium acetate trihydrate (>99%), uranyl acetate dihydrate (≥98%), and PEG 
(MW = 6000 g/mol) were purchased from Fluka. Ethylenediaminetetraacetic acid 
(EDTA) disodium salt dihydrate (>99%), tris(hydroxymethyl)aminomethane (Tris) 
(>99%), calcium chloride dihydrate (>99%), L-(+)-ascorbic acid (>99%), sodium 
chloride (99.5%), sodium azide (99%), and cesium chloride (>99%) were purchased 
from Acros; ethanol (p.a.) was purchased from Merck; ethidium bromide (~95%), 
Orange G (≥80%), and dithiothreitol (DTT) (99%) were obtained from Sigma-Aldrich. 
Agarose (electrophoresis grade) was purchased from Invitrogen. All reagents used for 
SDS-PAGE electrophoresis were purchased from Bio-Rad Laboratories.  
California Blackeye Cowpea Seeds were obtained from Main Street Seed and Supply, 
Co. (Michigan, USA) and from Groente & fruitspecialist "De Gezonde Apotheker" (The 
Netherlands). During storage they were kept dry in a cold room at 4°C. Carborundum 
(size 500) was obtained from Cats Import (Hoogvliet, The Netherlands). The potting 
soil (potting soil 4) was purchased from Hortimea groep (The Netherlands).  
 
 Buffers 
The following aqueous buffers were used in the experiments: 
Homogenization buffer: 0.2 M sodium acetate, 0.01 M ascorbic acid, 0.01 M disodium 
EDTA, buffered at pH = 4.8 
Virus buffer: 0.1 M sodium acetate, 0.001 M disodium EDTA, 0.001 M sodium azide, 
buffered at pH = 5.0 
 
 Equipment 
Plant pots with saucer (40–60, d ≈ 15 cm) 
Laboratory blender (1 L, Waring Laboratories) 
Lamps for the growth room (model HS2000Medium, Hortilux Schreder) 
Mortle and pestle 
Household sprayer 
Wooden garden stakes (approximately 50 cm in length) 
Scissors 
Cheesecloth (type KW 0023.0.14800, Henri Lampe BV, Sneek, The Netherlands). 
Erlenmeyer flask (2 L) 
Plastic funnel (25 cm diameter) 
Centrifuge (Sorvall RC 5B plus, Sorvall)  
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Rotor SLA-1500 (Sorvall, bottle P.P. 250 mL)  
Rotor SS-34 (Sorvall, tube P.P.-F 50 mL) 
Ultracentrifuge (Sorvall Discovery 90, Sorvall) 
Rotor Step Saver 70V6 (Sorvall, sealed tube PA 6 mL)  
Cotton 
Glass stirring rod (25 cm) 
Blade 
Plastic syringe with bent needle (10 mL) 
Cold room 
Growth room (16 h artificial light per day, T ≈ 25 °C) 
Dialysis tubing (Spectra/Por 4, MWCO: 12–14 kD, Flat width: 25 mm, Spectrum 
Laboratories) or D-tube dialyzer (MWCO: 12–14 kD, volume: 1000–3000 μL, 
Novagen) 
 
 Techniques for analysis 
UV/Vis spectroscopy was performed on a Varian Cary 50 spectrophotometer at room 
temperature by using a 1 cm quartz cuvette (Hellma, light path: 1 cm). The reference 
spectrum of the corresponding buffer was subtracted from all UV/Vis spectra. 
Fast protein liquid chromatography (FPLC) was performed on an Ettan Akta LC 
system equipped with a Superose 6 PC 3.2/30 column from Amersham Biosciences 
(flow rate 40 μL min−1). Injections of 20-mL aliquots of the samples on the FPLC 
column at room temperature were monitored with the help of UV detection at λ = 280 
and 260 nm. 
Transmission electron microscopy (TEM) micrographs were recorded on a JEOL JEM-
1010 instrument. Samples were prepared by drying a drop of the solution on a Formvar 
carbon-coated grid that had previously been made hydrophilic by glow discharge. The 
excess buffer on the grid was blotted away after 1 min with filter paper. Negative 
staining of the samples was achieved by applying a drop of uranyl acetate solution 
(0.2% in MilliQ filtered H2O ) onto the grid and blotting the excess liquid away after 
15 s with filter paper. The samples were left to dry in air for 15 min before analysis. 
Cryo-scanning electron microscopy (SEM) micrographs were recorded on a JEOL JSM-
6330F microscope.  
Gel electrophoresis was performed by using two different methods. SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed by using a 4% stacking 
and a 15% running polyacrylamide gel containing 10% SDS. Samples were treated with 
β-mercaptoethanol and heated prior to loading onto the gel. Gels were stained with 
0.05% (w/v) Coomassie Blue solution and destained with a solution of 5% (v/v) 
methanol and 7% (v/v) acetic acid in water (Coomassie Blue destainer). Agarose gel 
electrophoresis was performed by using gels that contained 1.25% agarose. To prepare 
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the gels, agarose (1.5 g) was dissolved in TAE buffer (120 mL; 40 mM Tris-acetate, 
1 mM disodium EDTA, pH = 8). An aqueous solution of ethidium bromide (10 μL, 
10 mg mL−1) was used as a staining agent and Orange G as the sample buffer. The gel 
was run at 100 mV. Ethidium bromide stained nucleic acid on the gel was visualized 
with UV light. Furthermore, the gel was stained with 0.05% (w/v) Coomassie Blue 
solution and destained with 40% (v/v) methanol and 10% (v/v) acetic acid solution in 
water (complete Coomassie Blue destainer).  
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CHAPTER 4  
CCMV Coat Protein Isolation and Assembly 
 
4.1 Introduction 
  
 Assembly and disassembly of CCMV 
The reassembly of the tobacco mosaic virus (TMV) from its constituent components 
(protein and RNA) was published in 1955 by Fraenkel-Conrat and Williams, and it is 
the first example of the reconstitution of a virus.[1]  TMV nucleic acid was recombined 
with its protein subunits at around pH 6 to form a nucleoprotein that still showed some 
virus activity. The reconstituted rod-like object appeared to be identical in shape and 
size to the intact TMV. The first time that attempts were made to reconstitute a spherical 
virus, that is, the cowpea chlorotic mottle virus (CCMV), was in 1967 by Bancroft and 
Hiebert.[2] CCMV was first disassembled and its components were isolated and purified. 
Afterwards, RNA and protein were mixed to form an infectious spherical nucleoprotein, 
which was similar in its general properties to the wild-type virus.  
Since then self-assembly properties of CCMV have been thoroughly investigated by 
Bancroft and others,[3-5] and although a lot of information has been obtained about the 
different properties of the CCMV and its different forms of association, until to date, the 
mechanism of assembly has still not been completely elucidated. The CCMV particle 
can completely disassemble and subsequently reassemble in different morphologies 
depending on parameters such as pH, ionic strength, and temperature.  
 
 Assembly and disassembly of the CCMV coat protein 
The viral RNA can be removed from CCMV and the coat protein (CP) subunits isolated 
and purified. These protein subunits can, under certain conditions, reaggregate and form 
structures that are identical or very similar to those of the original RNA-containing virus 
particle.[6] The self-assembly of the CCMV capsid devoid of RNA was first described 
by Bancroft et al. in 1968,[7,8] and has been thoroughly examined under a variety of 
conditions (different salt concentrations and different pH values) by him and other 
groups.[7-13] In Figure 4.1 the CCMV CP assembly as a function of pH and ionic 
strength, as proposed by Adolph and Butler in 1974 and later revised by Bruinsma et al. 
in 2003, is depicted.[10,14] The CPs can assemble and disassemble reversibly into many 
different structures: hollow single and multishell capsids, hexagonal sheets, and tubes. 
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A fairly monodisperse T = 3 capsid is encountered in the pH range between 3 and 5.5, 
whereas at neutral pH the dominant population consists of protein dimers. 
 
Figure 4.1 Equilibrium phase diagram of the capsid proteins as a function of pH and 
ionic strength.[14] Protein concentration varies between 0.5 and 1.0 mg mL−1, T = 5°C. 
 
The assembly and disassembly of the CCMV CP has also been studied in the presence 
of various negatively charged species.[15-17] The goal was to explore their effect on 
capsid assembly and to investigate to what extent synthetic anionic templates are 
different from RNA. Various polyanions, with different lengths and sizes, for example, 
various polynucleotides,[15] nucleic acids from other viruses,[4] and negatively charged 
polymers such as polystyrene sulfonate,[16,17] were mixed with the CCMV CP and the 
assembly process was studied. The inclusion of various species in the viral capsid is 
further discussed in Chapter 5. 
The understanding of the CCMV and coat-protein assembly has provided a lot of 
information about the ways to control the assembly process under different conditions. 
The construction of mutants by chemical modification of some of the CCMV CP amino 
acids, that is, by mutagenesis of wild-type CCMV RNA with nitrous acid, was the first 
attempt to control the properties of the virus, leading to the construction of temperature-
sensitive CCMV and salt-stable CCMV.[18,19] Fox et al. have shown how a single amino 
acid change in the primary structure of the CP, obtained by genetic modification and 
expression in Escherichia Coli, can lead to tertiary interactions that stabilize the virion 
under high-salt-concentration conditions.[20] 
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In the previous chapter the synthesis, purification, and characterization of CCMV was 
described in detail. Having the best protocols at hand the next step was to carry out 
similar studies (i.e., isolation, purification, and characterization) for the CCMV CP and 
to establish the conditions for their assembly and disassembly. 
 
 
4.2 Results and Discussion 
  
 Coat protein isolation 
The isolation of CCMV CP was first described by Bancroft et al.[2,4] They obtained CP 
by dialyzing the virus against a Tris buffer (20 mM, pH 7.4) containing 1 M NaCl and 
1 mM dithiothreitol (DTT) and removing the RNA by centrifugation. The purity of the 
protein was determined by UV/Vis spectroscopy and by examining the ratio of 
A280nm/A260nm, which is indicative of the amount of residual RNA (Figure 4.2a). The 
assembly product of the CPs was analyzed by TEM, which showed mostly spheres of 
28 nm diameter, which is the same dimension as that of the virus particles (Figure 4.2b).  
 
a) 
 
b) 
 
Figure 4.2 Characterization of the first example of a CCMV capsid.[7] a) UV/Vis 
spectra of the CCMV virus (dashed) at 0.12 mg mL−1 and capsid at 0.73 mg mL−1, both 
in 0.2 M NaCl, pH 5. b) Electron micrograph of the CCMV capsid in uranyl acetate (pH 
4.7). 
 
To reduce the amount of residual RNA, different protocols to prepare viral protein were 
compared by Verduin.[21] Using spectroscopic techniques, the protein yield and the 
degree of contamination with nucleic acid (quantified by the absorbance ratio A280/A260) 
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was examined for every protocol. The procedure that gave the best results is 
schematically depicted in Figure 4.3 and was used in our studies (see below).  
 
 
Figure 4.3 Schematic pathway for the isolation and assembly of the CCMV CP.  
 
The first step in the isolation of CCMV protein involves the removal of viral RNA from 
CCMV by dialyzing a virus suspension (10 mg mL−1 approximately) against a CaCl2 
and DTT-containing Tris-HCl buffer at pH 7.5. The Ca2+ions combine with the 
phosphate groups of RNA and form an insoluble salt, precipitating the RNA as soon as 
the virus disassembles due to the neutral pH conditions (Figure 4.4). DTT is used as an 
antioxidant to avoid the oxidation of sulfhydryl groups of the protein molecules.[5] The 
RNA precipitate formed during dialysis was removed by ultracentrifugation and the 
supernatant was further dialyzed against Tris-HCl buffer (pH 7.5) containing NaCl and 
DTT, to remove all remaining RNA and CaCl2. The dissociated CP, free of RNA, can 
be reassociated into spherical particles by dialyzing it against a pH 5 acetate buffer 
containing NaCl. This assembly/disassembly process is reversible (Figure 4.3).  
 
 
Figure 4.4 Precipitated RNA in the dialysis bag during the first step of the isolation of 
the CCMV CP. 
 
The removal of the RNA from the virus was followed with the help of FPLC (Figure 
4.5). A main peak appearing at 1.8 mL indicates almost complete disassembly of the CP 
into dimers once the pH is increased and the RNA removed (Figure 4.5a). The 
reassembly of the dimers into an empty capsid of the same size as the virus upon 
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decreasing the pH is shown in Figure 4.5b. Characteristic is the appearance of a peak at 
the same retention volume as the virus (Figure 4.5c).  
 
a) 
 
b) 
 
c) 
Figure 4.5 FPLC traces showing the CP isolation and its reassembly to form the CCMV 
capsid; a) CCMV CP dimers, b) CCMV protein capsid, and c) CCMV itself. UV/Vis 
detection of the FPLC instrument was set at 260 and 280 nm. 
 
Isolation of the CCMV capsid particles could also be monitored by UV/Vis 
spectroscopy (Figure 4.6). As already observed in the FPLC traces (Figure 4.5), the 
absorbance ratio A280/A260 changes drastically during the RNA removal process. Due to 
the high extinction coefficient of the RNA (εCCMV RNA = 27.81 × 106 M-1 cm-1), the 
CCMV virus has a maximum absorption at 260 nm (Figure 4.6a), whereas after RNA 
removal the maximum absorption shifts to 280 nm, the typical absorption of a protein, 
which has a much lower extinction coefficient (εCCMV CP = 4.33 × 106 M-1 cm-1) (Figure 
4.6b). Hence, for both the assembled and nonassembled forms of the CCMV CP, the 
UV/Vis spectra are almost the same, only the absorbance minimum at 250 nm is 
different at pH 5 and pH 7.5 due to the difference in scattering produced by the capsids 
and the dimers (the former are larger particles).  
The yield of the CCMV coat-protein isolation, and the purity of the protein, namely, the 
degree of contamination with RNA, can be obtained from the spectroscopic data, as 
already mentioned above. By comparing the initial protein content in the virus and the 
amount of final CP obtained, we could estimate that in our hands approximately 20–
30% of the protein present in the virus is lost during the purification process (based on a 
protein content of the virus of 76% (w/w)). Furthermore, the absorbance ratio A280/A260 
was about 1.3 for most of the experiments, indicating a higher degree of RNA 
contamination in our samples than that described by Verduin.[21] The reason for this 
difference is not fully understood. The initial virus concentration that was routinely used 
by us was 10 mg mL−1, although concentrations of up to 20 mg mL−1 of virus 
occasionally were employed as well, giving the same results.  
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a) b) 
 
Figure 4.6 UV/Vis spectroscopic analysis of the removal of the RNA from CCMV. 
UV/Vis spectra of: a) CCMV and b) the CCMV CP at pH 7.5 and 5. 
 
The removal of the RNA is also evident from TEM experiments (Figure 4.7). Since the 
RNA is removed the space in the capsid is larger than in the virus, which is reflected in 
the larger volume occupied by the staining dye compounds in the TEM pictures (Figure 
4.7b). For the TEM experiments the capsid samples were prepared in the same way as 
the virus samples (see Chapter 3). The capsids appeared to be more difficult to visualize 
than the virus particles and hexagonally patterned monolayers could not be easily 
prepared with the empty capsids. This might indicate that they possess a less compact 
and more floppy structure than the virus, due to the absence of RNA. 
 
a) 
 
b) 
 
Figure 4.7 Microscopy studies on CCMV and capsid. TEM micrographs of a) CCMV 
and b) capsid. The samples were negatively stained with 0.2% uranyl acetate.  
 
Unless used immediately the CCMV CP, once isolated, should be stored in assembled 
form at high salt concentration, that is, in acetate buffer of pH 5, at 1 M NaCl and at 
4 °C, to avoid protein degradation. When stored in disassociated form at pH 7.5 the 
capsid protein molecules easily lose amino acid residues 1 to 36 (MW = 16,300 Da), as 
is visible in the SDS-PAGE gel (Figure 4.8a).[22] The concentration of degraded protein 
(indicated by a band at lower molecular weight) is the highest for the sample containing 
CP at pH 7.5 (lane 7). All other samples, namely, virus (lanes 2, 4 and 5) and capsid 
 CCMV Coat Protein Isolation and Assembly 
 
 77
(lanes 3 and 6), show little degradation and the most intense band is the one 
corresponding to the nondegraded CP (MW = 20 kDa). The presence of degraded 
protein in the reassembled capsid samples seems to cause the formation of smaller 
capsids (T = 1 and “T = 2” particles), which is inconvenient for our experiments (see 
Chapter 2).[22] 
The virus, CP dimers, and capsid run differently in an agarose gel (Figure 4.8b). The 
virus at pH 5 runs relatively fast (lane 1), while the assembled protein capsid at the 
same pH does not run at all (lane 2). The disassociated CP, on the other hand, runs 
slower on the agarose gel than the virus (lane 3).  
 
a) 
 
b) 
 
Figure 4.8 Gel electrophoresis analysis of the removal of the RNA from the CCMV 
virus. a) SDS-PAGE gel of CCMV and the CCMV CP under different conditions and at 
different stages of the isolation process. Lanes: 1) marker, 2 and 4) CCMV at pH 5, 3 
and 6) CCMV CP at pH 5, 5) CCMV at pH 7.5, 7) CCMV CP at pH 7.5.  b) Agarose 
gel. Lanes: 1) CCMV, 2) CCMV CP at pH 5, 3) CCMV CP at pH 7.5. Both gels were 
stained with Coomassie Blue.  
 
As can be seen in the diagram in Figure 4.1, an ionic strength of 0.3 M is on the brink of 
the formation of the correct capsid assembly and the formation of larger assemblies. 
Initially, we carried out assembly experiments with an NaCl concentration of 0.3 M in a 
buffer of pH 5, giving well-assembled capsids from purified CCMV CP. Occasionally it 
was observed, however, that no capsid assembly occurred, as judged by TEM or FPLC. 
In later experiments we decided to use higher salt concentrations in the buffers. When 
NaCl concentrations of 0.5 or 1 M were used, the assembly of the capsid was always 
successful. This illustrates the importance of the salt concentration in the assembly 
process of the CCMV CP. 
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The formation of the larger assemblies was separately studied by FPLC and TEM 
(Figure 4.9). When the CP was assembled in a pH 5 buffer containing a salt 
concentration lower than 0.3 M NaCl, the appearance of a peak at low retention volume 
could be observed in the FPLC chromatograms (Figure 4.9a). This peak corresponds to 
the larger assemblies, such as double shell and lamellar structures (Figure 4.9b). When 
analyzed by UV/Vis spectroscopy, these large assemblies gave a clear increase in the 
absorbance minimum at 250 nm, probably due to an increased scattering of the solution. 
It is expected that not all of the larger assemblies can be distinguished separately by 
FPLC because of the exclusion limit of the column. 
 
 a) 
 
 b) 
Figure 4.9 The formation of large CCMV CP assemblies. a) FPLC chromatogram and 
b) TEM micrograph of the CCMV CP assembled at pH 5 using an NaCl concentration 
of 0.2 M.  
 
In Figure 4.10 the complete CCMV assembly process and the conditions used to reach 
each state in this process are summarized. It should be noted that manipulations with the 
capsid and the many times repeating of the assembly–disassembly cycle causes the 
appearance of the larger assemblies. It is also noteworthy that the capsid at pH 7.5 is 
very sensitive to degradation, leading to the formation of T = 1 or “T = 2” particles, 
when the CP is assembled.[22] These effects can be observed by FPLC and TEM, and are 
sometimes difficult to control.  
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Figure 4.10 Assembly pathway of the CCMV virus and the CCMV capsid depending on 
the pH and ionic strength. 
 
 
4.3 Conclusion 
 
The CCMV capsid could be successfully isolated following the protocol described by 
Verduin,[21] that is, by precipitating the RNA with CaCl2 at neutral pH. The adequate 
removal of the RNA and the assembly of the CP subunits to capsid was confirmed by 
several techniques, such as FPLC, UV/Vis spectroscopy, and TEM. Not only the pH but 
also the salt concentration turned to be an important parameter, which should be taken 
into account when performing the assembly process. Assembly buffers need to contain 
concentrations of NaCl higher than 0.3 M. In this way empty capsids 28 nm in diameter 
are formed, avoiding the formation of larger assemblies such as lamellar structures and 
double shells. The CP is susceptible to degradation, in particular when it is in the 
dimeric form at pH 7.5, as evidenced by SDS-PAGE. The CP should, therefore, be 
stored in its assembled form, that is, as a capsid in 1 M NaCl at pH 5 and at 4°C.  
We have described the procedure to remove the RNA from CCMV and the techniques 
to monitor the process of obtaining the CP and the capsid itself. The study of the capsid 
assembly as a function of the pH and ionic strength has given us insight as to how to 
control the capsid association process. The latter is of key importance to achieve the 
main goal of this thesis, that is, the use of the CCMV capsid as a container for enzymes. 
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4.4 Experimental Section 
  
 Materials 
Sodium acetate trihydrate (>99%) and uranyl acetate dihydrate (≥98%) were purchased 
from Fluka. Ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate (>99%), 
tris(hydroxymethyl)aminomethane (Tris) (>99%), calcium chloride dihydrate (>99%), 
sodium chloride (99.5%), sodium azide (99%), and cesium chloride (>99%) were 
purchased from Acros; ethanol (p.a.) was purchased from Merck; 
phenylmethanesulfonyl fluoride (PMSF) (≥98.5%), ethidium bromide (~95%), 
Orange G (≥80%), and dithiothreitol (DTT) (99%) were obtained from Sigma-Aldrich. 
Agarose (electrophoresis grade) was purchased from Invitrogen. All reagents used for 
SDS-PAGE electrophoresis were purchased from Bio-Rad Laboratories.  
 
Instrumentation 
UV/Vis spectroscopy was performed on a Varian Cary 50 spectrophotometer at room 
temperature using a 1 cm quartz cuvette (Hellma, light path: 1 cm). The reference 
spectra of the corresponding buffers were subtracted from all UV/Vis spectra. 
Fast protein liquid chromatography (FPLC) was performed on an Ettan Akta LC 
system equipped with a Superose 6 PC 3.2/30 column from Amersham Biosciences 
(flow rate 40 μL min−1). Injections (20-mL aliquots) of the samples on the FPLC 
column at room temperature were monitored by UV/Vis detection at 280 nm and 
260 nm. 
Transmission electron microscopy (TEM) micrographs were recorded on a JEOL JEM-
1010 instrument. Samples were prepared by drying a drop of the solution on a Formvar 
carbon-coated grid, which had been previously made hydrophilic by glow discharge. 
The excess buffer on the grid was blotted away after 1 min with filter paper. Negative 
staining of the samples was achieved by applying a drop of uranyl acetate solution 
(0.2% in MilliQ) onto the grid and blotting the excess liquid away after 15 s with filter 
paper. The samples were left to dry in air for 30 min before analysis. 
Gel electrophoresis. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed by using a 15% polyacrylamide gel containing 10% SDS. Samples were 
treated with β-mercaptoethanol and heated prior to loading onto the gel. Gels were 
stained with 0.05% (w/v) Coomassie Blue solution and destained with a solution of 5% 
(v/v) methanol and 7% (v/v) acetic acid in water (Coomassie Blue destainer). Agarose 
gel electrophoresis was performed by using gels with 1.25% agarose. To prepare the 
gels, agarose (1.5 g) was dissolved in TAE buffer (12 mL; 40 mM Tris-acetate, 1 mM 
disodium EDTA, pH = 8). Orange G was used as the sample buffer. The gel was run at 
100 mV (from cathode to anode), stained with 0.05% (w/v) Coomassie Blue solution, 
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and destained with 40% (v/v) methanol and 10% (v/v) acetic acid solution in water 
(complete Coomassie Blue destainer).  
Ultracentrifugation was performed using a Sorvall Micro (SM) ultracentrifuge (type 
RC-M150GX) with a S-120-AT2 type rotor. Thick-walled polycarbonate tubes 
(vol = 1 mL) provided by Sorvall were used. 
Dialysis was performed by using dialysis tubing (Spectra/Por 4, MWCO: 12–14 kD, 
Flat width: 25 mm) purchased from Spectrum Laboratories, and D-tube dialyzer 
(MWCO: 12–14 kD, volume: 1000–3000 uL) from Novagen. 
 
 Buffers 
The following aqueous buffers were used in the experiments: 
Virus buffer: 0.1 M sodium acetate, 0.001 M disodium EDTA, 0.001 M sodium azide, 
buffered at pH = 5.0 
RNA buffer: 0.05 M Tris-HCl, 0.5 M calcium chloride, 0.001 M dithiothreitol (DTT), 
buffered at pH = 7.5 
Clean buffer: 0.05 M Tris-HCl, >0.3 M sodium chloride, 0.001 M dithiothreitol (DTT), 
buffered at pH = 7.5 
 Capsid storage Buffer: 0.05 M sodium acetate, 1 M sodium chloride, 0.001 M sodium 
azide, buffered at pH = 5.0 
  
 Isolation of the CCMV coat protein 
A CCMV suspension (1–2 mL, c = 10 mg mL−1) in virus buffer was dialyzed against 
RNA buffer (1000 times excess in volume). After dialyzing overnight at 4°C the white 
precipitate of RNA was collected by ultracentrifugation. This was realized with the help 
of a Sorvall Micro ultracentrifuge and the S-120-AT2 Sorvall rotor (2 h at 47,000 rpm, 
T = 10°C, Acc/Decc = 9). The top three-quarters of the supernatant were removed with 
a micropipette and the yellow-white pellet containing precipitated RNA was discarded. 
The solution was then dialyzed against three changes of clean buffer (100–1000 times 
excess in volume, 3 h per change). The obtained dissociated protein, free of RNA, was 
associated into spherical particles by dialysis using the capsid storage buffer (100–1000 
times excess in volume, 3 h per change), and the protein was stored in this form at 4°C 
(no longer than 1 month) or dialyzed and used immediately, as explained in the next 
section. 
 
 Preparation of samples for assembly experiments 
Assembled CP in storage buffer was dissociated back to protein dimers before being 
used for the assembly studies. To this end the assembled protein was dialyzed against 
three changes of Tris-HCl buffer (100–1000 times excess in volume, 0.05 M, pH 7.5) 
(3 h per change) containing varying concentrations of NaCl, depending on the 
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requirements needed for the assembly experiments. Assembly studies were performed 
by bringing the CP dimer solution to the required conditions of pH and ionic strength by 
dialysis (100–1000 times excess in volume, 3 h per change). All buffers used in the 
disassembly and assembly studies contained 1 mM EDTA, 10 mM CaCl2, and 0.2 mM 
PMSF. 
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CHAPTER 5  
Structural Studies of CCMV and CCMV Capsid 
by Small-Angle Neutron Scattering and Dynamic 
Light Scattering 
 
5.1 Introduction 
 
 Virus assembly 
The three-dimensional structure of many spherical RNA viruses, such as the cowpea 
chlorotic mottle virus (CCMV) has been studied by different techniques including 
negative-staining electron microscopy (EM)[1] and X-ray crystallography.[2] In general 
CCMV is a well-studied virus and can be considered a model system for other spherical 
RNA viruses. CCMV with a diameter of 280 Å, swells at high pH in the absence of CaII 
ions, due to the repulsion between its carboxylate groups, while maintaining its overall 
structure. Under these conditions it displays pores 20 Å in diameter in its protein shell. 
The removal of RNA from CCMV and the reassembly of the empty capsid from the 
constituting coat proteins have been extensively studied under a variety of conditions 
such as pH and ionic strength, as is described in Chapter 4.[3-11] The capsid is an 
assembly of 180 identical protein units that assemble into stable dimers, which in turn 
organize themselves into a T = 3 structure of icosahedral symmetry, that is, a cluster 
with faces consisting of protein hexamers and pentamers. The removal of 25 to 34 
amino acids from the N-terminal part of the CCMV protein, which contains mainly 
basic residues, can occur spontaneously and may lead to a considerable heterogeneity of 
species in the capsid assembly.[12] Recently, we and others have started to explore the 
potential of the empty capsid,[13] which is a well-defined nanocapsule of homogeneous 
size (diameter 280 Å), as a scaffold for mineralization,[14-16] for the encapsulation of 
non-nucleic acid materials such as single enzyme molecules,[17] and synthetic polymers, 
for example, polyanethole sulfonate,[18] and polystyrene sulfonate (PSS).[19,20] 
Techniques such as X-ray crystallography, electron microscopy, gel filtration (e.g., fast 
protein liquid chromatography (FPLC)) and more recently mass spectrometry[21,22] and 
atomic force microscopy (AFM),[23,24] have proven to be valuable tools for the study of 
viruses and biohybrid assemblies of viruses. Although all of these techniques have 
yielded valuable and specific information, we felt that additional knowledge about the 
Chapter 5  
 
 
84 
size and shape of CCMV and the CCMV capsid might be obtained from solution 
scattering methods such as small angle neutron scattering (SANS) and dynamic light 
scattering (DLS).[25-28] In this chapter such SANS and DLS studies are described.  
 
 SANS 
SANS has been used to study the solution structure of biological macromolecules for 
over three decades. Since the measurements are performed in solution, SANS can 
provide unique structural information under conditions that more closely mimic the 
molecules’ natural environment than X-ray crystallography and non-cryogenic EM can 
do.[29,30] SANS also allows the effect of solution parameters such as pH and ionic 
strength to be assessed directly. Jacrot et al. were the first to study the protein–nucleic 
acid organization of a number of RNA viruses by SANS.[31] Their results confirmed the 
structure of the viruses obtained by other techniques, but furthermore provided a 
consistent set of data, from which low-resolution models could be built. It was 
concluded that there are differences between the viruses with respect to the degree of 
interpenetration of the RNA into the protein shells, related to the nature of the forces 
stabilizing the virus. Following this pioneering study, many other viral particles have 
been investigated by SANS,[32-40] of which the bromegrass mosaic virus (BMV)[41-43] is 
the virus most closely related to CCMV. 
SANS is a technique that is similar to other scattering techniques, which are often 
complementary, namely, small-angle X-ray scattering (SAXS) and light scattering (LS). 
In each of these techniques radiation is elastically scattered by a sample and the 
resulting scattering pattern, which is represented by the intensity as a function of the 
scattering angle (recalculated as the scattering vector q = (4π/λ)sin(θ/2) (Å-1)), is 
analyzed to provide information about the size and shape of the object. The type of 
radiation and the way in which this radiation interacts with matter are the main 
differences between these techniques. Light and X-rays are both scattered by the 
electrons surrounding the atomic nuclei, but neutrons are scattered by the nuclei 
themselves, a fact that has several important consequences.[30,44] The strength of the 
neutron–nucleus interaction varies completely irregularly with the atomic number Z; not 
even isotopes of the same element have the same neutron-scattering cross-section. The 
most significant isotopic variation is the one involving hydrogen and deuterium. The 
different scattering densities of these two isotopes is used in the so-called SANS 
“contrast variation method”.  
 
 The contrast variation method 
In complexes composed of two components with different neutron-scattering length 
densities, the scattering from one component can be separated from the other one by 
measuring the complex in water containing solvents with different H2O/D2O ratios 
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(Figure 5.1). This provides unique structural information about each individual 
component and the way the components interact with each other in the complex.[29,30] 
This method is very powerful for the investigation of the structure and dynamics of 
biological systems and related biomaterials.[45] Isotopic substitution of H for D is 
routinely used to change the scattering of a biomacromolecule without affecting its 
biochemistry. Often, this substitution is as simple as using D2O instead of H2O in the 
solvent to increase the contrast between the studied molecules and the solvent and to 
decrease the background due to the incoherent scattering by H. Because of the exchange 
of acidic protons with the solvent, water, the scattering length density of proteins and 
polynucleotides varies with the solvent (D2O/H2O) composition, whereas that of 
hydrocarbons like lipids and polystyrene (ρ = 1.42 × 10-14 cm Å-3) does not.[44] It can be 
concluded from Figure 5.1 that in 100% D2O, the contrast between solvent, protein, and 
hydrocarbon is optimal, whereas for RNA the contrast is better in 100 % H2O. 
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Figure 5.1 The average scattering density for various biological molecules as a 
function of the D2O concentration in the solution (adapted from the reference [46]). The 
crossing point of the water line with that of a solute is called the “matching” or 
isopicnic point.[30] The matching point corresponding to capsid protein and RNA are 
43% and 68% D2O/H2O, respectively. 
 
SANS, using the contrast variation method, can nicely complement X-ray 
crystallographic studies to provide low-resolution information on the radial distribution 
of protein and RNA in a virus, and the possible reorganisation that occurs upon swelling 
or disassembly of the virus. The method is generally applicable and allows a simple 
systematic comparison between viruses.[31]  
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The structure of CCMV and its assembly properties have been described in the previous 
chapters. The different states of CCMV and the CCMV capsid, depending on the pH 
and ionic strength, were characterized by using several techniques, such as FPLC and 
TEM, and the results are schematically represented in Scheme 5.1. In the present 
chapter we describe SANS studies on CCMV, which were carried out to see whether 
this technique would confirm the structural data obtained by other techniques and 
whether it would provide us with additional information about the CCMV structure. 
Subsequently, we have used SANS, including the contrast variation method, to analyze 
a biohybrid  assembly composed of the CCMV capsid and polystyrene sulfonate 
(PSS).[19] Furthermore, parallel to the SANS measurements, DLS studies have been 
performed to complement the SANS data and to support the postulated models. The 
combination of these two non-destructive techniques gives additional information about 
CCMV, its assembly properties, and the structure of the biohybrid particles. 
 
Scheme 5.1 Assembly pathway of CCMV and the CCMV capsid depending on the pH 
and ionic strength. 
 
 
5.2 Results and Discussion 
 
 CCMV and CCMV capsid assembly as studied by conventional techniques 
CCMV at pH 5 is a well-defined monodisperse particle of d = 28 nm as shown by TEM 
(Figure 5.2a). The swelling of the virus is clearly demonstrated by FPLC. The virus at 
pH 5 elutes at V = 1.1 mL, while at pH 7.5 a peak appears at a smaller elution volume, 
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corresponding to a larger particle (Figure 5.2b). The arrangement of the RNA chain 
within the virus particle and its interaction with the protein shell at pH 5 and 7.5, 
namely, for both the compact and swollen state, is not completely known. Studying the 
two states by SANS is therefore of high interest.  
 
a) b) 
 
Figure 5.2 a) Negative-staining TEM micrograph of the CCMV virus at pH 5 
(bar = 100 nm), b) FPLC of CCMV at pH 5 (compact form) and 7.5 (swollen form). 
 
As described in Chapter 4, the viral RNA can be removed from CCMV and the coat 
protein (CP) isolated. The latter can then be reassembled at pH 5 in the presence of 
NaCl to form the CCMV capsid, which has dimensions identical to those of the virus. 
The structure of the reassembled capsid is highly dependent on the pH and salt 
concentration, as can be concluded from the FPLC and TEM results depicted in Figure 
5.3. At pH 7.5 the capsid is mostly disassembled into protein dimers at salt 
concentrations between 0.2 and 1.0 M, whereas at pH 5 the salt concentration influences 
the assembly dramatically, in line with results from the literature (Figure 5.3a and 
c).[11,47] At low salt concentration (< 0.3 M NaCl), a rather polydisperse distribution of 
particles is obtained, containing different kinds of larger CP assemblies, that is, lamellar 
structures or larger capsids, which elute at V = 0.8 mL in the FPLC (Figure 5.3c and d). 
At high salt concentration (higher than c = 0.3 M), mainly well-defined capsids of 
d = 28 nm are formed, which, in TEM, show a larger cavity than the virus itself, 
presumably due to the absence of the RNA (Figure 5.3a and b). SANS and DLS are 
techniques that allow the direct study of these assemblies in solution at different pH 
values and salt concentrations while avoiding sample preparation steps.  
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a) b) 
c) 
 
d) 
 
 
Figure 5.3 FPLC chromatograms of the CCMV CP assemblies at 1 M NaCl (a) and at 
0.2 M NaCl (c), showing the traces at two different pH values. TEM micrographs (scale 
bar = 50 nm) corresponding to each of the samples at pH 5 at 1 M NaCl (b) and at 
0.2 M NaCl (d). 
 
 Effect of D2O on virus and capsid 
As described in the Introduction, the presence of D2O improves the contrast and 
therefore the information obtained from the SANS data. In order to be able to perform 
the SANS studies properly, it was felt necessary to study the influence of D2O on the 
assembly behavior of CCMV and the CCMV capsid. The effect of D2O was studied by 
FPLC and the results are shown in Figure 5.4. In the case of the CP (Figure 5.4a and b), 
the samples eluted at exactly the same time, which shows that the change from 
hydrogen to deuterium does not really affect the structure of the particles. However, in 
the case of the virus (Figure 5.4c and d), we observed that the D2O solutions tended to 
elute later, although the difference was small. The appearance of the particles in TEM 
appeared not to be affected (not shown). The delayed elution would suggest a decrease 
in particle size in D2O, but this is not confirmed with the SANS studies (see below). 
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a) 
 
b) 
 
c) 
 
d) 
 
Figure 5.4 FPLC chromatograms of CCMV CP at a) pH/pD 5 and b) pH/pD 7.5, and 
CCMV at c) pH/pD 5 and d) pH/pD 7.5, showing traces for both H2O and D2O 
solutions. The samples containing capsid protein contained 1 M NaCl whereas those 
containing CCMV contained no NaCl. 
 
 Interpretation of SANS 
It has recently been demonstrated that small-angle scattering (X-ray) data can be 
simulated with the help of the coordinates of the protein structure, for example, as 
determined by X-ray crystallography.[40] Such coordinates are available for the CCMV 
protein,[2] but not for the RNA and the polymer (see below) included in the viral cage. 
In our simulations of the SANS data we therefore approximated the virus structure by 
assuming that protein, polynucleotide, or polymer, and solvent shells were present with 
constant average scattering density lengths. The data was simulated with crude models 
and the parameters were subsequently refined with the programme FISH[48] to give the 
best agreement with the experimental traces. In this way the optimum values for 
parameters such as the radius of the particles and the size of the steps in the contrast in 
the scattering length densities can be determined. In this approximation, the shapes of 
the virus and capsid are approximated by spheres, although the virus is known to have a 
more complex symmetry, namely, that of an icosahedron. The first model to be applied 
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was a core–shell model, which is characterized by a core with a certain scattering length 
density ρ1 (most probably solvent with encapsulated molecules) and a shell with inner 
and outer diameter r1 and r2 and scattering length density ρ2 (capsid protein, with an 
RNA and/or polymer component), surrounded by a solvent region with scattering length 
density ρ3 (Scheme 5.2a and c). In this model, the ρ2/ρ3 contrast step was always 
assumed to be that between protein and solvent (Δρ = 3.25 for protein/D2O), but the 
step ρ1/ρ2 was not fixed in the refinement, to see if the scattering length density of the 
core could be identified as solvent, RNA, polymer, or a mixture of these. A selected set 
of samples were refined with a more complex model (Scheme 5.2b and d) in which the 
core was surrounded by an inner and outer shell of different constant scattering length 
density. In these cases, the outer shell was always assumed to be protein, and the 
contrast step ρ3/ρ4 was chosen accordingly, whereas the inner shell could be RNA, 
polymer, or dilute (“wet”) protein. The scattering curves are presented as the logarithm 
of the scattered intensity (log (I)) versus the scattering vector (q). This highlights the 
characteristic features at low q, but also amplifies the experimental noise at high q. The 
high q part of the scattering curve is used only to estimate the level of background 
scattering that should be incorporated in the simulation. 
a)                                                                         b) 
 
c) 
 
d) 
 
Scheme 5.2 Schematic scattering length densities in a, c) core–shell and b, d) core–2-
shell models. In b), the dashed lines from top to bottom indicate the levels of 68, 43, and 
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0 % D2O, where the solvent scattering length densities match those of RNA, protein, 
and H2O, respectively (see also Figure 5.1). 
 
In the next sections we will first discuss the effect of contrast variation in SANS studies 
on CCMV, followed by a core–shell interpretation of the scattering data of the virus at 
different pH values. Subsequently, the SANS results of the CCMV capsid at various salt 
concentrations and pH values using this same model, along with complementary DLS 
studies, will be discussed and compared with the data obtained for the virus. Finally, we 
will discuss core–2-shell models to interpret the neutron-scattering data of the virus, the 
empty capsid, and the capsid loaded with polystyrene sulfonate. 
 
 SANS and DLS studies on CCMV. The contrast variation method 
The results for the contrast variation studies on CCMV are shown in Figure 5.5. The 
parameters derived from the simulations are given in Table 5.1. It can be seen that 
CCMV gives a scattering curve typical for a (near-)spherical particle such as a virus.[31] 
Solutions of virus in 43 and 68% D2O were prepared to eliminate either the protein or 
the RNA contribution, respectively (see Figure 5.1).[31] At 68% a curve similar to that 
for 100% D2O is obtained, as expected for the protein capsid; even the curve at 0% 
D2O, where the contrast for RNA is expected to be larger than that for protein, 
resembles that in 100% D2O. This apparent resemblance is corroborated by the 
similarities in the outer radii obtained from the refined simulations, which are between 
r2 = 130 and 135 Å. The values found at the 68% D2O level, where the RNA 
contribution is matched, are r = 104.14 and 130.06 Å for the inner and outer radii, 
respectively; this is in good agreement with the values found in the crystallographic 
study (average interior radius 104 Å, outer radius between 120 and 142 Å).[2] At 43% 
D2O, where the contrast is expected to be optimal for RNA, the scattering curve is not 
well defined. This implies that the RNA structure is disordered to an extent that it 
cannot be approximated by a shell of the scattering length density of RNA, nor by any 
other simple structure. When a simulation was attempted, the outer radius refined to 
approximately the same value as that found for the protein shell, which suggests that a 
residual contrast for the protein contribution is being fitted rather than a genuine RNA 
contribution. In other viruses studied by SANS, some of which are closely related to 
CCMV, an RNA shell was clearly present.[31]  
In a combined X-ray crystallography/EM study on CCMV in the literature,[2,18] it was 
found that the regions where the electron density of the RNA is well defined are close to 
the inner surface of the virus. Under the circumstances (100, 43, 0% D2O) where the 
contrast is not optimized for the protein, the inner radius is significantly smaller than 
that found for 68% D2O and the outer radius slightly larger; this indicates that in these 
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cases the innermost part, and even some of the outermost part, of the apparent protein 
shell has a high RNA content. Interestingly, in the case of 100 and 0% D2O, the contrast 
step ρ1−ρ2 for the inner radius of the shell does not refine to the contrast step ρ2−ρ3 for 
the outer shell, which is fixed. This suggests that the core does not consist of pure 
buffer, but contains a significant amount of material with a higher scattering length 
density, namely, RNA. For 68% D2O, where the contrast of the solvent is matched to 
that of RNA, ρ1−ρ2 refines almost to the value fixed for ρ2−ρ3, indicating a near-perfect 
match of the scattering length density of the core with that of the solvent; this is another 
indication that the core contains some “wet” RNA. The issue of the localization of the 
RNA in the virus is further discussed in the core–2-shell simulations section (see 
below). As the CCMV was found to give a better contrast in D2O than in H2O, it was 
decided to perform all further studies of the virus and capsid in D2O. 
 
Table 5.1 Simulations (core–shell model; r, radius; ρ, contrast (10-14 cm Å-3), PD, 
polydispersity) of SANS data obtained from experiments with CCMV in solutions of 
varying D2O/H2O composition. 
D2O/H2O 
(v/v)a) 
Expected 
contrast 
(see Figure 5.1) 
ρ1−ρ2 r1 (Å) Δr (Å) r2 (Å) 
ρ2−ρ3 
(fixed) 
PD 
(%) 
100/0 protein>RNA 2.75 95.05 39.57 134.61 −3.25 4.09 
68/32 protein 1.31 104.14 25.92 130.06 −1.33 3.59 
43/57b) RNA −1.33 91.84 40.75 132.58 +1.33 15.69 
0/100 RNA>protein −2.69 61.22 74.12 135.34 +3.66 23.52 
a) Buffer: pH 5, 50 mM sodium acetate.  
b) Data not fitted; simulation of core shell with low contrast and high polydispersity. 
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Figure 5.5 SANS curves (dotted lines) of CCMV in solutions of varying D2O/H2O 
composition (buffer: pH 5, 50 mM sodium acetate) simulated (solid lines) with the 
parameters in Table 5.1. Top to bottom: 100, 68, 43, and 0% D2O. 
 
 Swelling of CCMV  
In a separate set of SANS experiments with a new sample, the pH-dependent swelling 
of the virus was studied in detail. The results are shown in Figure 5.6 and the 
parameters of the corresponding simulations in Table 5.2. Although attention was taken 
to ensure the same experimental conditions of 100% D2O was applied to the previous 
and present set of experiments, differences in r2 and the PD were obtained (compare 
Table 5.1 and Table 5.2). The observed <2% deviation should be noted but is likely to 
be a result of the experimental settings and since data sets within one series of data 
collections are compared, it is not likely to be of significant influence on the 
interpretation of the SANS results. 
Under the conditions mentioned in Table 5.2, the swelling of CCMV was detectable by 
SANS, as is the case for other viruses,[35,43,49] as a shift in the position of the subsidiary 
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maxima to lower q, indicating an increase in the virus radius. This increase (131.35 to 
137.12 Å for the outer radius, 95.67 to 101.18 Å for the inner radius) is smaller (4.3% 
for outer, 5.8% for inner radius) than the 10% swelling observed in earlier X-ray 
crystallography/EM studies.[2] Complementary DLS results, which we performed and 
are shown in Figure 5.7, also indicated a larger swelling (152.85 to 172.95 Å) than that 
derived from the SANS data. 
Table 5.2 Simulations (core–shell model; r, radius; ρ, contrast; PD, polydispersity) of 
SANS data obtained from experiments on CCMV at different pH values. 
Experimenta) Expected resultb) ρ1−ρ2 r1 (Å) Δr (Å) r2 (Å) ρ2−ρ3 
(fixed) 
PD (%)
pD 7.5 Swollen virus 2.81 101.18 35.95 137.12 −3.25 7.05 
pD 5 Virus, d = 280 Å  2.80 95.67 35.68 131.35 −3.25 6.27 
a) Buffers: pD 5, 50 mM sodium acetate; pD 7.5, 50 mM Tris-HCl.  
b) Expected on the basis of complementary studies in H2O. 
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Figure 5.6 SANS curves (dotted lines) of experiments performed with CCMV in 100% 
D2O at different pH values. The solid lines are simulated curves with the parameters in 
Table 5.2. Top virus at pD 7.5, bottom virus at pD 5.0. 
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Figure 5.7 Size analysis of DLS patterns obtained  for CCMV in H2O, at pH 5.0 
(50 mM sodium acetate) and at pH 7.5 (50 mM Tris-HCl).  
 
 SANS and DLS studies on the CCMV coat protein at 0.3 M NaCl 
SANS experiments on the CCMV capsid, which is expected to dissociate into CP 
dimers at higher pH, were initially performed at a salt concentration of 0.3 M NaCl. The 
results are depicted in Figure 5.8, and the parameters of the corresponding simulations 
are presented in Table 5.3.  
At pH 5, the capsid has a thinner shell than the virus and it has a slightly larger and 
shorter inner and outer radius, namely, 99 and 131 Å, respectively. This result is quite 
close to that obtained for the virus at optimum protein contrast (Figure 5.5); the 
structure of the remaining protein shell is the same when in the simulations the 
contribution of the RNA to the scattering is minimized either by removing it or by 
matching the solvent scattering length density. In the case of the virus, as noted in the 
contrast study, the contrast step ρ1−ρ2 for the inner radius of the shell does not refine to 
the contrast step ρ2−ρ3 for the outer shell, which suggests the presence of some 
dissolved RNA in the core of the virus (Table 5.1). For the capsid, however, at pH 5 and 
6.5, ρ1–ρ2 refines to almost the same value as fixed for ρ2−ρ3, suggesting that the core 
contains pure solvent, as expected. 
At higher pH, a tendency of the maxima in the scattering curve to shift to higher q 
values was observed, indicating a decrease in particle diameter. Concomitant with this 
shift, smearing, which indicates a higher polydispersity, was found. The results of the 
simulations reflected this decrease in particle radius and the values (pH 5, 131 Å; 
pH 6.5, 115 Å, pH 7.5, 85 Å) would point to the occurrence of capsids with T = 3 (180 
protein units), “T = 2” (120 units) and T = 1 (60 units) icosahedral symmetry, 
respectively (see Chapter 2 and Appendix).[12] Such a result would be unprecedented, 
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since all other results (see above) point to a dissociation of the capsid at high pH into 
CP dimers and not to the formation of “T = 2” and T = 1 particles. The only report in 
the literature[18] that might be relevant for the present study suggests a swelling of the 
capsid not a shrinking. We decided therefore to investigate the samples by DLS to 
determine if smaller particles were present or not.  
 
Table 5.3 Simulations (core–shell model; r, radius; ρ, contrast; PD, polydispersity) of 
SANS data obtained from experiments on CCMV CP at different pH values (0.3 M 
NaCl).  
Experimenta) Expected 
resultb) 
ρ1−ρ2 r1 (Å) Δr (Å) r2 (Å) ρ2−ρ3 
(fixed) 
PD 
(%) 
pD 5 Capsid 
d = 280 Å  
3.07 99.41 31.94 131.35 −3.25 7.54 
pD 6.5 (no data) 3.17 92.02 22.47 114.49 −3.25 13.38
pD 7.5c) CP dimers 3.63 67.44 17.30 84.75 −3.25 23.52
a) Buffers: pD 5, 50 mM sodium acetate; pD 6.5, 50 mM ammonium acetate; pD 7.5, 
50 mM Tris-HCl. Buffers contained 0.3 M NaCl. 
b) Expected on the basis of complementary studies in H2O. 
c) Core–shell model not applicable. 
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Figure 5.8 SANS curves (dotted lines) for the CCMV capsid (0.3 M NaCl) in 100% 
D2O. The solid lines are curves simulated with the parameters in Table 5.3. Top to 
bottom: capsids at pD 5.0, 6.5, and 7.5. 
 
The results of the DLS measurements on the CCMV capsid at 0.3 M NaCl are presented 
in Figure 5.9. At pH 5, the capsid shows a close to perfect homogenous size 
distribution, in line with the EM data and the SANS results. The hydrodynamic radius 
determined from DLS (r = 192.1 Å) is somewhat larger than the 130–135 Å value found 
with SANS for the outer radius of the protein shell. At pH 6.5, a bimodal distribution is 
found by DLS, with maxima at diameters of about 80 and 300 Å, indicating the 
coexistence of whole T = 3 capsids and CP dimers. However, because the curve was not 
corrected for the fact that the DLS intensity is proportional to the size of the object 
(I α d3), it can be concluded that the solution contains mainly CP dimers, whereas the 
core–shell simulation for the corresponding SANS would indicate the presence of 
capsids with a diameter of 230 Å. It has to be noted that the polydispersity in the SANS 
simulation refines to a relatively high value (13.38%). This might be an indication that 
the SANS sample also in fact has a bimodal distribution. This is difficult to establish 
since the contribution of the CP dimers to the SANS curve is not as easy to predict as 
that of a near-spherical capsid particle. At pH 7.5, the DLS pattern showed a bimodal 
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distribution and again we assume that the solution contains mainly CP dimers (d = 70–
90 Å). This agrees with the results obtained by size-exclusion chromatography (SEC), 
whereas the core–shell simulation of the SANS data suggested the presence of particles 
with a diameter of 170 Å, albeit with an ever higher polydispersity (23.52%) than the 
assembly of particles at pH 6.5. Again it is difficult to decide whether the SANS results 
at this pH should also be interpreted with a bimodal distribution. An indication that the 
SANS simulations are problematic in this case is the fact that ρ1−ρ2 refines to a higher 
absolute value than the one fixed for ρ2−ρ3, which is physically not realistic. 
 
From the results presented above it can be concluded that the SANS and DLS studies at 
0.3 M NaCl are not very conclusive. pH/Ionic strength phase diagrams based on EM 
studies in the literature[11,47] have shown that an ionic strength of 0.3 M NaCl is at an 
experimental condition where the T = 3 capsids may be converted to multilamellar 
capsids at low pH and the dimers to tubes at high pH. Hence at this ionic strength the 
coexistence of various species is very likely, and this is not a favorable starting point for 
the interpretation of the SANS experiments. We decided therefore to continue our 
studies at an ionic strength of 1 M NaCl, where T = 3 capsids and CP dimers are 
expected to exist at low and high pH, respectively. For the experiments with polystyrene 
sulfonate (PSS) (see below), a salt concentration of 0.5 M NaCl was chosen in line with 
the conditions reported in literature.[19,20] 
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Figure 5.9. pH dependence of the DLS patterns obtained for the CCMV CP in 100% 
H2O, 0.3 M NaCl. Buffers: a) pH 5, 50 mM sodium acetate ;b) pH 6.5, 50 mM 
ammonium acetate, and c) pH 7.5, 50 mM Tris-HCl.  
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 SANS and DLS studies on the CCMV capsid at high salt concentration 
The SANS results for the capsid at high salt concentration, that is, 1 M NaCl, at pH 5.0 
and 7.5 are shown in Figure 5.10, with the corresponding parameters derived from the 
refined simulations in Table 5.4. At pH 5 and 1 M NaCl, the empty capsid is 
comparable in size to that of the virus, although its outer diameter appears to be 
significantly reduced. The SANS curve of the empty capsid at pH 7.5 is almost 
featureless and attempts to simulate it on the basis of a core–shell model gave unreliable 
results, which is clear from the high polydispersity and the anomaly in the contrast 
steps. This strongly indicates that the capsid, unlike the virus, does not swell at high pH, 
but instead dissociates into particles that are too small to be observed by SANS, 
presumably CP dimers. This is consistent with the observations described in Chapter 4.  
 
Table 5.4 Simulations (core–shell model; r, radius; ρ, contrast; PD, polydispersity) of 
SANS data obtained from experiments on CCMV CP at different pD values (1 M NaCl).  
Experimenta) Expected resultb) ρ1−ρ2 r1 (Å) Δr (Å) r2 (Å) ρ2−ρ3 
(fixed) 
PD (%)
pD 5 Capsid d = 280 Å 3.23 94.75 33.22 127.98 −3.25 8.83 
pD 7.5c) CP dimers 3.74 54.37 7.42 61.80 −3.25 31.11 
a) Buffers: pD 5, 50 mM sodium acetate; pD 7.5, 50 mM Tris-HCl. Capsid buffers 
contained 1 M NaCl. 
b) Expected on the basis of complementary studies in H2O. 
c) Core–shell model not applicable. 
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Figure 5.10 SANS curves (dotted lines) of the CCMV capsid (1 M NaCl) in 100% D2O. 
The solid lines are simulated curves using the parameters in Table 5.4. Top capsid at 
pD 5.0, bottom capsid at pD 7.5. 
 
In order to better compare the SANS results at high and low salt concentrations and to 
obtain more information it was decided to carry out additional experiments at an NaCl 
concentration of 0.2 M. The results for the capsid at pH 5 and at the various salt 
concentrations are compared in Table 5.5 and in Figure 5.11. When the salt 
concentration is lowered, a decrease in the shell width of the capsid (Δr) is observed and 
an increase in the outer radius (r2). This is in agreement with what was observed in 
Chapter 4 and is shown in Figure 5.3, that is, that high salt concentrations stabilize the 
formation of monodisperse T = 3 capsids at pH 5, whereas low salt concentrations 
induce the formation of larger assemblies.  
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Table 5.5 Simulations (core–shell model; r, radius; ρ, contrast; PD, polydispersity) of 
SANS data obtained from experiments on CCMV CP at pD 5 and different salt 
concentrations.a) 
NaCl (M) ρ1−ρ2 r1 (Å) Δr (Å) r2 (Å) ρ2−ρ3 
(fixed) 
PD (%) 
1 3.23 94.75 33.22 127.98 −3.25 8.83 
0.3 3.07 99.41 31.94 131.35 −3.25 7.54 
0.2 2.84 114.00 21.76 135.76 −3.25 13.04 
   a) Buffer: pH 5, 50 mM sodium acetate. 
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Figure 5.11 SANS curves (dotted lines) of the CCMV capsid in 100% D2O, pD 5, at 
different salt concentrations. The solid lines are curves simulated with the parameters 
in Table 5.5. Top to bottom: 1, 0.3, 0.2 M NaCl. 
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Since the SANS data for the sample containing 0.2 M NaCl could not be fitted very 
well, we also performed DLS experiments at this ionic strength. In Figure 5.12 the DLS 
results for the various salt concentrations are compared. The DLS data shows the same 
trend as the SANS results, except that the capsid diameter shows a clearer increase in 
size, namely, from 289.9 to 384.2, and further to 490.9 Å, going from 1 to 0.3 and then 
to 0.2 M NaCl. Unexpectedly, in the DLS analysis all samples seem to have a highly 
monodisperse size distribution, opposite to what was observed by TEM (Figure 5.3). In 
the latter case, at low salt concentrations a mixture of species with different shapes and 
dimensions was observed. A possible explanation is that low salt concentrations weaken 
the interactions between the protein subunits, inducing the formation of larger capsids 
with thinner shells that are more susceptible to disassembly. During the sample 
preparation for TEM imaging, this might result in damage and the generation of a 
variety of species. DLS analysis of CCMV CP at pH 5 containing an even lower 
concentration of salt (0.1 M NaCl) did show a highly polydisperse mixture of species of 
different sizes that were not stable over time. After several minutes a clear scattering 
curve could no longer be observed and a white precipitate was formed. This points to 
the formation of large assemblies which, as we checked, were undetectable by FPLC, 
since their size was beyond the exclusion limit of the FPLC column (Superose 6). 
 
 
Figure 5.12 DLS curves of CCMV CP at pH 5 and at different salt concentrations. 
a) 0.2 M NaCl, b) 0.3 M NaCl, and c) 1 M NaCl. 
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 SANS core–2-shell simulations for CCMV and CCMV capsid  
The core–shell model used for the interpretation of the SANS experiments so far has led 
to satisfactory simulations for the virus and the capsid under various circumstances, and 
has given interesting information on the size of the shell, which is dominated by the 
capsid protein. As for the RNA component of the virus, it has given only indirect 
information, derived from the differences in the thickness and volume of the shell, and 
the discrepancy in the inner and outer contrast steps. It was considered to be of interest 
to see if the RNA structure could be defined better by simulating the SANS data with a 
core–2-shell model, consisting of a core, a weakly scattering inner shell (presumably 
containing dilute RNA and/or protein), and a more strongly scattering outer shell 
consisting of protein (Scheme 5.2b). 
In Figure 5.13, the experimental traces and the core–2-shell simulations of the SANS 
data for CCMV and the CCMV capsid are compiled together with the results obtained 
for capsids with encapsulated PSS (see next section). The corresponding parameters are 
given in Table 5.6, and the corresponding radial scattering length density profiles for 
CCMV, CCMV capsid, and one of the CCMV capsid-PSS samples in Figure 5.14. 
For the virus (Figure 5.13, Figure 5.14, and Table 5.6), the outcome of the core–2-shell 
simulation approach is a weakly (ρ1,2 = −0.59) scattering inner shell (40–100 Å) and an 
outer protein shell (100–130 Å). The latter has an outer diameter that is virtually 
identical to that found in the core–shell simulation (Table 5.2), but the inner diameter is 
approximately 5 Å larger. The weakly scattering inner shell can be interpreted as being 
the result of a dilute solution of RNA bound to the inner surface of the capsid protein.  
Table 5.6 Simulations (core–2-shell model; r, radius; ρ, contrast; Δ, thickness; PD, 
polydispersity) of SANS data of the experiments shown in Figure 5.13.  
Sample r1 ρ1,2 Δinner r2 ρ2,3 Δouter r3 ρ3,4 PD 
V 5 40.53 −0.59 59.80 100.33 −2.66 29.83 130.16 3.25 6.28 
V 7.5 44.96 −0.58 62.16 107.12 −2.67 28.40 135.52 3.25 7.10 
C 5 84.25 −0.71 15.98 100.23 −2.54 26.32 126.55 3.25 9.04 
P 10 49.85 −5.20 21.82 71.67 +1.95 11.53 83.20 3.25 15.72 
P 2 51.36 −4.74 15.46 66.82 +1.49 10.14 76.96 3.25 17.50 
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Figure 5.13 SANS curves (dotted lines) of various CCMV and CCMV capsid samples in 
100% D2O and pD 5. The solid lines are simulated curves using the parameters in 
Table 5.6. Top to bottom: V 5, V 7.5, C 5, P 10, and P 2. 
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Figure 5.14. Scattering length density profiles derived from the core–2-shell 
simulations carried out on SANS data obtained for (top) CCMV, (middle) CCMV 
capsid, and (bottom) CCMV capsid loaded with PSS. 
 
Analysis of the pH-induced swelling of the virus by the core–2-shell model (compare 
V5 and V7.5 in Figure 5.13 and Table 5.6) reveals that the aqueous core and the wet 
RNA shell increase by approximately 4 and 2 Å in diameter and thickness, respectively. 
The thickness of the protein shell decreases slightly but its volume still increases 
somewhat because of the increase in diameter. Presumably, the basic N-terminal part of 
the capsid protein, the electron density of which is not well defined in the crystal 
structure,[2] plays a role in the binding of the RNA. Interestingly, simulation of the 
CCMV capsid with the core–2-shell model (Figure 5.13, Figure 5.14, and Table 5.6) 
reveals the presence of a thin (10–15 Å) weakly scattering inner shell, which could be 
protein. The protein nature of this inner shell is corroborated by the finding that the 
core–2-shell analysis of the empty capsid (0.3 M NaCl) gives the same outcome for 
measurements performed at 68 (protein contrast selected) and 100% D2O (Figure 5.15 
and Table 5.7). 
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Table 5.7 Simulations (core–2-shell model; r, radius; ρ, contrast; Δ, thickness; PD, 
polydispersity) of SANS data of the experiments shown in Figure 5.15. 
Experiment r1 ρ1,2 Δinner r2 ρ2,3 Δouter r3 ρ3,4 PD 
pD 5  
0.3 M NaCl 
95.28 −1.42 9.38 104.66 −1.66 26.28 130.94 3.25 7.56 
pD 5 
68%D2O, 
0.3 M NaCl 
92.12 −0.57 9.07 101.19 −0.74 28.87 130.06 1.33 10.13 
 
 
 
Figure 5.15. SANS curves (dotted lines) of CCMV and the CCMV capsid at pD 5.0. The 
solid lines are simulated with the parameters shown in Table 5.7. Top CCMV capsid, 
100% D2O, 0.3 M NaCl; bottom CCMV capsid, 68% D2O, 0.3 M NaCl. 
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 SANS studies on CCMV capsid loaded with PSS by using a core–2-shell model 
In our group, Sikkema et al. have demonstrated that the self-assembling properties of 
CCMV CP lacking part of its N terminus can be employed to create a monodisperse 
160 Å T = 1 icosahedral nanoparticle upon encapsulation of a disperse polymer at 
pH 7.5.[19] 
For the analysis of the SANS data of the capsid with encapsulated PSS,[19] it turned out 
that a core–2-shell model approach was vital; these data, therefore, were simulated with 
a core–2-shell model where the inner shell was a strongly scattering polymer shell and 
the outer shell a comparatively weakly scattering protein shell. In the initial simulations 
of this type, the contrast steps were restrained so that ρ1−ρ2 and ρ2−ρ3 steps together 
were equal to the ρ3−ρ4 step (which is the protein/D2O contrast step, Scheme 5.2), and, 
in the case of the capsid–PSS system, the ρ2–ρ3 and ρ3–ρ4 steps together were equal to 
the ρ1–ρ2 step. This situation was kept in the final simulations, in which such restraints 
were removed, indicating that the core–2-shell simulations adequately describe a 
situation where the scattering length density of the core (ρ1) is equal to that of the 
surrounding solvent (ρ4). In Figure 5.13, the experimental traces and the core–2-shell 
simulations of the SANS data for capsids with encapsulated PSS are shown. The 
corresponding parameters are given in Table 5.6, and the corresponding radial scattering 
length density profile of one of the CCMV capsid-PSS samples in Figure 5.14. 
The SANS experiments show that the incorporation of the PSS in the CCMV capsid 
leads to much smaller and much more polydisperse particles than is the case for the 
virus and capsid (Figure 5.14); the outer radii calculated for the two samples (P10 and 
P2) are in the 75–85 Å range and the polydispersities range from 15 to 18%. This is in 
line with the earlier conclusion from EM and DLS that the incorporation of PSS 
presumably leads to the formation of T = 1 rather than T = 3 capsids.[19] The SANS data 
allow us to define the polymer and protein shells more precisely. There is an inner 
solvent core with a radius of around 50 Å. This core is surrounded by a polymer shell of 
15 Å in the case of the PSS of molecular weight Mr 2000 (P2), and 22 Å for the PSS of 
molecular weight Mr 10,000 (P10), and a protein shell of 10 Å in both cases. 
Interestingly, the PSS appears to have a much stronger effect on the capsid structure 
than RNA; a more condensed structure than the original virus appears, which, however, 
still has a well-defined but thinner shell of protein with a smaller outer diameter. 
 
 
5.3 Conclusion  
 
SANS has allowed us to study the CCMV structure in solution under various pH and 
salt concentration conditions. The optimum contrast was achieved in D2O buffers, and 
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the protein component could be defined as a separate shell in the core–shell simulations 
(outer radius 130 Å). Only indirect information could be obtained on the way the RNA 
molecules are arranged in the virus. There are parts of RNA intercalated with the 
protein shell and even parts protruding from the protein shell to the outside of the virus, 
and there is dilute “wet” RNA associated with the inside of the protein shell. 
Complementary DLS studies were performed in cases for which a bimodal size 
distribution was obtained. The expected swelling of the virus upon changing the pH 
from pH 5 to 7.5 was detectable, but not as strong as the 10% swelling derived from 
DLS, EM, and X-ray crystallography. The empty capsid was of a size comparable to 
that of the virus (marginally smaller), and was found to dissociate into dimers upon 
increasing the pH. Incorporation of PSS in the CCMV capsid led to the formation of 
smaller capsids (outer radius 80 Å) corresponding to T = 1 geometry, with a solvent 
core, a polymer inner shell, and a protein outer shell.  
 
 
5.4 Experimental Section 
 
 Materials 
Sodium acetate trihydrate (>99%) and uranyl acetate dihydrate (≥98%) were purchased 
from Fluka. Ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate (>99%), 
tris(hydroxymethyl)aminomethane (Tris) (>99%), calcium chloride dihydrate (>99%), 
sodium chloride (99.5%), and sodium azide (99%) were purchased from Acros. 
Phenylmethanesulfonyl fluoride (PMSF) (≥98.5%) and dithiothreitol (DTT) (99%) were 
obtained from Sigma-Aldrich.  
 
 Instrumentation 
UV/Vis spectroscopy was performed on a Varian Cary 50 spectrophotometer at room 
temperature using a 1 cm quartz cuvette (Hellma, light path: 1 cm). The reference 
spectrum of the corresponding buffers were subtracted from all UV/Vis spectra. 
Fast protein liquid chromatography (FPLC) was performed on an Ettan Akta LC 
system equipped with a Superose 6 PC 3.2/30 column from Amersham Biosciences 
(flow rate 40 μL min−1). Injections of 20 mL aliquots of the samples on the FPLC 
column at room temperature were monitored by UV/Vis detection at 280 and 260 nm. 
Transmission electron microscopy (TEM) micrographs were recorded on a JEOL JEM-
1010 instrument. Samples were prepared by drying a drop of the solution on a Formvar 
carbon-coated grid, which had been previously made hydrophilic by glow discharge. 
The excess buffer on the grid was blotted away after 1 min with filter paper. Negative 
staining of the samples was achieved by applying a drop of uranyl acetate solution 
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(0.2% in MilliQ) onto the grid and blotting the excess liquid away after 15 s with filter 
paper. The samples were left to dry in air for 30 min before analysis. 
Dialysis was performed by using dialysis tubing (Spectra/Por 4, MWCO: 12–14 kD, 
Flat width: 25 mm) purchased from Spectrum Laboratories, and D-tube dialyzer 
(MWCO: 12–14 kD or 6–8 kDa, volume: 1000–3000 µL) from Novagen. 
Dynamic light scattering (DLS) measurements were carried out on native CCMV or 
coat-protein solutions at different pH and/or salt concentrations. The concentration 
ranged from 0.16 to 1.6 mg mL−1 for the CCMV samples and from 0.13 to 1.3 mg mL−1 
for the CP samples. The acquisition was performed at 15 °C at an angle of 173° 
(backscattering mode) with a Zetasizer Nano S from Malvern using a 4mW He-Ne laser 
at 633 nm. Analysis of the data was performed using the Nano DTS v.5.10 software. 
Reported values and graphs have been selected from the experiments in an equilibrium 
state, that is, when no further change was observed after one day.  
SANS measurements were performed using a 12 mm diameter neutron beam on the 
LOQ beam line at the ISIS pulsed neutron source (CCLRC Rutherford-Appleton 
Laboratory, Didcot, UK). LOQ uses pulses of neutrons of wavelengths between 2.2 Å 
and 10 Å which are separated by time-of-flight and detected by a 64 × 64 cm, two-
dimensional detector at 4.1 m from the sample. Wavelength-dependent corrections were 
made to allow for the incident spectrum, detector efficiencies, and measured sample 
transmissions to create a composite SANS pattern (see reference [50] for a more 
detailed description). This gives a scattering vector q = (4π/λ) sin (θ/2) in the range of 
q = 0.010−0.028 Å-1. Comparisons with scattering from a partially deuterated 
polystyrene standard allowed absolute scattering cross sections to be determined with an 
error of ± 2.0%. Quartz cuvettes with a light path of 2 mm (type 110-QS, Hellma) were 
used to perform most SANS measurements, except the the swelling studies, in which 
case banjo cells (disk shape cells, 12 mm) were used. Cuvettes of 1 mm light path were 
used for samples containing H2O.  
SANS data analysis.  
The SANS scattering curves were simulated with crude models based on a core–shell or 
a core with 2 shells, as described in the text and Scheme 5.2, using the SANS simulation 
programme FISH.[48] The parameters were refined to give the best agreement with the 
experimental traces, to extract the optimum values for parameters such as the radius of 
the particles and the size of the steps in the contrast in the scattering length densities. 
 
 Isolation of CCMV and CCMV CP  
The purification of the CCMV and the CCMV CP isolation was performed as described 
in Chapters 3 and 4. The approximate concentrations of the virus and the capsid in the 
initials stock solutions were c = 10–15 mg mL−1 and c = 4–8 mg mL−1, respectively. 
Two different sets of SANS experiments were performed by using two different virus 
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and capsid batches. The concentrations were intended to be as similar as possible within 
the range described above. 
 
 Preparation of CCMV and CCMV capsid samples under different pH and ionic 
strength conditions 
To prepare the SANS samples, different aliquots of CCMV and CCMV capsid stock 
solutions (V ≈ 500 µL) were dialyzed against the corresponding buffer in H2O (see 
buffer conditions in Table 5.8). Part of these solutions was kept for analysis of the 
samples in H2O and the rest was dialyzed against the same buffer prepared in D2O. In 
all cases, the samples were dialyzed against a minimum of two changes of buffer 
(V ≈ 400 mL; 3 h per change). The background solutions were taken from the last 
dialysis buffer after the last change, to have exactly the same H2O/D2O ratio in the 
sample and in the background solution. For those buffers containing D2O, the pH was 
corrected and corresponded to pD = pH + 0.3314 n + 0.0766 n2, in which n is the 
volume fraction of D2O and pH is the pH meter reading.[35] Buffers and samples were 
stored at 4 °C and the dialyses were performed in a cold room at 4 °C. 
 
Table 5.8 Buffer conditions used for the different virus and capsid samples.  
Samples Buffer Conditionsa) 
Virus pH 5 50 mM sodium acetate 
Virus pH 7.5 50 mM Tris-HCl 
Capsid pH 5 
50 mM sodium 
acetate 
200 mM NaCl 
50 mM sodium 
acetate 
300 mM NaCl 
50 mM sodium 
acetate 
1 M NaCl 
Capsid pH 6.5  
50 mM ammonium 
actetate 
300 mM NaCl 
 
Capsid pH 7.5  
50 mM Tris-HCl 
300 mM NaCl 
50 mM Tris-HCl 
1 M NaCl 
a) All buffers used in the assembly studies additionally contained 1 mM EDTA, 10 mM 
CaCl2, and 0.2 mM PMSF. 
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 Preparation of PSS-containing particles 
CCMV capsid samples with encapsulated PSS were prepared and characterized as 
decribed previously.[19] For the SANS experiments, capsid protein and PSS were 
dissolved in 100 % D2O buffered at pD 7.5 containing 0.5 M NaCl and mixed to a final 
concentrations of 3.6 × 10-4 and 2.7 × 10-4 M for protein and polymer, respectively. 
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CHAPTER 6  
Encapsulation of Proteins in the CCMV Capsid 
 
6.1 Introduction 
  
 Protein cages  
Nature has developed a variety of self-assembled protein cages that can act as spatially 
well-defined host systems. Examples include viral capsids, ferritins, heat shock proteins, 
and the recently described “encapsulins”.[1,2] Protein-cage architectures provide three 
surfaces (interior, exterior, and subunit interfaces) to which one can impart function by 
design. Atomic-resolution structural information, in conjunction with genetic and 
chemical modification, allows the rational incorporation of small molecules, for 
example, peptides, or metallic particles at precise locations in the protein cage and on its 
surface. In recent years, protein cages have increasingly been investigated and used in 
the laboratory as scaffolds for metallization and the growth of minerals, resulting in 
metalized or mineralized nano-objects. They have also been used as nanocages for the 
entrapment of compounds and as nanoreactors.[1,3-5]  
In 1991 Mann and co-workers showed, for the first time, that protein cages have the 
potential to act as a constrained reaction environment in the synthesis of inorganic 
materials of nanometer dimensions.[6,7] They used the mineralization properties of 
ferritin to produce metal particles from metal ions other than the natural hydrates of 
iron(III) oxide. Since then, ferritin has been applied as a size-constrained reaction vessel 
for the production of different types of metal nanoparticles,[8-10] and even to produce 
ferromagnetic nanocrystals leading to the construction of a magnetic protein.[11-13] A 
similar approach was followed to prepare a magnetic ferritin that was further engineered 
to act as a cell-specific targeting device, opening the possibility of employing protein 
cages in the field of biomedicine.[14] Furthermore, the metal–nanocluster formed in the 
ferritin protein was shown to work as a catalyst in different types of reactions.[15,16] For 
example, a Pd–nanocluster was encapsulated in the apoferritin cavity by in situ 
reduction of PdII ions. Subsequently, the catalytic activity of this complex in the 
hydrogenation of olefins was evaluated and it was found that the catalytic system is 
capable discriminating between substrates via the pores in the protein mantle (Scheme 
6.1).[17]  
Chapter 6 
 116
 
Scheme 6.1 Size-selective catalytic hydrogenation of olefins by the Pd–apoferritin 
hybrid.[17] 
 
The investigations on ferritin paved the way for the use of other proteins and virus 
capsids as size- and shape-constrained reaction vessels. The hollow self-assembled 
protein structure of lumazine synthase, a bacterial enzyme, and the small heat shock 
protein cage from Methanococcus jannaschii (MjHsp) were also shown to be a suitable 
mineralization template for the formation of iron oxide particles,[18,19] which in some 
cases have also been used for catalytic reactions.[20] Furthermore, a genetically modified 
MjHsp protein cage was shown to have the ability to house and selectively release the 
antitumor agent doxorubicin.[21]  
In materials science, viruses are currently increasingly applied as scaffolds for chemical 
synthesis. Molecules of interest are connected to the viral surface by means of 
bioconjugation chemistry or molecular-biology approaches. In this way, nanoparticles 
of viral origin can be fabricated that show a defined number and arrangement of 
functional molecules on their surface.[22-24] Some viruses can be conveniently 
disassembled and reassembled by changing the environmental conditions, such as the 
pH of the medium. This feature provides the unique possibility to use viruses for 
encapsulation, which is appropriate for the design of size-constrained nanocontainers 
and nanoreactors. One of the most explored virus with these characteristics is CCMV 
(which is discussed separately below), however, other viruses have been used as well. 
For example, the MS2 bacteriophage, which has the possibility of forming genome-free, 
empty capsid shells, has been chemically modified on both the outer and inner 
surface.[25,26] An alternative approach for the encapsulation of nanoparticles in protein 
cages has been to direct the assembly of viral capsid subunits around a preformed 
nanoparticle. For example, the interaction between oligonucleotides attached to gold 
nanoparticles and the positive N terminus of coat protein subunits has been used to 
entrap these particles within the capsids of the red clover necrotic mosaic virus 
(RCNMV),[27] the brome mosaic virus (BMV),[28,29] and the animal virus alphavirus.[30] 
By using similar approaches, magnetic nanoparticles have also been encapsulated 
within the BMV virus.[31]  
 
Encapsulation of Proteins in the CCMV Capsid 
 117
 CCMV as a host 
By making use of its reversible assembly–disassembly properties, CCMV has been 
applied as a host for the reversibly gated entrapment of organic and inorganic 
compounds.[32] The entrapment of different guest compounds has been carried out by 
taking advantage of the positively charged inner cavity of the CCMV protein capsid and 
the pH-dependent gating.[5] For example, it has been used for directing the nucleation of 
mineralization reactions to form spatially constrained nanoparticles of polyoxometalate 
salts (tungstates, molybdates, and vanadates).[33] Subsequently, through a combination 
of protein design and genetic engineering, the charge on the interior surface of the 
CCMV capsid has been altered from positive to negative, which provided an adequate 
environment for directing the mineral nucleation of transition-metal oxides.[34] Recently, 
Prussian blue salts have been synthesized in situ within the cavity of the CCMV capsid, 
yielding highly monodisperse nanoparticles of this mineral.[35]  
Inclusion of polyanions in the CCMV capsid has been shown to give a variety of 
structures, including nanotubes and spheres of various sizes.[36-39] Polystyrene sulfonate 
(PSS) has been shown to produce T = 1 particles at neutral pH[40] and capsids with 
“T = 2” or T = 3 symmetry at pH 5, depending on the molecular weight of the 
polymer.[41] Moreover, tubular structures with tunable lengths have also been observed, 
namely when double-stranded DNA (dsDNA) was used as the macromolecular 
polymeric cargo.[42]  
In Chapter 4 properties of the CCMV capsid were studied in detail and the conditions 
for its assembly and disassembly established. In the present chapter and in Chapter 7 we 
will use this knowledge to encapsulate proteins and enzymes in the capsid interior, the 
objective being to construct a viral nanoreactor. As a proof of principle and to optimize 
the procedure of protein encapsulation, first different model proteins were included in 
the CCMV capsid. Some important issues to consider are i) what approach should be 
followed to encapsulate the guest protein, ii) what are the best techniques to characterize 
the system once it contains the guest protein, and iii) how efficient can the process be 
made. The volume of the internal cavity of the viral capsid is very small, and as a result 
the amounts of encapsulated guest will be low. Hence it will be difficult to characterize 
viral host–guest systems making that sufficiently sensitive techniques are needed. 
 
 
6.2 Results and Discussion 
 
The approach that was followed to encapsulate proteins is depicted in Scheme 6.2. It 
involves the statistical encapsulation of the guest by disassembling and subsequently 
reassembling the capsid in the presence of the protein. The encapsulation efficiency of 
the process, namely, the number of guest proteins per capsid, is determined by the 
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starting concentration of the protein. The capsid disassembles into protein dimers by 
raising the pH from 5 to 7.5. An excess of guest material was added to the dimer 
solution at different guest protein/dimer ratios, depending on the protein used, and the 
pH was lowered to 5 by dialysis against a buffer of pH 5. As mentioned in Chapter 4, 
this process can be monitored by FPLC and TEM, and in this way it is possible to 
follow the complete disassembly of the capsid into dimers and examine the correct 
formation of the capsid once the guest protein is encapsulated.  
 
Scheme 6.2 Schematic pathway for the inclusion of a protein in the CCMV capsid. After 
disassembling the CCMV capsid into dimers (step I, pH 7.5), the guest protein (P) is 
added and the CCMV capsid is assembled again by decreasing the pH (step II, pH 5).  
 
Control experiments were carried out simultaneously to determine the extent of protein 
adsorption to the outer surface of the capsid. In the first control experiment, the capsid 
and guest protein, using the same concentration as described for the encapsulation 
experiment, were mixed in sodium acetate buffer (0.05 M, pH 5), and subsequently 
dialyzed against the same pH 5 buffer. Disassembly of the initial capsid does not take 
place under these conditions and any detected protein is therefore the result of protein 
adsorption to the outer surface of the capsid or inclusion in the protein shell. 
Two further control experiments were carried out following the same procedure as 
described above for the protein encapsulation experiments, but omitting either the guest 
protein or the capsid protein. 
 
 Proof of concept: encapsulation of myoglobin 
Myoglobin (Mb) was the first model protein that was chosen to be encapsulated in the 
CCMV capsid. Ample experience with this protein in our laboratory, its low price, small 
size, together with the fact that it has an easily detectable chromophore in the form of a 
heme group, makes myoglobin a good choice for a proof of principle experiment. 
The encapsulation was carried out by using 500 equivalents of myoglobin per capsid 
particle (one capsid particle corresponds to 90 capsid protein dimers) with a capsid 
concentration of 15 mg mL-1. The formation of the capsid in the presence of myoglobin 
was confirmed by FPLC and TEM (Figure 6.1). The reassembled, filled capsid (Figure 
6.1b) eluted at the same retention volume as the initial capsid (Figure 6.1a) when 
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analyzed by FPLC, indicating that both capsids have the same size and shape. Also 
TEM micrographs (Figure 6.1a and b, insets) proved that the capsids were formed in the 
presence of protein. Concentrated fractions from the FPLC corresponding to the peak at 
1.1 mL were analyzed by UV/Vis spectroscopy. These fractions are free from 
nonencapsulated myoglobin because the protein elutes at a higher retention volume 
(V = 1.9 mL) than the capsid (Figure 6.1b and c). The myoglobin-containing capsid 
displayed a signal at λ = 409 nm in the UV/Vis spectrum, characteristic of the 
myoglobin-heme group, indicating the successful inclusion of the protein (Figure 6.1d). 
 
Figure 6.1 Inclusion of myoglobin in the CCMV capsid. a) FPLC chromatogram of the 
CCMV capsid. Inset: TEM (negative staining) image of the CCMV capsid (scale 
bar = 100 nm). b) FPLC chromatogram of the myoglobin-containing CCMV capsid. 
Inset: TEM (negative staining) image of the myoglobin-containing CCMV capsid (scale 
bar = 100 nm). c) FPLC chromatogram of myoglobin. d) UV/Vis spectra of the 
myoglobin-containing CCMV fraction (see arrow in panel b) and the corresponding 
fraction of the control experiment. Inset: magnification of the traces at λ = 409 nm. 
 
From the UV/Vis absorption data of the capsid (at λ = 280 nm) and the myoglobin (at 
λ = 409 nm), and the corresponding extinction coefficients, we could calculate the final 
guest/host ratio corresponding to this experiment (Equation 6-1). Under the applied 
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experimental conditions, it was calculated that an average of two myoglobin molecules 
were encapsulated within a single CCMV capsid. This result is in reasonable agreement 
with the ratio calculated for a statistical process, in which there is no driving force to 
encapsulate the protein. Taking into account the initial concentration of myoglobin in 
the mixture and the volume of the capsid inner cavity, it was calculated that an average 
of 3.5 myoglobin molecules would be encapsulated per capsid. The initial myoglobin 
concentration in the mixture is expected to be lower due to some protein precipitation, 
explaining the slight deviation in encapsulation efficiency.  
 
Equation 6-1 
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 Enhancing the detection sensitivity: encapsulation of dronpa 
Although the encapsulation of myoglobin was confirmed by UV/Vis spectroscopy, the 
obtained signal intensity was very low (Figure 6.1d). To improve the UV/Vis signal we 
had three options: i) to increase the amount of encapsulated protein, which was difficult 
because inclusion is a statistical process (as mentioned above), ii) to increase the 
myoglobin-containing capsid concentration in the fraction to be analyzed, and iii) to use 
a more sensitive technique to monitor the encapsulation process, which would also 
mean the use of a probe molecule. The second option was tested for myoglobin but 
higher concentrations were difficult to obtain for experimental reasons. The third option 
appeared to be the most realistic one and we decided to use the protein dronpa as a 
model protein for inclusion in the CCMV capsid. Dronpa is an engineered mutant of a 
green fluorescent protein (GFP)-like protein that was cloned from the Pectiniidae 
species of coral and exhibits reversible photoswitching behavior (Figure 6.2a).[43,44] The 
latter led to the naming “Dronpa,” after “dron,” a ninja term for vanishing, and “pa,” 
which stands for photoactivation. This protein has an absorption maximum at 
λ = 503 nm and emits bright fluorescence at λ = 518 nm. It has photochromic behavior 
because its fluorescence can be switched on and off by using two different wavelengths 
of light. Although the highest fluorescence quantum yield occurs at high pH, at pH = 5 
the protein still shows enough fluorescence to be used as a fluorophore in our inclusion 
experiments (Figure 6.2b).1 
 
                                                 
1 Because of the photochemical properties of dronpa interesting physical phenomena can be 
expected when the protein is encased in the small volume of a virus particle.[43] This feature is 
beyond the scope of this thesis. 
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a) 
 
b) 
 
Figure 6.2 The engineered mutant dronpa. a) Crystallographic structure of dronpa 
represented in ribbon format.[45] b) Excitation (λem =518 nm) and emission 
(λexc =503 nm) spectra of dronpa at pH = 5 (c = 1.3 × 10−6 M in buffer solution). 
 
The encapsulation of dronpa was carried out by following the same procedure as used 
for the protein myoglobin and its inclusion in the CCMV capsid was investigated by 
fluorescence spectroscopy and SDS-PAGE (SDS-polyacrylamide gel electrophoresis). 
The concentrated CCMV capsid samples obtained through purification by FPLC, 
showed strong emission when excited at λ = 503 nm (Figure 6.3a), which indicated that 
dronpa molecules co-eluted with the CCMV capsids. The protein appeared to be mainly 
included inside the cavities of the capsids and was not adsorbed on the capsid outside 
surface, as was concluded from the low emission obtained in the control experiment, in 
which no disassembly–assembly cycle was applied (Figure 6.3a). The samples were 
analyzed by SDS-PAGE to further prove the protein encapsulation (Figure 6.3b). Two 
different bands were observed for the samples of the inclusion experiments, 
corresponding to the molecular weight of dronpa (29,200 Da) and that of the CCMV 
protein subunits. The control experiment containing only CCMV capsid (lanes 2, 4, and 
6) showed a band corresponding to the viral protein subunits (20,212 Da) and multiple 
lower-molecular-weight bands due to protein degradation (typical in old capsid samples, 
see Chapter 4). The sample containing only dronpa (29,200 Da) showed a single band 
(lane 7). Both the inclusion experiment (lane 3) and the control experiment, in which no 
disassembly–assembly cycle was applied (lane 5), showed multiple bands 
corresponding to the CCMV capsid, but the dronpa band was only present in the former 
experiment (lane 3). The smeared bands in lanes 3 and 5 are due to intentional 
overloading of the samples to improve the detection of dronpa. 
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a) b) 
 
Figure 6.3 Inclusion of the protein dronpa in the CCMV capsid. a) Emission spectra 
(λexc = 503 nm) of the dronpa-containing CCMV capsid fraction and the corresponding 
fraction of the control experiment in which no disassembly–assembly cycle was applied. 
b) SDS-PAGE gel of the CCMV capsid (lanes 2, 4, and 6), the dronpa-containing 
CCMV capsid (lane 3), the control containing the mixture for which no disassembly–
assembly cycle was applied (lane 5), and dronpa (lane 7). 
 
The above two experiments with myoglobin and dronpa prove that the encapsulation of 
a protein inside the cavity of the CCMV capsid is possible and show the techniques that 
can be used to monitor this process. This opens the way to the encapsulation of enzymes 
and the study of the substrate conversion by an enzyme-containing capsid, which will be 
discussed in Chapter 7. Towards this goal, the access of substrate to the cavity of the 
viral capsid is an important issue that needs to be investigated. Therefore, the porosity 
of the CCMV capsid was studied by using the streptavidin–biotin system. Following the 
same procedure employed for myoglobin and dronpa, it was possible to encapsulate the 
protein streptavidin in the CCMV capsid. Biotin is known to strongly bind to 
streptavidin and by labeling both biomolecules, FRET experiments can be used to 
monitor the occurrence of biotin transport across the capsid wall. These experiments are 
described in the next section.  
 
 Encapsulation of streptavidin: study of the diffusion of biotin molecules through 
the CCMV capsid pores2 
Streptavidin (SAv) is a homotetrameric protein, which is expressed in the bacterium 
Streptomyces avidinii.[46] It has a molecular weight of approximately 60 kDa and a size 
of 5.4 × 5.8 × 5.8 nm.[47] Every subunit has one binding site and each of them can 
independently bind one biotin (Bt) molecule. The resulting SAv–Bt complex has the 
                                                 
2 Part of the work described herein has been performed by Laura Osorio Planes as part of her 
Master degree under the supervision of Dr. Andrés de la Escosura and the author. 
Encapsulation of Proteins in the CCMV Capsid 
 123
highest interaction between a protein and a ligand known in nature 
(ka = 2.5 × 1013 M−1).[48] 
The strong interaction between Bt and SAv has found broad applications in 
biotechnology. It is also of interest to note that Bt-modified virus particles have been 
combined with SAv as a linker molecule to form self-assembled layer structures on a 
surface through a layer-by-layer approach.[49,50] In the present case the encapsulation of 
SAv in the CCMV capsid aims to create a molecular trap for the binding of Bt (and its 
derivatives). When Bt is added to a solution containing capsids with entrapped SAv 
molecules, its binding to this protein is a measure for the porosity of the capsid 
membrane. 
The encapsulation of SAv was carried out by following the same procedure as described 
for myoglobin and dronpa. SAv was labeled with the Alexa-Fluor 488 dye to monitor 
the inclusion by fluorescence spectroscopy; 1.6 equivalents of SAv per capsid particle 
were added, a much smaller amount than in the encapsulation of myoglobin (see above). 
After purification of the complex by using FPLC, co-elution of the capsid and SAv was 
demonstrated by fluorescence spectroscopy, that is, a distinct emission at λ = 520 nm 
was observed. The control experiment (no disassembly–assembly cyclus) yielded a 
much lower fluorescence intensity. The observed residual fluorescence is probably due 
to SAv molecules that are adsorbed to the outside surface of the capsid. These 
experiments indicate that the protein was successfully included inside the capsid. The 
correct reassembly of the SAv-containing capsid was confirmed by TEM experiments 
(not shown), but due to the low concentration of protein and its low extinction 
coefficient no additional evidence for SAv inclusion could be obtained by UV/Vis 
spectroscopy and SDS-PAGE. 
To study complex formation between CCMV encapsulated SAv and externally added 
Bt, initially a 4’-hydroxyazobenzene-2-carboxylic acid (HABA)–SAv assay was carried 
out.[51] This spectroscopic assay allows one to study the displacement of the dye HABA 
bound to SAv by Bt. Unfortunately, the concentration of SAv inside the CCMV capsid 
was so low that no differences could be detected between bound and unbound HABA 
by UV/Vis spectroscopy. A more sensitive approach is to use biocytin Alexa-Fluor 546 
(Bt-546), which is a commercially available Bt-labeled fluorescent dye that allows the 
monitoring of the SAv–Bt interaction by fluorescence spectroscopy (so-called Förster 
resonance energy transfer (FRET) experiment).  
When Bt-546 is in close proximity to SAv-488 and the complex is excited at λ = 494 nm 
(λexc of the Alexa Fluor 488), energy transfer between the two chromophores occurs, 
causing a decrease in the emission at λ = 520 nm (λem of the Alexa Fluor 488) and the 
concomitant appearance of a new signal at λ = 566 nm (λem of the Bt-546).[52] SAv-488-
containing capsids were titrated with Bt-546 and a clear quenching was found to occur 
already after the addition of 0.5 equivalents of Bt-546 per SAv binding site (Figure 6.4 
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a). The same procedure was followed for the control experiment (CCMV capsid mixed 
with SAv-488 at pH 5 followed by purification) and in this case almost no quenching 
was observed (Figure 6.4b). 
The occurrence of FRET could be also shown by SDS-PAGE, in which case the gel was 
loaded with different SAv-488 samples to which Bt-546 was added or not (Figure 6.4c). 
The gel was developed with a Fuji FLA-5100 fluorescence scanner operating at an 
excitation wavelength of λexc = 473 nm and provided with an LPB (510 nm) detection 
filter. In these experiments no band is expected when Bt-546 binds to SAv-488, see 
lanes 2, 4, and 10. Lane 10 shows a small residual band probably due to the large excess 
of Bt-546, which was used. This compound partially absorbs at λ = 473 nm.  
The above experiments show that Bt can pass the protein shell of the CCMV capsid. 
Although SAv is not catalytically active, such a system might be used for the inclusion 
within the capsid of catalysts that are attached to Bt. Such a possibility makes the SAv-
containing CCMV capsid an interesting object for further investigation. 
 
a) 
 
b) 
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c) 
 
 
Figure 6.4 Analyses of Sav-488 and Bt-546 mixing and encapsulation experiments. 
a) Fluorescence spectra (λexc = 494 nm) of SAv-488-containing capsids after the 
addition of different equivalents of the quenching agent Bt-546 (the numbers 
correspond to Bt-546 per SAv binding site). b) Fluorescence spectra (λexc = 494 nm) of 
the control experiment, in which SAv-488 was mixed with the capsids and no 
disassembly–assembly cycle was applied. Several equivalents of the quenching agent 
Bt-546 (the numbers correspond to Bt-546 per SAv binding site) were added. c) Native 
SDS-PAGE visualized by using a fluorescence scanner (λexc = 473 nm, λem > 510 nm). 
The different lanes correspond to SAv-488-containing capsid before (lane 1) and after 
(lane 2) the addition of Bt-546 (10 equiv); the control experiment before (lane 3) and 
after (lane 4) the addition of Bt-546(10 equiv); SAv-488 after (lane 10) and before 
(lane 11) the addition of Bt-546 (100 equiv); unlabeled SAv after the addition of Bt-546 
(10 equiv) (lane 12), and SAv-488 after the addition of unlabeled Bt (lane 13). Lanes 5–
9 were not loaded and lane 14 is to the marker.  
 
 
6.3 Conclusion 
 
The assembly–disassembly properties of the CCMV coat protein studied in Chapter 4 
were used to encapsulate different proteins in the capsid. The encapsulation of 
myoglobin, dronpa, and SAv was successfully achieved and in the case of myoglobin it 
was shown that on average not more than two proteins were entrapped per capsid. 
Fluorescence spectroscopy in contrast to UV/Vis spectroscopy proved to be a sensitive 
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technique to monitor the encapsulation of the proteins, in particular for dronpa. For this 
reason nonfluorescent proteins, such as SAv, need to be labeled with a fluorophore.  
The successful encapsulation of proteins within the CCMV capsid, and the fact that the 
capsid is permeable for small molecules, as shown by the diffusion of Bt across the 
protein shell of the SAv-containing capsid, allows for the construction of a viral 
nanoreactor. In such a system an enzyme is encapsulated in the CCMV capsid and 
substrate and product molecules can diffuse freely in and out of the reactor (see 
Chapter 7). 
 
 
6.4 Experimental Section 
  
 Materials 
Sodium acetate trihydrate (>99%) and uranyl acetate dihydrate (≥98%) were purchased 
from Fluka. Ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate (>99%), 
Tris(hydroxymethyl)aminomethane (Tris) (>99%), calcium chloride dihydrate (>99%), 
sodium chloride (99.5%), sodium azide (99%), and cesium chloride (>99%) were 
purchased from Acros. Ethanol (p.a.) was purchased from Merck. Myoglobin from 
equine heart (Product number: M1882, ≥90%), streptavidin (Product number: S4762), 
biotin (Product number: 14400, ≥99%), phenylmethanesulfonyl fluoride (PMSF) 
(≥98.5%), ethidium bromide (~95%), Orange G (≥80%), 4’-hydroxyazobenzene-2-
carboxylic acid (HABA) (Product number: H5126, ≥98%), and dithiothreitol (DTT) 
(99%) were obtained from Sigma-Aldrich. Streptavidin was labeled with Alexa Fluor® 
488 via carboxylic acid TFP ester bis(triethylammonium salt) of this dye, following the 
protocol provided with the labeling kit by the supplier (Molecular Probes, Invitrogen). 
Agarose (electrophoresis grade) and Alexa Fluor 546 biocytin (Catalog number: 
A12923) were purchased from Invitrogen. All reagents used for SDS-PAGE 
electrophoresis were purchased from Bio-Rad Laboratories. Dronpa was kindly 
provided by Prof. Johan Hofkens, University of Leuven (Belgium). 
 
 Instrumentation 
UV/Vis spectroscopy was performed on a Varian Cary 50 spectrophotometer at room 
temperature using a 1 cm quartz cuvette (Hellma, path length l = 1 cm) or a 45 μL 
quartz fluorescence cuvette (Hellma, path length l = 3 mm). The reference spectrum of 
the corresponding buffers was subtracted from all UV/Vis spectra. 
Fluorescence spectroscopy was performed on a Perkin-Elmer LS 50B fluorescence 
spectrophotometer. Experiments were carried out at T = 10°C by using a 45 μL quartz 
fluorescence cuvette (Hellma, path length l = 3 mm). 
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Fast protein liquid chromatography (FPLC) was performed on an Ettan Akta LC 
system equipped with a Superose 6 PC 3.2/30 column from Amersham Biosciences 
(flow rate: 40 μL min-1). Injections of 20–100 mL aliquots of the samples on the FPLC 
column at room temperature were monitored by using UV/Vis detection at λ = 280 nm 
and the wavelength corresponding to the chromophore present in the guest protein. 
Transmission electron microscopy (TEM) micrographs were recorded on a JEOL JEM-
1010 instrument. Samples were prepared by drying a drop of the solution on a Formvar 
carbon-coated grid, which had been previously made hydrophilic by glow discharge. 
The excess buffer on the grid was blotted away after 1 min with filter paper. Negative 
staining of the samples was achieved by applying a drop of uranyl acetate solution 
(0.2% in MilliQ) onto the grid and blotting the excess liquid away after 15 s with filter 
paper. The samples were left to dry in air for 30 min before analysis. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by using a 4% 
stacking and 15% running polyacrylamide gel containing 10% SDS (1% SDS in the 
case of native conditions). Samples for gels under non-native conditions were treated 
with β-mercaptoethanol and heated prior to loading onto the gel. Gels were stained with 
0.05% (w/v) Coomassie Blue solution and destained with a solution of 5% (v/v) 
methanol and 7% (v/v) acetic acid in water (Coomassie Blue destainer).  
A Fuji FLA-5100 fluorescence scanner ("1 laser 1 image" mode), was used for gel 
analysis when the gels were loaded with fluorescent samples (λexc = 473 nm, detection 
filter LPB (510 nm)).  
Dialysis was performed by using dialysis tubing (Spectra/Por 4, MWCO: 12–14 kD, flat 
width: 25 mm) purchased from Spectrum Laboratories, or D-tube dialyzer (MWCO: 6–
8 kD, volume: 50 to 800 μL) from Novagen. 
 
 Protein encapsulation experiments  
The purification of the CCMV virus and the isolation of the coat protein were 
performed as described in Chapters 3 and 4. The coat protein was used immediately 
after isolation to avoid degradation. Occasionally, it was used from a coat protein 
sample stored in capsid storage buffer (0.05 M sodium acetate, 1 mM NaCl, 1 mM 
sodium azide, pH 5) kept at 4°C. Such a solution was never more than two-weeks old 
and it was always checked for degradation before use.  
A solution containing the CCMV coat protein (see Table 6.1) in sodium acetate buffer 
(0.05 M, pH 5) was dialyzed against three changes of Tris–HCl buffer (500 mL, 0.05 M, 
pH 7.5) (3 h per change). When the solution had reached pH 7.5, the guest protein 
solution (see table below) in Tris–HCl (0.05 M, pH 5) was added in excess, and the 
resulting solution was incubated for 1 to 2 h. Dialysis of the incubated solution against 
the initial sodium acetate buffer was carried out under the same dialysis conditions as 
described above. The samples were concentrated and the free guest protein was 
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removed using centrifugal filter devices (Centricon YM-100, Millipore). Samples were 
further purified by FPLC and concentrated when needed by using centrifugal filter 
devices (Centricon YM-100, Millipore). 
All buffer solutions contained 1 mM EDTA, 300 mM NaCl, 10 mM CaCl2, and 0.2 mM 
phenylmethylsulphonyl fluoride (PMSF). Buffers were stored at 4°C, and the dialysis 
was performed in a cold room at 4°C. In later experiments better results were obtained 
when 500 mM of NaCl instead of 300 mM was used. An increase in the amount of salt 
enhances the stability of the assembled capsid (for further details about the assembly 
process, see Chapter 4). 
 
Table 6.1 Concentrations and volumes of guest proteins used in the experiments 
  
Guest 
protein 
Guest protein solution Capsid solution Guest protein in final solution 
Conc. (M) Added 
volume 
(mL) 
Conc. (M) Added 
volume 
(mL) 
Added 
equiv per 
capsid 
Final conc. 
(M) 
Guest 
protein per 
capsida) 
Mb  1.16 × 10−2  0.1 4.37 × 10−6 0.5 532 1.94 × 10−3  3.57 
dronpa  3.50 × 10−4  0.18 4.37 × 10−6 0.3 48 1.31 × 10−4  0.24 
SAv  3.38 × 10−6  0.29 2.03 × 10−6 0.3 1.6 1.66 × 10−6  3× 10−3 
 a) Considering the fact that the encapsulation is a statistical process, the guest proteins per capsid were 
calculated by multiplying the concentration of guest protein in the final solution by the inner volume of 
the capsid (V = 3.05 × 10−15 µL) and by Avogadro’s number (NA = 6.022 × 1023). 
 
The final average guest protein/capsid ratio could only be calculated by UV/Vis 
spectroscopy for the protein myoglobin. For practical reasons myoglobin allowed us to 
work with this protein in higher concentration than with the other two proteins and as a 
result a higher number of guest protein molecules could be encapsulated and detected 
by UV/Vis spectroscopy. Once encapsulated, the dronpa and the labeled SAv could be 
easily detected by fluorescence spectroscopy. Unfortunately, because of the low 
concentration and the low extinction coefficient of both chromophores, no peak was 
observed by UV/Vis spectroscopy, therefore, no guest protein/capsid ratio could be 
calculated. 
 
 Control encapsulation experiments 
For the control experiments, in which guest protein and capsid are mixed without 
performing a disassembly–assembly cycle, the next procedure was followed: Guest 
protein solution in sodium acetate buffer (0.05 M, pH 5) was added to a solution 
containing CCMV coat protein in sodium acetate buffer (0.05 M, pH 5), using the same 
volumes and concentrations as described for the encapsulation experiment. The mixture 
was subsequently dialyzed against three changes of the same sodium acetate buffer 
(500 mL, 0.05 M, pH 5) (3 h per change). 
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Two further control experiments were carried out by following the same procedure as 
described above for the protein encapsulation experiments, but omitting either the guest 
protein or the capsid protein. 
All buffer solutions contained 1 mM EDTA, 300 mM NaCl, 10 mM CaCl2, and 0.2 mM 
PMSF. Buffers were stored at 4°C and the dialysis was performed in a cold room at 
4°C. Later experiments showed better results when 500 mM of NaCl were used instead 
of 300 mM. An increase in the amount of salt enhances the stability of the assembled 
capsid (for further details about the assembly process, see Chapter 4). 
 
 FRET experiments. Study of biotin–546 transport across the CCMV-capsid shell. 
In a first series of test experiments titrations were carried out in which labeled and 
unlabeled biotin were added to SAv-488 in solution. In subsequent experiments, 
aliquots (V = 1 µL) of a Bt-546 solution (c = 5.68 × 10−5 M) were added to a sample 
(V = 40 µL) of SAv-488-containing CCMV capsid (c (SAv) ≈ 9.47 × 10−7 M). For the 
control experiments, aliquots (V = 1 µL) of a Bt-546 solution (c = 7.58 × 10−6 M) were 
added to a sample (V = 40 µL) in which no disassembly–assembly cycle was applied 
(c (SAv) ≈ 3.79 × 10−7 M). 
All spectra were corrected for dilution and the solutions were prepared in 0.05 M 
sodium acetate buffer (pH 5).  
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CHAPTER 7  
A Virus-Based Single-Enzyme Nanoreactor 
 
7.1 Introduction 
 
Most enzyme studies are carried out in bulk aqueous solution, at the so-called ensemble 
level, but more recently, studies have appeared in which enzyme activity is measured at 
the level of one single molecule, revealing previously unseen properties.[1-8] To this end, 
enzymes have been chemically or physically anchored to a surface, which is often 
disadvantageous because it may lead to denaturation. In their natural environment, 
enzymes are present in a confined reaction space, which inspired us to develop a generic 
method to carry out single-enzyme experiments in the restricted spatial environment of 
a virus capsid. In recent reports, protein capsids and viruses have been studied as 
containers, as potential reaction vessels,[9-12] as well-defined hosts,[13-16] as 
nanotemplates,[17-22] and as synthetic platforms.[23-25] To the best of our knowledge, no 
enzyme-loaded nanocontainer has been assembled and studied at the single-enzyme 
level.  
The reversible pH-dependent assembly–disassembly properties of the CCMV capsid 
provide a unique molecular gating mechanism for controlling the containment and 
release of entrapped material.[15,26] The use of the CCMV capsid as a protein container 
was first optimized with the proteins myoglobin, dronpa, and streptavidin to control the 
encapsulation and characterization process (Chapter 6). By using the same approach, 
this chapter reports the incorporation of an individual horseradish peroxidase (HRP) 
enzyme molecule in the cavity of the CCMV capsid (Scheme 7.1). Furthermore, single-
molecule studies on the enzymatic behavior of the HRP-containing capsid by using 
confocal fluorescence microscopy are described. We aim to use this HRP-containing 
CCMV capsid as a model system to investigate single-enzyme processes in a more 
natural environment than in previous studies.[6]  
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Scheme 7.1 Schematic pathway for the assembly of a viral nanoreactor. After 
disassembling the CCMV capsid into coat protein dimers (step 1, pH 7.5), the enzyme 
(E) is added and the CCMV capsid is reassembled again by decreasing the pH (step 2, 
pH 5). The HRP-containing capsid is spin-coated on a cover glass and its catalytic 
activity is studied by using a confocal fluorescence microscope after the addition of a 
substrate (S) that it is converted into a fluorescent product (P) by the enzyme (step 3). 
 
 Single-molecule fluorescence microscopy: instrumentation and analysis 
In contrast with ensemble measurements that only yield information on average 
properties, single-molecule experiments provide information on individuals, such as 
distributions and time trajectories of properties that would otherwise be hidden. During 
the last 15 years the spectroscopic study of single molecules has become an almost 
routine task for researchers in different scientific fields, from fundamental physics 
through material sciences to biology. While successful approaches to detect and study 
single atoms or molecules on surfaces have used near-field interactions with tunneling 
electrons (scanning tunneling microscopy (STM)) or forces from sharp tips (atomic 
force microscopy (AFM)), optical methods have the advantage that they enable the 
observation of single molecules from a certain distance and unperturbed by these 
tips.[6,7,27] Moreover, advances in optical spectroscopy and microscopy have made it 
possible not only to detect and identify immobilized or freely diffusing fluorescent 
molecules, but also to realize spectroscopic measurements on these molecules and 
monitor their dynamic behavior. Currently the only feasible way to detect a single 
molecule optically is through fluorescence, and hence, this method is known as single-
molecule fluorescence spectroscopy (SMFS); it combines ultrasensitivity with the 
required high time resolution for in situ measurements.  
Nowadays, confocal fluorescence microscopy has become one of the most widely used 
modes for the detection of single molecules.[27] The typical setup of a confocal 
fluorescence microscope is depicted in Figure 7.1. The excitation light of a laser beam is 
focused through an oil- or water-immersion objective lens in a diffraction-limited focus 
onto the sample. The fluorescence generated by a single molecule residing in the 
confocal volume is collected by the same objective lens and the emission light is 
separated from the excitation light by a dichroic mirror. Before reaching the detector, 
the fluorescence light passes appropriate filters and a small pinhole (50–100 µm in 
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diameter), rejecting background fluorescence and out-of-focus light, respectively 
(Figure 7.1a). The emitted fluorescence can be measured by a point detector, such as an 
avalanche photodiode (APD), which detects photons very efficiently while having a low 
dark current, resulting in a good signal-to-noise ratio. When using the confocal 
technique for SMFS, one molecule is studied at a time and when imaging of extended 
areas is required, this is possible by scanning the sample with respect to the laser focus 
point or vice versa.[27,28]  
 
a) b) 
 
Figure 7.1 a) Schematic experimental setup of a single-molecule confocal fluorescence 
microscopy experiment. b) Confocal fluorescence microscope used for the single-
molecule studies of the HRP-containing CCMV capsid. 
 
 Fluorescence correlation spectroscopy 
Fluorescence correlation spectroscopy (FCS) is one of the many different methods for 
the high-resolution spatial and temporal analysis of extremely dilute concentrations of 
biomolecules.[27-30] To enhance detection sensitivity and background suppression, Rigler 
et al. combined, for the first time, FCS with a confocal setup[31] and in the following 
years the analytical and diagnostic potential of this methodology was demonstrated. The 
basic principle behind FCS is that the detected fluorescence will fluctuate, which can be 
due to in situ chemical reactions or diffusion of each fluorescent species in and out of 
the sampling volume. A correlation analysis of the fluctuating intensity signal yields the 
diffusion constant of the system under study. By recording and correlating the 
fluorescence fluctuations of singly labeled or fluorescent molecules excited by laser 
beam, FCS gives information on molecular mobility and photophysical and 
photochemical reactions.  
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By applying SMFS to the HRP-containing CCMV capsid, we intend to obtain 
information on the catalytic activity of the enzyme and on the influence of the confined 
space of the viral capsid on the enzymatic activity. 
 
 
7.2 Results and Discussion 
  
 Encapsulation of HRP in the CCMV capsid 
The study of the inclusion of myoglobin and dronpa, described in Chapter 6, provided 
us with the optimal experimental conditions for the statistical encapsulation of a protein 
within the CCMV capsid and with the methodology to monitor the process. The loading 
of HRP was carried out by the pH-dependent disassembly−assembly protocol (Scheme 
7.1), which was monitored by TEM and FPLC. Initially, the capsid was transformed 
into protein dimers, indicated by a peak at V = 1.78 mL in the FPLC. After addition of 
HRP, the capsid was reassembled while incorporating the guest enzyme. Because the 
objective was to perform single-enzyme studies, the concentration of the enzyme was 
selected to be such that there was only one or no molecules of enzyme present per 
capsid. As follows from the experiments on myoglobin and dronpa in Chapter 6, the 
final HRP per capsid ratio will only depend on the concentration of HRP in solution; the 
amount of capsid or the HRP/capsid ratio do not influence the degree of inclusion. By 
multiplying the concentration of guest protein in the final solution by the inner volume 
of the capsid, and by Avogadro’s number, we could calculate that on average 0.37 HRP 
units would be encapsulated per capsid. 
Co-elution of the guest protein and the capsid was observed in the HRP encapsulation 
experiment. Detailed FPLC, TEM, and fluorescence spectroscopic analyses of HRP 
encapsulation are shown in Figure 7.2. FPLC traces of the HRP-containing CCMV 
capsid pointed to the successful reassembly of the viral cage after the encapsulation 
process (Figure 7.2b), showing the same elution volume (V = 1.12 mL) as the original 
capsid (Figure 7.2a). The signal at V = 1.8 mL in Figure 7.2b corresponds to the elution 
volume of free HRP (Figure 7.2c; the high absorbance at 403 nm is due to the heme 
group present in the protein). The material eluting at V = 0.9 mL in Figure 7.2a and b 
corresponds to the elution volume of larger aggregates formed by the viral coat protein, 
as described in detail in Chapter 4. The correct reassembly of the capsids with and 
without HRP was further proven by cryo-TEM analysis (Figure 7.2a and b, insets). In 
both cases identical particles were observed. Additional evidence for co-elution of the 
capsid and HRP (V = 1.12 mL) comes from analysis of the concentrated fractions of 
FPLC by fluorescence spectroscopy. Although HRP has a heme group that gives a 
UV/Vis band at λ = 403 nm, the experiments with myoglobin and dronpa (Chapter 6) 
showed that fluorescence was a better technique to monitor the encapsulation of guest 
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proteins. Therefore, the HRP utilized in the experiments was labeled with the 
fluorescent dye Alexa Fluor 532 (λexc = 530 nm). The FPLC fraction corresponding to 
the CCMV capsid containing this guest enzyme (see the arrow in Figure 7.2b) displayed 
significant emission when excited at λ = 530 nm, indicating that inclusion of the 
enzyme had occurred (Figure 7.2d).  
 
 
Figure 7.2 Inclusion of HRP in the CCMV capsid. a) Size-exclusion FPLC of the 
CCMV capsid with the absorbance of eluted materials monitored at two different 
wavelengths. Inset: cryo-TEM image of the CCMV capsid (scale bar = 20 nm). b) Size-
exclusion FPLC of the HRP-containing CCMV capsid. The peak at an elution volume of 
1.8 mL corresponds to free HRP (see part c)). The arrow points to a fraction that was 
collected for further analysis (see part d)). Inset: cryo-TEM image of the HRP-
containing CCMV capsid (bar = 20 nm). c) Size-exclusion FPLC of HRP. d) Emission 
spectra (λexc = 530 nm) of the HRP-containing CCMV capsid fraction collected from 
FPLC experiments (as indicated in part b)) and the corresponding fraction of the 
CCMV capsid devoid of HRP obtained in an analogous fashion. 
 
As in the case of myoglobin, dronpa, and streptavidin (Chapter 6), an additional 
experiment was performed to compare the encapsulation product with a control 
experiment in which no assembly/disassembly cycle was applied to investigate the 
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extent of protein adsorption to the outer surface of the capsid. In this case HRP was 
labeled with an Alexa Fluor 488 fluorescent dye (λexc = 494 nm). The capsid and HRP, 
using the same concentration as that for the encapsulation experiment, were mixed at 
pH 5, and subsequently, dialyzed against the same pH 5 buffer. After FPLC 
purification, the fractions corresponding to both the experiment and the control were 
analyzed by fluorescence spectroscopy (Figure 7.3a). In the case of the control 
experiment, some emission at λ = 520 nm was present, which indicates that a minor 
amount of the enzyme is adsorped to the capsid outer surface. Test experiments using 
the ABTS colorimetric assay (ABTS = 2,2´-azino bis(3-ethylbenzthiazoline-6-sulphonic 
acid)) revealed that the HRP-containing CCMV capsid still possessed substantial 
enzymatic activity (Figure 7.3b). 
 
a) 
 
b) 
Figure 7.3 a) Emission spectra (λexc = 494 nm) of the HRP-containing CCMV capsid 
fraction and the corresponding fraction of the control experiment. The HRP was labeled 
with the fluorescent probe Alexa Fluor 488 (λexc = 494 nm). b) Activity experiment on 
HRP encapsulated within the CCMV capsid using an ABTS/H2O2 assay and the control 
experiment in which no disassembly/assembly cycle was applied. The H2O2 was 
generated in situ by the glucose oxidase/glucose couple. 
 
 Single molecule analysis of the HRP-containing CCMV capsid  
The enzymatic activity of the HRP molecules inside the CCMV capsid was examined at 
the single-molecule level with a confocal fluorescence microscope using the fluorogenic 
substrate dihydrorhodamine 6G.[1] Dihydrorhodamine 6G acts as a hydrogen donor in 
the enzymatic reduction of hydrogen peroxide by HRP, yielding the highly fluorescent 
product rhodamine 6G, which can be easily monitored (Scheme 7.2).  
A Virus-Based Single-Enzyme Nanoreactor 
139 
 
Scheme 7.2 The substrate dihydrorhodamine 6G is turned into rhodamine 6G in the 
presence of HRP and hydrogen peroxide. 
 
Two solutions were prepared: one containing HRP encapsulated inside some of the 
CCMV capsids and a control solution containing a mixture of empty CCMV capsids 
and free HRP. Additional control solutions were prepared in which either no HRP or no 
capsid was present. The solutions were deposited on separate hydrophilic cover slips 
and, after the addition of a mixture of substrate and hydrogen peroxide, were examined 
with a laser scanning confocal microscope. The two experiments are schematically 
depicted in Figure 7.4a and b. Typical images of the activity of HRP inside the CCMV 
capsid after 10 min of incubation of the mixture are shown in Figure 7.4c. Bright 
diffraction-limited spots are clearly visible, which are attributed to diffusion of the 
substrate through the capsid pores, conversion, and accumulation of product molecules 
inside the capsid. During scanning of several images a decrease in fluorescence 
intensity due to photobleaching and an increase in the background fluorescence became 
visible (Figure 7.4e), which points to the continuous formation of product molecules 
slowly diffusing out of the capsids into the solution. The increase of background 
fluorescence can also be partially due to some auto-oxidation of the substrate present in 
solution. Furthermore, by determining the number of capsids per unit area by AFM and 
comparing it with the number of fluorescent (active) particles, as determined by 
fluorescence confocal microscopy (Figure 7.4c and inset) in the same area, we 
confirmed that approximately 1 in every 130 capsids contains an active HRP. This 
fraction is smaller than that calculated statistically (see above) and would indicate that 
only part of the encapsulated enzymes retain their activity.  
An image of the analysis of the control solution containing the mixture of 
nonencapsulated HRP and empty CCMV capsid is shown in Figure 7.4d. Localized 
fluorescence is again observed, but at a much reduced intensity; however, no indication 
of accumulation of product molecules is detected in this case. In both experiments the 
localized fluorescence is the result of the continuous formation of the enzyme–product 
complex,[3] but when the enzyme is encased inside the virus capsid the disappearance of 
the fluorescence is delayed because of product accumulation in the capsid. Interestingly, 
in the blank experiment in which HRP was deposited in the absence of the CCMV 
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capsid, no fluorescence was observed, probably as a result of denaturation of the 
enzyme on the glass surface.  
 
Figure 7.4 HRP enzyme activity in the presence of single CCMV capsids. a) When HRP 
is encapsulated inside a capsid, substrate molecules (S) diffuse into the capsid and are 
subsequently converted into product molecules (P), which accumulate before diffusing 
out through the capsid pores. b) If HRP is adsorbed on the outside of a capsid, diffusion 
of S or P in or out of the capsid has no effect on the activity of the enzyme. c) A typical 
confocal fluorescence image (1.68 µm × 1.68 µm) showing the formation of a 
fluorescent product (rhodamine 6G) from a nonfluorescent substrate 
(dihydrorhodamine 6G) by HRP encapsulated inside a capsid. Inset: AFM image (to 
scale) at the same sample location, showing that only a small fraction of the capsids 
contain an active enzyme molecule. d) A mixture of nonencapsulated HRP and CCMV 
capsid shows localized activity; no product accumulation is observed. e) Consecutive 
scanning confocal fluorescence images of HRP encapsulated in CCMV capsid during 
the catalytic conversion of dihydrorhodamine 6G. The first image shows accumulated 
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product molecules, which, over time, are bleached until a constant level is obtained. 
During this time the background fluorescence level increases. The time interval between 
the images is 144 s. 
To further prove that the bright fluorescent spots in Figure 7.4c are the result of 
enzymatic activity localized inside the capsid, the fluorescence of one of these bright 
spots was followed over time (Figure 7.5a). A strongly fluctuating intensity trace was 
clearly visible over time, whereas a time trace at a dark area away from the capsid 
showed only poissonian background fluorescence. In the case of the nonencapsulated 
enzyme in the presence of empty capsid, time traces measured at the fluorescent spots 
(Figure 7.5b) also showed a strongly fluctuating behavior. The enzyme traces were 
characterized by alternating bursts of fluorescence, followed by relatively long periods 
of background noise. Initially, we intended to investigate the enzyme behavior by 
analyzing the individual turnovers, as previously performed in our group for the study 
of the catalytic activity of single lipase enzymes by using confocal fluorescence 
microscopy.[6,8] However, this was not a possibility because in the case of the 
encapsulated HRP the time trace does not reach the background level after each 
turnover and this is required to apply statistics to the turnovers measured. Therefore, 
another approach was followed to analyze the above observations, namely, by using 
FCS. Autocorrelation curves G(t) were calculated from the time traces in Figure 7.5a 
and b, according to Equation (1):  
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The curves are plotted in Figure 7.5c, and interestingly, the two curves show completely 
different signatures. The curve for the HRP-included CCMV complex (red squares in 
Figure 7.5c) fits well with the simple diffusion model given in Equation (2): 
 
)/(1
11)(
DtN
tG τ+= , 
(2) 
in which N  is the average number of fluorescent product molecules in the observed 
volume and τD is the characteristic diffusion time.[32] In the present example, the best fit 
is obtained for τD = 19.5 ms. For rhodamine in pure water, a τD value of 0.04 ms is 
reported,[33] a difference of almost three orders of magnitude compared with the HRP-
containing CCMV capsid. We attribute this difference in τD to the hampered diffusion 
of the product molecules through the pores in the CCMV capsid wall. Although the 
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diffusion model appears to fit the data nicely, apart from the aimed conversion, 
processes such as auto-oxidation also probably play a role. Despite this simplification, 
the model provides solid information about the timescales of the processes that occur 
and the accumulation of product within the capsid. 
The simple diffusion model in Equation (2) could not describe the autocorrelation curve 
for the nonencapsulated HRP enzyme. In this case, the curve was fitted best by using 
Equation (3), 
τ/)( tAetG −= , 
(3) 
which is a model for a thermodynamic equilibrium[34] between a fluorescent and a non-
fluorescent state, in this case the steady-state equilibrium  
 
 enzyme Æ enzyme–substrate complex Æ fluorescent enzyme 
  –product complex* Æ enzyme. 
 
In Equation (3), A is a pre-exponential constant and τ is the turnover time; this, together 
with the observation that the activity is localized, leads us to conclude that the HRP 
enzyme molecules are adsorbed to the outside of the capsid. 
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 c) 
 
Figure 7.5 Single-capsid experiments. a,b) Fluorescence intensity time traces measured 
on bright spots in the confocal fluorescence images obtained from samples in which 
HRP is either a) encapsulated inside a capsid (as depicted in Figure 7.4a) or b) simply 
mixed with empty CCMV capsids (as depicted in Figure 7.4b). Insets: left, 10 s zoom-in; 
right, background fluorescence measured at dark areas of the images. c) Fluorescence 
autocorrelation curves of the traces in a and b. Squares: Fluorescence autocorrelation 
curve of the HRP–CCMV capsid inclusion complex during catalysis. The continuous 
line is the best fit obtained by using a diffusion model. Circles: fluorescence 
autocorrelation curve of the mixture of non-encapsulated HRP and the CCMV capsid. 
The continuous line is the best fit obtained by using a model for a chemical 
equilibrium.[34] To emphasize the difference between the two models, each curve is also 
fitted with the model used for the other case (dotted lines), yielding very poor fits.  
 
 Confocal analysis of the CCMV capsid permeability when varying pH 
The pore size of the intact CCMV is known to depend on the pH.[35] At pH 5 the virus is 
compact with small pores (< 2 nm), but at pH 7.5 it is swollen and contains pores of 
≥ 2 nm. Upon standing at this pH, depending on the salt concentration, the virus slowly 
disassembles into dimers such information on pore size is not available in the literature 
for the CCMV capsid. To investigate the influence of the pore size on the behavior of 
the capsid nanoreactor, the apparent diffusion times τD of one single capsid at several pH 
values were measured (Figure 7.6). After addition of substrate and having localized a 
fluorescent spot corresponding to a single capsid, aliquots of NaOH solution were added 
to the sample on the glass support. Two minutes after every addition, time traces were 
collected, always on the same spot. The time traces were subsequently autocorrelated 
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for every pH value (Figure 7.6a) and all curves fitted well with a diffusion model. The 
diffusion time τD clearly decreased when the pH was increased and revealed a step at 
around pH 5.7, as observed in the plot in Figure 7.6b. This experiment indicates that the 
permeability of the capsid wall increases by a factor of 2–3 when the pH increases, 
which is probably associated with the formation of larger pore sizes. We can rule out the 
possibility that the decrease of τD by increasing the pH is due to an effect of the pH on 
the HRP activity. The optimum pH for HRP is in the range of 6.0 to 6.5, and the activity 
at 7.5 is 84% of the maximum activity, which means that upon increasing the pH fewer 
products are formed per unit of time. These observations, furthermore, indicate that the 
monitored processes take place inside the capsid cavity. 
 
 
Figure 7.6 a) Fluorescence autocorrelation curves obtained when studying the 
permeability of the HRP-containing CCMV capsid is studied as a function of pH. 
b) Measured correlation times τD as a function of pH during the enzymatic formation of 
rhodamine 6G by the HRP–CCMV capsid inclusion complex showing a step at pH 5.7, 
indicating a sudden increase in pore size. 
 
 
7.3 Conclusion 
 
The assembly–disassembly properties of CCMV allowed us to encapsulate HRP in the 
CCMV capsid by using the inclusion protocol described in Chapter 6 for different 
proteins. In this way we were able to construct the first enzyme-loaded viral 
nanoreactor. The inclusion of HRP is a statistical process in which the number of 
encased enzymes is determined by the starting concentration of the enzyme. Under the 
applied experimental conditions, it can be assumed that, as intended, not more than one 
HRP enzyme molecule was encapsulated within a CCMV particle. The activity of the 
encapsulated enzyme was studied at the single-capsid level by using confocal 
fluorescence microscopy. The resulting data provided information about the location of 
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the enzyme, that is, in the CCMV capsid or on the capsid outer surface, and about the 
permeability of the viral capsid when changing the solution conditions, namely, pH.  
 
 
7.4 Experimental Section 
  
 Materials 
Sodium acetate trihydrate (>99%) and uranyl acetate dihydrate (≥98%), D-(+)-glucose 
monohydrate (≥99.5%), and ABTS (≥99%) were purchased from Fluka. 
Ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate (>99%), 
tris(hydroxymethyl)aminomethane (Tris) (>99%), calcium chloride dihydrate (>99%), 
and sodium chloride (99.5%) were purchased from Acros. Type XII HRP (E.C. 
1.11.1.7), type X-S from Aspergillus niger glucose oxidase (E.C. 1.1.3.4), and 
phenylmethanesulfonyl fluoride (PMSF) (≥98.5%) were purchased from Sigma Aldrich. 
HRP was labeled by using Alexa-Fluor 532 succinimidyl ester or Alexa Fluor 488 
carboxylic acid TFP ester, bis(triethylammonium salt), following the protocol provided 
with the labeling kits by the supplier (Molecular Probes, Invitrogen). Dihydrorhodamine 
6G was purchased from Molecular Probes, Invitrogen.  
 
 Instrumentation 
UV/Vis spectroscopy was performed on a Varian Cary 50 spectrophotometer at room 
temperature using a 45 μL quartz fluorescence cell (Hellma, light path: 3 mm). The 
reference spectrum of the corresponding buffers were subtracted from all UV/Vis 
spectra. 
Fluorescence spectroscopy was performed on a Perkin–Elmer LS 50B fluorescence 
spectrophotometer. Experiments were carried out using a 45 μL quartz fluorescence cell 
(Hellma, light path: 3 mm) at 10 °C. 
Fast protein liquid chromatography (FPLC) was performed on an Ettan Akta LC 
system equipped with a Superose 6 PC 3.2/30 column from Amersham Biosciences 
(flow rate: 40 μL min−1). Injections of 20 μL aliquots of the samples on the FPLC 
column at room temperature were monitored by UV/Vis detection at 403 nm, 280 nm, 
and 260 nm. 
Dialysis was performed by using dialysis tubing (Spectra/Por 4, MWCO: 12–14 kD, 
Flat width: 25 mm) purchased from Spectrum Laboratories and a D-tube dialyzer 
(MWCO: 12–14 kD, volume: 1–3 mL) from Novagen. 
Cryo-transmission electron microscopy images were obtained by applying small 
aliquots (3 μl) of the solutions to Quantifoil grids (R2/2 Quantifoil Jena) within the 
environmental chamber (relative humidity 100%) of an automated vitrification robot, 
namely, an FEI Vitrobot™ Mark III at 22 °C. The Quantifoil grids were treated with a 
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surface plasma treatment using a Cressington 208 carbon coater operating at 5 mA for 
40 s prior to the sample preparation and vitrification procedure. The sample vitrification 
procedure consisted of automated blotting and plunging into liquid ethane. After 
vitrification the grids were transferred to a Gatan cryo-holder operating at 
approximately −170 °C. TEM was performed under low-dose conditions on an FEI 
Titan Krios equipped with a field emission gun (FEG) operating at 300 kV. Images 
were recorded by using a Gatan GIF energy filter and a 2k × 2k Gatan CCD camera. 
Confocal fluorescence microscope setup: Laser light (Spectra-Physics 2080 argon ion 
laser, 488 nm) was coupled into a single-mode optical fibre, passed through a 488-nm 
interference filter, reflected by a dichroic beam splitter (Chroma, 505dcxr) and focused 
on the sample by an oil immersion ×100 objective lens (Karl Zeiss, NA = 1.30), which 
was mounted on a Karl Zeiss Axiovert 200 inverted microscope. The confocal volume 
of the sample beam was determined to be 0.5 fl. The power density at the sample was 
1–2 kW cm−2. Fluorescent light emitted from the focal volume was collected by the 
same objective, passed through the dichroic beamsplitter, filtered (Chroma, HQ500lp), 
guided through a 50 μm pinhole, and finally focused on an avalanche photo diode 
(Perkin–Elmer SPCM-AQR-14), which was coupled to a National Instruments PCI-
6036E data acquisition card operating at 20 MHz. The sample was mounted onto a JPK 
TAO nanopositioner. Data collection and analyses were carried out with programs 
written in National Instruments LabVIEW 7.1. 
Atomic force microscopy (AFM) measurements were performed on a JPK (Berlin, DE) 
Nanowizard machine with a 100 × 100 μm XY scanner and a TAO (tip-assisted optics) 
module. Experiments were carried out with 125 μm long silicon tips (Nanoworld 
[Neuchatêl, CH] NCH 20 POINTPROBE) with average nominal resonant frequencies 
of 320 kHz and average nominal force constants of 42 N m−1. Scanning was performed 
in the tapping mode at a speed of 1 line s−1 with amplitude setpoints of 0.7 V. JPK SPM 
software was used to control the AFM and to process (linear leveling) the data. The 
sample was prepared by spin-coating onto a thoroughly cleaned objective glass after 
which the measurements were carried out.  
 
 HRP encapsulation experiment 
HRP encapsulation in the CCMV capsid: The purification of CCMV and the isolation 
of its coat protein were performed as described in Chapters 3 and 4. A solution 
containing the proteins that comprise the CCMV coat (300 μl, 22.1 mg mL−1) in sodium 
acetate buffer (0.05 M, pH 5) was dialyzed against three changes of Tris–HCl buffer 
(500 mL, 0.05 M, pH 7.5) (3 h per change). When the solution had reached pH 7.5, the 
guest enzyme solution (300 μl) in Tris–HCl buffer (0.05 M, pH 7.5) was added in 
excess (66 equiv of HRP per capsid particle—one capsid particle corresponds to 90 
capsid protein dimers) and the resulting solution was incubated for 1.5 h. Dialysis of the 
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incubated solution against the initial sodium acetate buffer was carried out under the 
same dialysis conditions as above. The samples were concentrated and the free guest 
enzyme was removed by using centrifugal filter devices (Centricon YM-100, Millipore). 
The samples obtained from the encapsulation and control experiments were analyzed 
and purified by FPLC. Injections of 20 μl aliquots of the samples on the FPLC column 
at room temperature were monitored by using UV detection at 280 and 403 nm. 
Fractions of 60 μl were collected and those corresponding to the purified HRP-
containing CCMV capsid, were further analyzed by fluorescence spectroscopy and 
TEM. The HRP used in the experiments was labeled with Alexa Fluor 532 dye 
(λexc = 530 nm).  
All buffer used solutions contained 1 mM EDTA, 300 mM NaCl, 10 mM CaCl2, and 
0.2 mM phenylmethylsulphonyl fluoride. Buffers were stored at 4 °C, and the dialysis 
was performed in a cold room at 4 °C. Later experiments showed better results when 
500 mM of NaCl was used instead of 300 mM. An increase in the amount of salt 
enhances the stability of the assembled capsid (for further details about the assembly see 
Chapter 4). 
 Activity of HRP-containing CCMV capsids in bulk: The purified fractions of the HRP-
containing CCMV capsids obtained after FPLC were subjected to the HRP activity 
assay. An ABTS/glucose oxidase (GOx)/glucose solution was prepared in a sodium 
acetate buffer (1 mL, 0.05 M, pH 5) with [ABTS] = 0.26 mM, [GOx] = 10–6 mM, and 
[glucose] = 41 mM. Subsequently, an aliquot (5 μL) of the fraction containing HRP 
encapsulated in the CCMV capsid, or the corresponding fraction of the control 
experiment, was added to 115 μL of the solution. The enzyme activity was monitored 
by measuring the absorbance at 405 nm using UV/Vis spectroscopy on a Perkin-Elmer 
Wallac 1420 Victor multilabel counter. A similar experiment was performed for free 
HRP in solution.  
 
 Confocal fluorescence microscopy studies 
Study of the encapsulated HRP activity at the single-molecule level by confocal 
fluorescence microscopy: A solution of the HRP-containing CCMV capsid (10 μl, 
3 μg L−1) was spin-coated at 4000 r.p.m. on a clean, hydrophilic cover glass after which 
the glass was quickly rinsed with 4 × 1 mL of MilliQ water while spinning. After 
mounting the sample on the microscope, 200 μl of a solution containing 120 μM of 
H2O2 and 0.5 μM of dihydrorhodamine 6G was added. Dihydrorhodamine 6G acts as a 
hydrogen donor in the enzymatic reduction of hydrogen peroxide by HRP, yielding the 
highly fluorescent product rhodamine 6G. As a control experiment for the activity 
studies at the single-molecule level, a mixture of nonencapsulated HRP and CCMV 
capsid solution was prepared and analyzed by confocal fluorescence microscopy in the 
same way as described above for the HRP-containing CCMV capsid. 
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Study of the CCMV capsid permeability by confocal fluorescence microscopy: To 
investigate the influence of the pH on the behaviour of the viral nanoreactor, the 
apparent diffusion times τD of a single capsid at several pH values were measured. 
Samples were prepared in the same way as described above. After the addition of the 
substrate and having localized a fluorescent spot corresponding to a single HRP-
containing capsid, 2-µL aliquots of a NaOH solution (0.1 M) were added every 5–
7 min. The volume of the aliquots was chosen based on the results on larger scale 
experiments, in which the pH was monitored by using a pH-meter. During the confocal 
experiments, the pH was confirmed with the help of pH indicator paper. After every 
addition, the area where the spot was localized was scanned to check its position and a 
2 min time trace was measured, always on the same spot. The autocorrelation curves 
were calculated from the time traces for every pH and the diffusion time τD was deduced 
for every one of them. All curves fitted well with the diffusion model, but the 
correlation time τD varied upon changing the pH. 
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CHAPTER 8  
Controlled Integration of Polymers into Viral 
Capsids 
 
8.1 Introduction 
 
Based on their reciprocal relationship, biology and chemistry are converging more and 
more into a new discipline called chemical biology. This discipline aims to understand 
biological issues at the chemical level, for instance, by the probing of biomolecules with 
synthetic compounds that interact with them. An opposite trend is also receiving much 
attention, namely, the synthesis of new materials and catalytic systems inspired by 
biological structures and pathways.[1,2] In this context viruses are also playing a role as a 
biological object that can be chemically modified. Viruses are biological entities that 
operate at the interface of non-living and living matter and as such they occupy a special 
and unique position.[3] Although they are structurally complex, viruses do not have a 
metabolism of their own and their chemical machinery is relatively simple to 
manipulate. The size and shape of viruses, as well as the number and location of the 
functional groups on their inner and outer surfaces, are precisely defined. A new 
emerging field uses viruses as platforms for the controlled positioning of chemical 
species with different functions at the nanoscopic level.[4,5]  
The decoration of the outer surfaces of icosahedral and rod-like viruses, using genetic 
and chemical manipulation has been explored in recent years by a number of groups. 
Different moieties, including metal nanoparticles, fluorescent dyes, biotin, histidine 
tags, carbohydrates, DNA, peptides, proteins, conducting compounds, and luminescent 
quantum dots, have been attached to a variety of viruses.[4-8] Also the use of the hollow 
cavities of icosahedral viral capsids and other protein cages has been explored, for 
example, as nanocontainers. For instance, inorganic nanoparticles, can be easily 
synthesized by nucleating mineralization reactions inside nucleic acid free viral capsids 
of different sizes.[9,10] The catalysis of organic reactions within these nanocontainers is 
also possible. Reactions catalyzed by encapsulated metal clusters,[11-14] palladium 
complexes,[15] and enzymes, have been reported in the literature.[16] 
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The covalent attachment of natural[17,18] and synthetic organic polymers to the exterior 
surface of a virus particle is an interesting approach to broaden the applications of 
viruses in medicine and nanotechnology.[19] Such modification might change the 
stability of the viral cages. Synthetic polymers may also impart solubility in organic 
solvents and new self-assembling properties to the virus particles. To date only three 
examples of the functionalization of the outer surface of viral capsids with synthetic 
polymers are known in the literature. The outer surfaces of the tobacco mosaic virus 
(TMV),[20] the cowpea mosaic virus (CPMV),[21-23] and the bacteriophage MS2[24] have 
been modified with poly(ethylene glycol) (PEG) and the resulting conjugates were 
found to display new solubility properties and altered immunogenicity, consistent with 
the known chemical and biological properties of PEG.[25,26]  
The encapsulation of synthetic polymers inside viral capsids allows the formation of so-
called virus-like particles (VLPs), which have the potential to be used as new building 
blocks for the preparation of nanostructured materials.[27] Given their large size, 
macromolecules cannot penetrate a virus through its pores, requiring that the virus 
particle displays the ability to reversibly disassemble/assemble to allow the polymer 
molecule to be encapsulated. One of the most widely studied viruses in this context is 
the cowpea chlorotic mottle virus (CCMV).[28] The icosahedral capsid of CCMV has an 
outer diameter of 28 nm and a well-defined inner cavity with a diameter of 18 nm. It is 
formed from 90 homodimers of 20 kDa coat protein (CP) subunits arranged with T = 3 
Caspar-Klug symmetry around a central RNA strand. The CP consists of 189 amino 
acids with nine basic residues at the N-terminal RNA binding domain. An interesting 
property of CCMV is its reversible disassembly–assembly behavior depending on the 
pH and ionic strength.[29] By varying these conditions, CCMV virions can be 
disassembled in vitro into protein dimers and, after removal of the RNA, re-assembled 
again to form empty capsids. This pH-dependent behavior, has been used to encapsulate 
a number of species, such as proteins,[16] inorganic nanoparticles,[30,31] and 
polymers.[32,33]  
Despite the fact that the CCMV capsid was assembled in vitro for the first time more 
than 40 years ago,[34] the mechanistic understanding of the assembly process is still not 
completely clear, especially with regards to the occurrence of polymorphism when the 
viral proteins are assembled in the presence of different types of cargoes. The CCMV 
coat protein can form, depending on the conditions, a variety of structures including 
tubes and icosahedral capsids with Caspar-Klug triangulation numbers of T = 1, 3, 4, 
and 7 (see Appendix).[35,36] Inclusion of negatively charged polymers strongly 
influences the CP self-assembly process, giving rise to the formation of VLPs with only 
one of the above-mentioned symmetries. Polystyrene sulfonate (PSS), for example, is 
able to produce T = 1 particles at neutral pH[32] and particles with a T = 2 or 3 geometry 
at pH 5,[33] whereas tubular structures are obtained when double-stranded DNA is used 
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as the polymeric cargo.[37] The covalent modification of the protein molecules on the 
outer surface of CCMV capsids is also expected to alter their stability and assembly 
properties in a similar way as observed for other types of viruses.[38] This may be 
particularly relevant when organic polymers are used as decoration motifs, owing to the 
characteristic phase behavior of these polymers. Understanding the interplay between 
the different effects that the incorporation of organic polymers, either inside the viral 
capsid or covalently attached to the outer surface, can have on the stability and 
assembly of VLPs appears to be a crucial factor in the design and preparation of virus–
polymer hybrid materials. 
As part of our efforts to develop methodologies that enable the precise positioning of 
different synthetic polymers in viral architectures, we describe herein the controlled 
attachment of PEG to the outer surface of the CCMV capsid and the incorporation of 
PSS into the inner cavity of this virus. Our strategy relies on the combined use of the 
assembly–disassembly properties of the viral protein and the successive incorporation of 
the two polymers (Scheme 8.1). First, the native CCMV is modified by the covalent 
binding of PEG chains to its surface. At this stage the interfering functionalization of 
internal lysine and arginine residues is blocked because they strongly interact with the 
viral nucleic acid that is still present inside the capsids. After complete dissociation of 
the modified virus into protein subunits and precipitation of the RNA, the addition of 
PSS results in the formation of VLPs. PSS does not only play the role of guest during 
the encapsulation process, but also acts as a template for the assembly. The electrostatic 
interactions between PSS and the positive N termini of the CPs are the driving force to 
overcome the lower tendency of PEG-functionalized protein subunits to associate with 
each other. 
 
Scheme 8.1 Schematic pathway for the formation of PSS–CCMV–PEG virus-like 
particles. 
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8.2 Results and Discussion 
 
 Formation of PEG-functionalized CCMV 
According to the crystallographic data of the CCMV structure, there are four lysine 
groups per subunit accessible on the exterior surface, from which only three seem to be 
available for functionalization.[39,40] This abundance of reactive amine groups on the 
virus surface allows for facile and high-yielding modification by using N-
hydroxysuccinimide (NHS) esters. Hence, the current study began with the synthesis of 
α-NHS ester ω-fluorescein-functionalized PEG with Mn = 3000 Da (compound 1 in 
Scheme 8.2). Labeling with a fluorescein moiety was used as a means to advance the 
characterization of the CCMV–PEG hybrids.  
In the first step α-amine ω-carboxylic acid PEG (Mn = 3000) was treated with 
fluorescein carrying an NHS-activated ester moiety to obtain polymer 2 (Scheme 8.2). 
Complete conversion was indicated by 1H NMR spectroscopy, which showed that the 
signals corresponding to the protons next to the amine moiety (δ = 3.1 ppm) in the 
polymer had disappeared, confirming the successful attachment of the fluorescent dye. 
Subsequently, the remaining carboxylic acid functionality of PEG was converted into an 
activated ester by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) coupling with NHS. The stoichiometry was chosen such that only the α-
carboxylic acid group of PEG was activated and not the carboxylic acid moiety on the 
fluorescein. 1H NMR spectroscopy and MALDI-TOF analysis confirmed the formation 
of compound 1. 
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Scheme 8.2 Synthesis of α-NHS ester ω-fluorescein-functionalized PEG (1).  
 
The attachment of PEG chains to CCMV was accomplished by mixing compound 1 
with a solution of this virus in phosphate buffer (pH 7.5) (Scheme 8.3) at various 
CCMV CP / PEG molar ratios (samples A (1:50), B (1:25), C (1:10), and D (1:1)). The 
mixtures were incubated for 2 h at room temperature and subsequently kept overnight at 
4 ºC. As a control experiment CCMV was mixed with α-carboxylic acid ω-fluorescein 
functionalized PEG-3000 (2) (Scheme 8.2), the unactivated polymer derivative, in a 
CP / PEG molar ratio of 1:50. In all cases, the virus–polymer products were purified by 
SEC using a Sephadex G-100 preparative column. A clear separation between the 
functionalized virus and the excess polymer was observed for the samples containing 1. 
 
 
Scheme 8.3 Functionalization of the CCMV surface-exposed amine groups with 1. 
 
The presence of virus–polymer conjugates was confirmed by UV/Vis spectroscopy, fast 
protein liquid chromatography (FPLC), transmission electron microscopy (TEM), and 
gel electrophoresis (Figure 8.1). The FPLC chromatograms of all samples (A–D) 
showed peaks at a retention volume of V = 0.90 mL, which is lower than the 
characteristic elution volume of the virus under the same conditions (V = 1.06 mL) 
(Figure 8.1a), suggesting the formation of larger particles.[41] The formation of 
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polymer–virus conjugates was further evidenced by the clear absorption at λ = 490 nm 
(for the peak at V = 0.90 mL) resulting from the fluorescein moiety attached to the 
polymer. The UV/Vis spectra of fractions taken directly from the FPLC column at 
V = 0.90 mL showed absorption bands from both the polymer (λ = 490 nm) and the 
virus (λ = 260 nm), corroborating the FPLC results.  
The same conclusion could be drawn from agarose gel experiments, in which the virus–
polymer conjugates were found to run slower than the native virus (Figure 8.1b). SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) confirmed the covalent attachment of 
several polymeric chains to the protein subunits, namely, the presence of additional 
bands above the underivatized capsid proteins (Figure 8.1c and d). The average number 
of PEG chains per protein subunit could be estimated from the ratio of the absorbance 
values at λ = 490 and 260 nm for the FPLC fractions at V = 0.90 mL. A good 
correlation with the initial ratios of protein and polymeric material used to prepare the 
reaction mixtures was observed. A maximum number of 2–3 PEG chains per protein 
subunit were found in the case of a 1:50 initial CP / PEG ratio (Figure 8.1e), which is in 
good agreement with the anticipated number of available amine groups on the outer 
surface of CCMV. The SDS-PAGE results suggest that the degree of functionalization 
of the coat protein is similar for all samples B–D (Figure 8.1c), while sample A contains 
small amounts of protein having a higher degree of functionalization (Figure 8.1d). The 
varying ratios of PEG / CP observed in Figure 8.1e likely originate from differences in 
the amount of PEG-functionalized CP subunits in the conjugates rather than to their 
different degrees of functionalization. According to Figure 8.1e and taking in account 
that there is always a mixture of PEG-functionalized and non-functionalized CP in all 
samples, the degree of functionalization for samples B–D corresponds to a CP monomer 
functionalized with 3 PEG tails. 
The CCMV–PEG particles were deposited on a carbon-coated copper grid and studied 
with TEM (Figure 8.1a, inset). The measured virus particle diameters were in agreement 
with the diameter of the wild-type virus (ca. 28 nm). None of the above techniques 
showed evidence for the formation of CCMV–PEG conjugates in the control 
experiment. 
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Figure 8.1 Analysis of the CCMV–PEG conjugates. a) FPLC chromatograms of SEC-
purified sample B (1:25), and wild-type CCMV under the same conditions of pH and 
ionic strength (detection at 280 nm (grey), at 260 nm (black), and at 490 nm (dash)). 
Inset: TEM micrograph of the FPLC fraction corresponding to the CCMV–PEG 
conjugate. b) Agarose gels showing the CCMV–PEG conjugates (lane 1), CCMV virus 
(lane 2), and CCMV + inactivated polymer 2 (lane 3) visualized under a fluorescence 
image analyzer. RNA detection (left) and protein detection (Coomassie Blue staining, 
right). c) SDS-PAGE gel showing the protein size marker (lane 1), CCMV virus 
(lane 2), CCMV + inactivated polymer 2 (lane 3), and samples A (1:50; lane 4), B 
(1:25; lane 5), C (1:10; lane 6), and D (1:1; lane 7), all visualized using Coomassie 
Blue staining. d) SDS-PAGE gel showing the protein size marker (lane 1), different 
batch of sample A (1:50; lane 2), and CCMV + inactivated polymer (2) (lane 3), all 
visualized using Coomassie Blue staining. The bands that appear above 40 kDa 
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observed for 2 and 3, correspond to dimers that have not been completely released 
during the denaturation process. e) Plot showing the estimated number of PEG chains 
per CP subunit versus the initial PEG / CP molar ratios used to prepare the reaction 
mixtures. 
   
 Stability of PEG-functionalized CCMV 
During the characterization of samples A–D by FPLC it was observed that a substantial 
decrease in the intensity of the peak at V = 0.90 mL occurred after successive injections 
of the same sample. It seemed from these data that the grafting of PEG chains onto 
CCMV forced, to a certain degree, the disassembly of its capsid. To unravel the details 
and extent of this process, the stability of the CCMV–PEG assemblies was 
systematically studied over time. All samples showed the same behaviour, therefore, 
only the results for sample B are shown (Figure 8.2). The mixture obtained after the 
reaction and the preliminary SEC purification (Sephadex G-100) was analyzed by FPLC 
at different times over a three week period. Besides the peak at V = 0.90 mL, two 
additional peaks were initially present in every FPLC chromatogram (Figure 8.2a), 
which seem to correspond to polymer aggregates (V = 1.60 mL) and the polymer itself 
(V = 1.95 mL), which in addition co-elutes with non assembled derivatized and 
underivatized CP (see below). Their assignment is discussed in the Experimental 
Section in detail (see Section 8.4). A decrease in the intensity of the peak at 
V = 0.90 mL, recorded by following the absorbance at λ = 280 nm, was observed over 
time (Figure 8.2b). Simultaneously, the intensity of the peak at V = 1.95 mL increased, 
while the peak at V = 1.65 mL stayed more or less constant. This result points to the 
disassembly of the conjugates into species that elute at similar retention volumes as the 
polymer.  
To obtain more insight into the disassembly process, the fraction at V = 0.90 mL from 
the FPLC chromatogram in Figure 8.2a, which contains the pure CCMV–PEG 
conjugates, was also re-injected at different time intervals. The evolution of the pure 
CCMV–PEG conjugates over time showed the same tendency as that observed for the 
original samples A–D. Whereas only the peak associated with the conjugates 
(V = 0.90 mL) appeared in the FPLC chromatograms after one day, the intensity of this 
peak rapidly decreased over time, concomitantly with the formation of a new peak at 
V = 1.95 mL (Figure 8.2c). This process can be illustrated by plotting the ratio of the 
intensities of the two peaks at various wavelengths as a function of time (Figure 8.2d). 
Analysis by SDS-PAGE, UV/Vis, and infrared spectroscopy confirmed the presence of 
both protein and polymer in the fraction corresponding to the 1.95 mL peak (Figure 8.6 
in the Experimental Section). The elution volume of the peak is larger than that of the 
unfunctionalized CP dimers (V = 1.78 mL), suggesting that PEG-functionalized CP 
monomers and not dimers are generated during the disassembly. Nevertheless, it cannot 
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be excluded that the peak consists of both functionalized and unfunctionalized CP 
subunits.  
a) 
 
b) 
c) 
 
d)
Figure 8.2 Stability studies on sample B (sample was first purified on Sephadex G-100). 
a) FPLC chromatogram after 1 day. b) Absorbance at λ = 280 nm as a function of time 
for the different peaks observed after injection of sample B. c) FPLC chromatogram of 
the re-injected fraction at V = 0.90 mL in a) one day after the first injection. Inset: 
magnification of the peak at V = 1.95 mL. d) Plot of the ratio of intensities of peaks at 
V = 0.90 and 1.95 mL for the re-injected fraction as a function of time.  
 
The whole set of experiments suggests a scenario for the disassembly of CCMV–PEG 
conjugates as depicted in Scheme 8.4. The slow but irreversible dissociation of the 
CCMV–PEG conjugates is probably a consequence of the disruption of protein–protein 
interactions caused by steric interference due to the presence of the PEG chains. The 
influence that organic substituents can exert on the assembly of viral capsids has 
previously been studied for the hepatitis B virus (HBV), the assembly process of which 
was misdirected to the formation of much larger particles than that of the native 
virus.[38] The stability studies described above provide more information on this kind of 
phenomenon. The tendency of the CCMV–PEG conjugates to dissociate should be 
taken into account as a very likely side process if one aims to decorate CCMV with 
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organic polymers. The potential instability of these CCMV assemblies, however, does 
not exclude further experiments, as described below. 
 
Scheme 8.4 Tentative scenario proposed for the disassembly of CCMV–PEG conjugates 
into CP bearing PEG chains and nonfunctionalized CP. 
 
 Assembly of PSS–CCMV capsid–PEG virus-like particles 
Before studying the reassembly of the PEG-functionalized coat proteins into virus-like 
particles, the RNA, which was still present, had to be removed. Dialysis of samples A–
D against Tris-HCl buffer (pH 7.5, 1.0 M NaCl) allowed the viral genomic material to 
precipitate. After ultracentrifugation and collection of the supernatant, the samples were 
free from RNA, as evidenced by the absence of the characteristic absorption at 
λ = 260 nm (Figure 8.3a). SDS-PAGE analysis of the supernatant revealed that both 
functionalized and unfunctionalized CP subunits were isolated (Figure 8.3b). 
Furthermore, it could be concluded from their high elution volume in the FPLC 
chromatograms (Figure 8.3c) that the CP subunits were still present in their monomeric 
form.  
a) b) 
 
c) 
Figure 8.3 Analysis of the isolated product after RNA removal from the CCMV–PEG 
conjugates. a) UV/Vis spectrum of the supernatant. The usually high absorbance value 
at λ = 260 nm, due to the presence of RNA, is now shifted to λ = 280 nm, the 
characteristic wavelength maximum of the protein. b) SDS-PAGE of the isolated PEG–
CP (supernatant after ultracentrifugation). c) FPLC chromatogram of the supernatant.  
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By following the approach described by Sikkema et al.,[32] the isolated PEG-
functionalized coat proteins were re-assembled using PSS (Mw = 70,000 g mol−1) as the 
template. The assembly was performed at pH 7.5 with a ratio of approximately 15 PSS 
repeating units per CP, which is within the optimal range of values described for the 
formation of T = 1 particles.[42] One interesting question is what effect the presence of 
PEG chains attached to the CP will have on the assembly process. A convenient way to 
evaluate this would be to assemble mixtures that have different compositions of 
functionalized and unfunctionalized CP to test the extent to which the particles are 
formed as well as their degree of coverage with PEG chains. To this end, five different 
mixtures of CP and PEG–CP (samples E–I, containing 0, 25, 50, 75, and 100% PEG–
CP, respectively), in the presence of PSS, were prepared and studied. The 
unfunctionalized CP was prepared as described in Chapter 4. 
After mixing the components of samples E–I at pH = 7.5 and incubating for 30 min at 
room temperature, the mixtures were purified by FPLC chromatography and further 
analyzed by fluorescence spectroscopy, SDS-PAGE, and TEM (Figure 8.4). A peak at 
V = 1.35 mL in the FPLC chromatograms indicated the formation of T = 1 particles for 
the various CP / PEG-CP ratios employed in the experiment (Figure 8.4a and b). All 
samples gave similar chromatograms, and differed only in the intensity of this peak at 
different wavelengths. Moreover, the presence of an absorbance at λ = 280 and 490 nm 
demonstrated that both the CP and polymer were constituents of the material eluting at 
V = 1.35 mL. This result was further confirmed by the fluorescence spectrum of this 
FPLC fraction, which showed a clear emission at λ = 520 nm when excited at 
λ = 490 nm (Figure 8.4c) due to the presence of the fluorescein dye. On the contrary, no 
absorption at λ = 490 nm and fluorescence at λ = 520 nm were detected for sample A, 
which contained no PEG–CP. In addition to the peak at V = 1.35 mL, there were peaks 
of other material eluting at higher volumes in the chromatograms. The nature of this 
material is as yet unknown, although it probably consists of highly PEG-functionalized 
CP monomers and residual polymer, which are not able to assemble around the PSS.  
Interestingly, the FPLC chromatograms of samples E–I did not change over time. It 
therefore seems that the PSS–CCMV capsid–PEG particles are more robust than their 
CCMV–PEG conjugate predecessors. The particles were also found to be stable at 
pH 5.0 because dialysis against an acetate buffer at this pH value did not lead to 
substantial changes in the FPLC results. The electrostatic interactions between the 
negative charges of PSS and the positively charged N terminus of the coat protein 
molecules are likely to be the reason for this remarkable increase in robustness. 
The degree of coverage of the PSS–CCMV capsid–PEG particles with PEG chains, 
when using different CP / PEG-CP ratios, was evaluated by plotting the emission at 
λ = 522 nm (λexc = 490 nm) of the FPLC fractions at V = 1.35 mL, normalized to the 
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total concentration of CP present, versus the amount of PEG–CP used in the initial 
assembly mixture. An almost linear relationship was obtained, which showed statistical 
incorporation of PEG onto the T = 1 capsids (Figure 8.4d). 
a) 
 
b) 
c) 
 
d) 
e) 
 
 
f) 
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Figure 8.4  Characterization of PSS–CCMV capsid–PEG assemblies. FPLC 
chromatogram of the PSS–CCMV capsid–PEG assemblies formed using a) 0% PEG–
CP sample (E) and b) 100% PEG–CP sample (I). c) Emission spectra (λexc = 490 nm) 
of the FPLC fractions at V = 1.35 mL of the PSS–CCMV capsid–PEG samples E–I 
prepared with different CP / PEG–CP ratios. d) Emission at λ = 522 nm 
(λexc = 490 nm) of the FPLC fractions at V = 1.35 mL versus the amount of PEG–CP 
used for the assembly in samples E–I. e) Agarose gel of pure PSS–CCMV capsid–PEG 
T = 1 particles (purified by FPLC) prepared from mixtures with different PEG–CP 
content having different amounts of PEG chains: 0 (lane 1), 25 (lane 2), 50 (lane 3), 75 
(lane 4), and 100% PEG–CP (lane 5). The gel was visualized with a fluorescence 
scanner. f) TEM micrograph of the PSS–CCMV capsid–PEG T = 1 particles taken from 
sample G (50% PEG–CP). g) Zoom in on the TEM micrograph shown in (f). h) Size 
distribution of the PSS-CCMV-PEG T = 1 particles shown in (f).  
 
Samples E–I and their FPLC fractions at V = 1.35 mL were further characterized by 
agarose gel electrophoresis (Figure 8.4e). The gel was visualized with the help of a 
fluorescence scanner to detect the fluorescein-labeled PEG chains. The FPLC fractions 
showed single bands running faster than those of the wild-type virus, as expected for 
smaller particles. The fact that these bands are visible by fluorescence is a strong proof 
that PEG is present on the outside of the T = 1 capsids (note the absence of such a band 
in the case of sample E, 0% PEG-CP, lane 1). The degree to which PEG-
functionalization of the particles occurred could even be inferred from the dependence 
of their running speed in the gel on the initial amount of PEG–CP used in the assembly 
mixtures (Figure 8.4e). 
Finally, the PSS–CCMV–PEG particles were studied by TEM (Figure 8.4f–h). This 
study confirmed that the particles are monodisperse spherical capsids with an average 
diameter of 18.5 nm. The particles showed a slightly larger size than the T = 1 particles 
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reported by Sikkema et al.,[32] probably caused by the presence of the PEG tails attached 
to the outer surface of the protein cage. 
 
 
8.3 Conclusion and Outlook  
 
Based on its reversible pH-dependent disassembly/assembly behavior, the CCMV 
capsid is a suitable nanocontainer for the encapsulation of proteins, inorganic 
nanoparticles, and organic polymers.[19] The external functionalization of this capsid 
with synthetic organic polymers will broaden the field of potential applications, for 
example, its use as a nanoreactor or as a building block for the preparation of 
nanostructured materials. We have shown that the covalent attachment of polymer tails 
to the outer surface of the CCMV capsid leads to some thermodynamic instability, 
which forces the virus to disassemble over a period of days. The irreversible 
dissociation of CP dimers, probably due to steric interference between the protein–
protein subunits as a result of the proximity of the PEG chains, is responsible for the 
shift of the equilibrium to complete disassembly of the viral particles. This effect limits 
the potential application of the CCMV–polymer biohybrids, however, this problem can 
be overcome if a PSS guest is present in the modified viral capsids. The methodology 
described herein allows for complete control over the amount of PEG chains attached to 
the PSS–CCMV capsid–PEG particles. Moreover, there is a remarkable increase in their 
robustness compared with the CCMV–PEG conjugates; an important requirement if 
VLPs are to be used in nanotechnology. The polymers chosen for this work are not yet 
functional, but the approach exemplifies a possible future strategy for the design and 
preparation of more sophisticated VLPs. Any negatively charged synthetic polymer 
could in principle be used as a template to direct the viral capsid assembly towards the 
formation of a stable and precisely defined architecture. The use of functional polymers 
both on the inside and the outside of the capsids may impart new properties to the 
particles. Our strategy implies that these properties can be tuned by the proper choice of 
the external polymer and the polymer template. In this regard, the controlled integration 
of polymers with viral capsids represents a promising approach for the synthesis of 
nanostructured materials. 
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8.4 Experimental Section 
 
 Materials 
Uranyl acetate dihydrate (≥98%) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) (≥98%) were purchased from Fluka. Sodium dihydrogen 
phosphate monohydrate (≥99%) and disodium hydrogen phosphate dihydrate (≥99%) 
were purchased from Merck. Fluorescein-NHS (>99%) was purchased from Pierce. 
Ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate (>99%), 
Tris(hydroxymethyl)aminomethane (Tris) (>99%), triethylamine (99%), and sodium 
chloride (99.5%) were purchased from Acros. Ethidium bromide (~95%), Orange G 
(≥80%), N-hydroxysuccinimide (98%), dithiothreitol (DTT) (99%), and poly(sodium 4-
styrene sulfonate) (Mn = 70,000) were obtained from Sigma-Aldrich. Agarose 
(electrophoresis grade) was purchased from Invitrogen. All reagents used for SDS-
PAGE electrophoresis were purchased from Bio-Rad Laboratories. HOOC-PEG-NH2 
(Mn = 3000 Da) was purchased from Rapp Polymere. CH2Cl2 was distilled from CaH2 
under nitrogen 
 
Instrumentation 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Inova 400 
spectrometer at 298 K. 1H NMR shifts (δ) are reported in parts per million (ppm) 
relative to the residual proton peak of the solvent, δ = 7.26 for CDCl3. Multiplicities are 
reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and dd (doublet 
of doublets). The number of protons for a given resonance is shown as nH and are 
derived from spectral integration. 
Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectra 
were measured on a Bruker Biflex III spectrometer. Indole acrylic acid (IAA) was used 
as a matrix. Samples were prepared by mixing 45 µL of a solution of matrix 
(20 mg mL−1) in THF with 5 µL of a solution of polymer (2 mg mL−1) in THF. From 
this mixture, 1 μL of the sample was spotted onto the target plate. 
Infrared spectroscopy was performed on a Thermo Mattson IR300 spectrometer 
equipped with a Harrick ATR. Samples were prepared by evaporating the solvent 
(water), re-dissolving the residue in THF, depositing a drop in the measuring plate, and 
leaving it to dry for 2 min in a nitrogen stream. 
Fluorescence spectroscopy measurements were performed on a Perkin-Elmer LS 55 
fluorescence spectrophotometer. Experiments were carried out using a 40 μL quartz 
fluorescence cuvette (Hellma, path length: 3 mm) or a 1 mL quartz fluorescence cuvette 
(Hellma, path length: 4 mm). 
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UV/Vis spectroscopy measurements were performed on a Varian Cary 50 
spectrophotometer using a 1 mL quartz fluorescence cuvette (Hellma, path length: 
4 mm) and a 40 μL quartz fluorescence cuvette (Hellma, path length: 3 mm). 
Fast protein liquid chromatography (FPLC) was performed on an Ettan Akta LC 
system equipped with a Superose 6 PC 3.2/30 column from Amersham Biosciences 
(flow rate 40 μL min−1). Injections of 50 μL aliquots of the samples were monitored by 
using UV detection at λ = 260, 280, and 490 nm. Fractions of 60 μL were collected and 
further analyzed when necessary. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using a 10% 
polyacrylamide gel containing 10% SDS. The samples were treated with β-
mercaptoethanol and heated before being loaded onto the gel. Gels were visualized by 
Coomassie Blue staining or in cases when the protein concentration was low by silver 
staining. 
Agarose gel electrophoresis was performed from a 1.2% agarose solution mixed with 
10 μL of an ethidium bromide solution (10 mg mL-1). Samples (20 µL) were mixed with 
DNA-loading buffer (6 µL) and loaded onto the gel. Gels were run at 100 V for 1.5 h. 
Gels were analyzed with the help of a FLA-5100 fluorescence scanner. The used 
excitation wavelengths were λ = 473 and 532 nm. Gels were also stained using 
Coomassie Blue. 
Transmission electron microscopy (TEM) micrographs were recorded on a JEOL JEM-
1010 instrument. CCMV–PEG samples were prepared by drying a drop of the solution 
on a carbon-coated or hydrophilized (by glow discharge) formvar-carbon-coated copper 
grid. The excess buffer on the grid was blotted away after 3 min by using filter paper. 
PSS–CCMV capsid–PEG samples were prepared in the same way, but on hydrophilized 
(by glow discharge) formvar carbon grids and blotting the excess solution away after 
1 min. Negative staining of the samples was achieved by application of a drop of a 
uranyl acetate solution (0.2% in MilliQ) onto the grid and blotting the excess liquid 
away after 15 s with filter paper. The samples were left to dry in air for 30 min before 
analysis. 
Ultracentrifugation was performed in a Sorvall Micro (SM) ultracentrifuge (type RC-
M150GX) with a S-120-AT2 type rotor. Thick-walled polycarbonate tubes (V = 1 mL) 
provided by Sorvall were used. 
Dialysis was performed by using dialysis tubing (Spectra/Por 4, MWCO: 12–14 kDa, 
Flat width: 25 mm) purchased from Spectrum Laboratories or D-Tubes Dialyzers 
(MWCO: 6–8 kDa or 12–14 kDa) from Calbiochem. 
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 Synthesis 
α-Carboxylic acid ω-fluorescein functionalized PEG (2) 
All glassware was flame dried and the reaction 
was performed under an argon atmosphere. 
Triethylamine (450 μL, 3.24 mmol) was added to 
a solution of HOOC-PEG-NH2 (1.63 g, 
0.54 mmol) in anhydrous CH2Cl2 (30 mL). After 
stirring for 15 min NHS-fluorescein (328 mg, 0.69 mmol) was added and the mixture 
was stirred for an additional 44 h at room temperature. Upon dilution with CH2Cl2, the 
mixture was sequentially washed with a 10% aqueous citric acid solution and a 
saturated aqueous solution of NaHCO3. The organic phase was dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure to afford an orange solid 
(1.37 g, 73%). 1H NMR (CDCl3, 400 MHz): δ = 1.9 (t, 2H), 2.6 (t, 2H), 3.5–3.7 (m, 
protons PEG + 4H (CH2CH2CH2O)), 6.5–6.8 (m, 6H), 8.1 (m, 1H), 8.3 (m, 1H), 8.6 (s, 
1H).  
 
α-NHS ester ω-fluorescein functionalized PEG (1)  
All glassware was flame dried and the reaction 
was performed under an argon atmosphere. 
Compound 2 (1.0 g, 0.29 mmol) and N-
hydroxysuccinimide (37 mg, 0.32 mmol) were 
dissolved in anhydrous CH2Cl2 (40 mL). The 
mixture was cooled to 0 °C in an ice bath and 
EDC (85 mg, 0.44 mmol) was added. After stirring for 1 h at 0 °C, the reaction mixture 
was warmed to room temperature and it was allowed to stir overnight. The mixture was 
then diluted with CH2Cl2 and washed with an aqueous saturated solution of NH4Cl. 
After drying over anhydrous Na2SO4, the organic phase was concentrated under reduced 
pressure to afford an orange solid (753 mg, 73%). 1H NMR (CDCl3, 400 MHz): δ = 2.0 
(m, 2H), 2.7 (t, 2H), 2.8 (s, 4H), 3.5–3.7 (m, protons PEG + 2H (CH2CH2CH2O)), 6.5–
6.7 (m, 6H), 8.1 (m, 1H), 8.3 (m, 1H), 8.6 (s, 1H); MALDI-TOF (IAA): m/z calcd for 
[M+H]+: 3597.9 (for n = 68); found: 3598.4. 
 
Coupling of 1 to CCMV.  
A CCMV solution (8.48 mg mL−1, 2.5 mL) in sodium acetate buffer (0.05 M, 1.0 M 
NaCl, pH 5.0) was dialyzed against phosphate buffer (0.1 M, 0.001 M EDTA, pH 7.5) 
over a period of 9 h (with buffer changes every 3 h, T = 4 °C) using a 12–14 kDa 
MWCO dialysis membrane. Samples A–D with different CP / 1 ratios (1:50 (A), 1:25 
(B), 1:10 (C) and 1:1 (D)) were prepared by the addition of variable aliquots of a stock 
solution of compound 1 (0.081 M) in the same phosphate buffer to the CCMV solution 
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(500 uL, 1.61 × 10−4 mmols) (Table 8.1). Additional phosphate buffer was added, when 
necessary, to provide final volumes of 600 μL for all samples. A control sample was 
prepared in the same way as that used for sample A with compound 2 instead of 1. 
 
Table 8.1 Preparation of CCMV–PEG conjugates using different CP / 1 ratios. Amount 
of compound 1 added to the CCMV solution for every sample. 
Experiment Molar ratio CP / 1 
Concentration of 1 in 
final solution (mmol) 
Volume of stock solution of 
1 (μL) 
A 1 : 50 8.10 × 10−3 100 
B 1 : 25 4.03 × 10−3 50 
C 1 : 10 1.61 × 10−3 20 
D 1 : 1 1.61 × 10−4 2 
 
Samples A–D were incubated on a roller mixer for 2 h at room temperature and 
subsequently overnight at 4 °C. The samples were protected from light at all times. The 
excess fluorescein-functionalized PEG was removed by size-exclusion chromatography 
(SEC, Sephadex G-100) with the same phosphate buffer as eluent. The PEG-
functionalized virus (orange in color) eluted before the excess of 1 (bright yellow). All 
fractions were analyzed by FPLC, SDS-PAGE, TEM, and UV/Vis spectroscopy.  
 
Isolation of the PEG-functionalized CCMV coat protein (removal of the viral RNA)  
A purified PEG-functionalized CCMV solution (ca. 5 mg mL−1, 1 mL; sample C) was 
extensively dialyzed overnight against Tris-HCl buffer (0.02 M, 1 M NaCl, 0.001 M 
DTT, pH 7.5) using a 6–8 kDa MWCO dialysis membrane. The solution was 
ultracentrifuged at 45000 rpm for 16 h at 4 °C. The top three-quarters of the supernatant 
was removed with a micropipette and analyzed by FPLC, SDS-PAGE, and UV/Vis 
spectroscopy. The unfunctionalized coat protein obtained from CCMV, as described in 
the literature, [16,43,44] was used as a control. 
 
Assembly of PSS-CCMV capsid-PEG virus-like particles  
Two different solutions of CP (600 μL, 0.82 mg mL−1) and PEG–CP (300 μL, 
1.20 mg mL−1, isolated from sample C), both in the same Tris-HCl buffer (0.02 M, 
1.0 M NaCl, 0.001 M DTT, pH 7.5), were dialyzed separately against phosphate buffer 
(0.1 M, 0.3 M NaCl, 0.001 M EDTA, pH 7.5). PSS (Mn = 70000 Da, 17 mg, 
2.42 × 10−4 mmol) was dissolved into the same phosphate buffer (170 μL) and diluted 
50 times to obtain a PSS stock solution (2.86 × 10−5 M). 
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The assembly mixtures, containing different relative amounts of CP and PEG–CP 
(samples E (0% PEG–CP), F (25% PEG–CP), G (50% PEG–CP), H (75% PEG–CP) 
and I (100% PEG–CP)), were prepared by adding volumes of the stock solutions of 
both components, according to Table 8.2, to the PSS stock solution (20 µL, 
1.94 × 10−4 mmol repeating units). A CP / PSS repeating unit ratio of approximately 
1:40 was used in all cases. The samples were protected from light and incubated on a 
roller mixer for 30 min at room temperature, followed by storage at 4 °C. The 
characterization of samples E–I was performed by FPLC and agarose gel 
electrophoresis, and the purified FPLC fractions were further analyzed by fluorescence 
spectroscopy, TEM, SDS-PAGE, and agarose gel electrophoresis.  
 
Table 8.2 Amounts of PEG–CP and CP used for the different experiments to form PEG-
functionalized T = 1 CCMV capsid particles containing PSS in their interior.  
Experiment 
PEG–CP 
(% (v/v)) 
PEG–CP solution 
(µL) 
CP solution 
(µL) 
Approximate amount of CP 
present in the final mixture 
(mmol) 
E 0 – 100 4.1 × 10−6 
F 25 25 75 4.6 × 10−6 
G 50 50 50 5.0 × 10−6 
H 75 75 25 5.5 × 10−6 
I 100 100 - 6 × 10−6 
 
 
Analysis of the peaks at V = 1.60 and 1.95 mL in the FPLC chromatograms of the 
CCMV–PEG conjugates. 
A solution of 1 was injected in the FPLC column to facilitate the assignment of the 
peaks at V = 1.60 and 1.95 mL observed in the FPLC chromatograms of the CCMV–
PEG samples A–D. Three different peaks appeared in the FPLC chromatogram of 
polymer 1 (Figure 8.5a). These peaks were also present, in small proportion, in the 
FPLC chromatograms of the CCMV–PEG samples A–D (Figure 8.2a), indicating that 
the excess of polymer 1 could not be completely removed during the preliminary 
purification by SEC on Sephadex G-100. Only the smallest species eluting at 
V = 2.1 mL was totally eliminated. After comparing the UV/Vis (Figure 8.5b) and IR 
(not shown) spectral data of the FPLC fractions corresponding to these three peaks with 
data of non-injected compound 1, the species could be identified. The fraction at 
V = 2.1 mL contained PEG that was not functionalized with a fluorescein moiety, which 
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was evident from the absence of absorbance at λ = 490 nm in the FPLC chromatogram 
(Figure 8.5a). The fraction at V = 1.95 mL contained the fluorescein-functionalized PEG 
from which the NHS ester (1715 cm-1) had been hydrolyzed. The peak at V = 1.60 mL 
was the most difficult one to elucidate. The IR spectrum of this FPLC fraction showed 
the presence of NHS-functionalized polymer. In addition, the low elution volume and 
low absorbance value at λ = 490 nm (self-quenching of the fluorescein dye to 
aggregation) suggested that this peak was related to polymer aggregates, although other 
possibilities, such as the oligomerization of PEG (1) by esterification of the NHS-
activated carboxylic acid with the hydroxyl group of the fluorescein moiety, cannot be 
excluded. 
 
a) b) 
 
Figure 8.5 a) FPLC chromatogram of 1 (c = 12.4 mg mL-1, injected volume = 20 µL). 
b) UV/Vis spectra of nonpurified 1 (c = 0.25 mg mL-1, l = 4 mm) and of the fractions 
collected after injection of 1 into the FPLC column (corresponding to the 3 peaks in the 
chromatogram in (a)).  
 
The fractions corresponding to the peaks at V = 1.60 and 1.95 mL in the FPLC 
chromatograms of the CCMV–PEG samples A–D (Figure 8.2a) contained the same 
species as those described above for polymer 1, as suggested by their similar elution 
volumes and UV/Vis absorbance values in the chromatograms. SDS-PAGE and IR 
spectroscopy analysis, however, also showed the presence of protein in the fraction at 
V = 1.95 mL (Figure 8.6). It therefore seems that the CCMV–PEG conjugates 
disassemble into CP monomers over time, which elute at similar elution volumes as 
those found for polymer 1 and related species. Furthermore, the content of protein 
compared with polymer increases with time in this fraction due to the slow disassembly 
of the conjugates, as shown in Figure 8.2. 
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Figure 8.6 SDS-PAGE of the FPLC fraction (V = 1.95 mL) isolated after the injection 
of a two-week-old CCMV–PEG conjugate sample (sample A) on the FPLC column. 
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Appendix 
  
 
1. Triangulation number  
 
Triangulation numbers (T numbers) are commonly used in virology to describe the 
geometry of icosahedral viruses. The basic principles were outlined by Caspar and Klug 
(1962) who extended mathematical knowledge to biological structures.[1]  
As noted by Crick and Watson, the capsids of viruses are formed from a minimum 
number of gene products given the small size of viral genomes. On this basis, spherical 
viruses have the symmetry of regular polyhedra of which all faces are identical perfect 
polygons and all protein units sit in identical environments. The largest shell of this kind 
is an icosahedron consisting of 60 equivalent subunits. An icosahedron is a polyhedral 
structure that has 20 equilateral triangles arranged around the face of a sphere (Figure 
1a) and is defined by having 2-, 3-, and 5-fold axes of symmetry (Figure 1b). Many 
viral capsids display icosahedral symmetry, but are formed by more than 60 subunits. 
To understand the structure of such viruses it is necessary to rely on the quasi-
equivalent assembly geometric principle developed by Caspar & Klug. 
 
a) 
 
b) 
Figure 1 a) Structure of an icosahedron. b) The three different symmetry axes of an 
icosahedron. 
 
Caspar and Klug proposed a geometrical scheme for the general construction of 
icosahedral shells with an arbitrarily large number of subunits. Capsid proteins can 
usually be grouped into ‘‘capsomers’’ of either hexamer/pentamer units or trimer units. 
The conceptual basis for viral quasi-equivalence is the interchangeable formation of 
hexamers and pentamers by the same protein molecule. Closed icosahedral structures 
can be built up from pentamers and hexamers as indicated in Figure 2.[2] The structures 
can be constructed from a sheet of hexamers in which pentamers are inserted in place of 
certain hexamers according to selection rules described by a “trangulation” (T) number. 
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Each triangular face of the icosahedrons contains 3T subunits where T = h2 + hk + k2 
and h and k correspond to the indices for the hexamer chosen to define the equilateral 
triangle. T adopts special integer values such as 1, 3, 4, 7, and 13, and the number of 
proteins constituting an icosahedral shell equals 60T (Figure 2c). Electron and x-ray 
diffraction studies have confirmed that the T-number classification applies to almost all 
sphere-like viruses.[3] 
 
 
Figure 2 Geometric principles for generating icosahedral quasi-equivalent surface 
lattices. a) Hexamers are initially considered planar (an array of hexamers forms a flat 
sheet as shown) and pentamers are considered convex; they introduce curvature into 
the sheet of hexamers when they are inserted. The closed icosahedral shell, composed of 
hexamers and pentamers, is generated by inserting 12 pentamers at the appropriate 
positions in the hexamer net. b) Seven hexamer units (bold outline in (a)) defined by the 
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T=3 lattice are shown. The icosahedral asymmetric unit is one-third of this face and it 
contains three quasi-equivalent units (two units from the hexamer that coincides with 
the 3-fold axis and one unit from the pentamer). A three-dimensional model of the 
lattice can be generated by arranging 20 identical faces of the icosahedron as shown; 
this can then be folded into a quasi-equivalent icosahedron. c) Cardboard models of 
several icosahedral quasi-equivalent surface lattices constructed by using the method 
described above.[2] 
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2. List of terms and abbreviations 
 
ABTS   2,2´-azino bis(3-ethylbenzthiazoline-6-sulphonic acid) 
AFM   atomic force microscopy 
Bt   biotin 
CCMV  cowpea chlorotic mottle virus 
CP   coat protein 
CPMV   cowpea mosaic virus 
DLS   dynamic light scattering 
DNA   deoxyribonucleic acid 
Dps   DNA-binding proteins from starved cells 
DTT   dithiothreitol 
EDC   1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
EDTA   ethylenediaminetetraacetic acid 
EM   electron microscopy 
FCS   fluorescence correlation spectroscopy 
FPLC   fast protein liquid chromatography 
FRET   fluorescence resonance energy transfer 
HABA   4’-hydroxyazobenzene-2-carboxylic acid 
HRP    horseradish peroxidase 
HSFn   horse spleen apoferritin 
sHsp   small heat shock protein 
IR   infrared (spectroscopy) 
MALDI-TOF  matrix-assisted laser desorption / ionization time of flight 
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Mb   myoglobin 
MRI   magnetic resonance imaging 
NHS   N-hydroxy succinimide 
NMR   nuclear magnetic resonance (spectroscopy)  
PAGE   polyacrylamide gel electrophoresis 
PEG   poly(ethylene glycol) 
PMSF   phenylmethanesulfonyl fluoride 
POD   pentamer of dimers 
PSS   polystyrene sulfonate 
RNA   ribonucleic acid 
ssRNA   single stranded ribonucleic acid 
SANS   small-angle neutron scattering 
SAv   streptavidin 
SEC   size exclusion chromatography 
SEM   scanning electron microscopy 
TEM   transmission electron microscopy 
THF   tetrahydrofuran 
TMV   tobacco mosaic virus 
Tris   tris(hydroxymethyl)aminomethane 
UV/Vis  ultraviolet-visual (spectroscopy) 
VLP   virus-like particle 
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Summary 
  
 
Viruses are commonly composed of an outer protein shell (capsid) that encapsulates the 
infectious genetic material. Many kinds of viruses exist and they offer a large repertoire 
of structures with different sizes and shapes within the nanometer range. Furthermore, 
they are highly monodisperse and relatively easy to modify both chemically and 
genetically to introduce designed functionality to the capsid; these features make them 
very attractive as building blocks in nanotechnology. This thesis describes the approach 
to construct a virus-based nanoreactor by the encapsulation of enzymes within the 
cowpea chlorotic mottle virus (CCMV), benefitting from the unique assembly 
properties of this virus. The motives for using virus particles in nanotechnology and an 
overview of work that has been carried out to date is given in Chapters 1 and 2. 
 
CCMV is a spherical plant virus that consists of 180 identical coat protein (CP) 
subunits, which assemble around single-stranded RNA. The virus is isolated from 
cowpea plants and purified following different extraction and precipitation steps. A 
detailed protocol of the procedure performed in our laboratory is described in Chapter 3. 
Transmission electron microscopy (TEM), UV/Vis spectroscopy, and fast protein liquid 
chromatography (FPLC) are the most common techniques used to characterize the virus 
and to determine its purity in terms of shape, size, and RNA/protein content. 
 
CCMV has special assembly properties, that is, its structure can assemble and 
disassemble depending on the pH and the ionic strength of the solution. These 
properties allowed us to remove the genetic material from the CCMV particles and to 
isolate the CPs. The CPs can be subsequently reassembled to form a protein capsid with 
the same size as the original virus, but without the RNA encapsulated. This capsid can 
be reversibly disassembled into the CP dimers and reassembled again by simply 
changing the pH. The procedure to remove the RNA from the CCMV and the study of 
the CP assembly properties are described in Chapter 4.  
 
Furthermore, solution scattering techniques, such as dynamic light scattering (DLS) and 
small-angle neutron scattering (SANS) allowed us to study the structure of CCMV and 
the CCMV capsid under different pH and ionic strength conditions, as described in 
Chapter 5. Since the measurements are performed in solution, in contrast to TEM and 
FPLC, these techniques provide structural information under conditions that more 
closely mimic the natural environment of the molecules. The SANS measurements, 
performed at the ISIS facility (U.K.), provided information on how the RNA and the 
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proteins are arranged in different viral assemblies. Additionally, it provided structural 
information on particles that were derived by the incorporation of polystyrene sulfonate 
(PSS) in the CCMV capsid. 
 
With their unique assembly properties, the potential of CCMV capsids to host enzymes 
and function as nanoreactors was studied by the encapsulation of three different model 
proteins, namely, myoglobin, dronpa, and streptavidin. The model proteins were mixed 
with the disassembled CP at pH 7.5 and the mixture was brought to pH 5, driving the 
CP to assemble into a capsid that incorporates the model protein in its interior. The 
results derived from the inclusion of the model proteins, described in Chapter 6, are the 
basis for the construction of an actual viral nanoreactor prepared by encapsulating the 
enzyme horseradish peroxidase in the CCMV capsid. This is described in Chapter 7. 
Diluted statistical encapsulation of the process allowed the inclusion of a maximum of 
one enzyme per capsid. By using confocal fluorescence microscopy, we could study the 
assembly and the enzymatic activity of the nanoreactor and we were able to distinguish 
whether the enzyme is inside the capsid or adsorbed on the outer surface. 
 
The CCMV protein surface offers a diversity of functional groups for further 
functionalization. Chapter 8 describes how the outer surface of CCMV was modified 
with polyethylene glycol (PEG) at the amine groups from the exposed lysine residues. 
Although CCMV was successfully functionalized, the protein architecture turned out to 
be unstable over time. A more stable structure was obtained when, after removal of the 
RNA, the negatively charged polymer PSS was used as a template to assemble the 
isolated PEG-functionalized CP into a PSS-containing PEG-decorated capsid.  
 
The studies reported in this thesis describe the first fundamental steps in the 
construction of a nanoreactor by encapsulating enzymes in the viral protein capsid. 
CCMV was chosen because of its unique assembly properties. This thesis not only 
describes the investigations in which CCMV is used as a platform for nanotechnology, 
but also reports in detail the procedures used to purify the virus and basic studies of its 
assembly properties, which are required to carry out such investigations. Furthermore, 
the controlled integration of two different synthetic polymers at the outer surface and in 
the core of the CCMV capsid, yielding tunable hybrid systems, offers many new 
possibilities in the fields of nanotechnology and biomedicine. 
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Samenvatting 
 
 
De meeste virussen zijn opgebouwd uit een eiwitmantel (capside), die ervoor zorgt dat 
het infectueuze genetische materiaal ingekapseld is. De grote variëteit aan virussen biedt 
een grote verscheidenheid aan capsules met dimensies in de orde van tien nanometer, in 
allerlei soorten en vormen. Virussen bezitten vaak een hoge mate van monodispersiteit 
en zijn bovendien eenvoudig chemisch of genetisch te modificeren, zodat een gewenste 
functionaliteit aan het capside gegeven kan worden. Deze specifieke eigenschappen 
maken virussen bijzonder aantrekkelijk om te gebruiken als bouwstenen in 
nanotechnologie. In dit proefschrift wordt een methode beschreven om een nano-reactor 
te maken die gebaseerd is op virussen. Het virus dat daarvoor gekozen is, is het cowpea 
chlorotic mottle virus (CCMV); dit virus bezit unieke en reversibele assemblage 
eigenschappen waardoor het mogelijk is om een enzym op te sluiten in het virus. In 
Hoofdstukken 1 en 2 wordt, naast een motivatie voor het gebruik van virussen in 
nanotechnologie, de recente literatuur besproken, omtrent het onderzoek dat is 
beschreven in dit proefschrift. 
 
CCMV wordt geïsoleerd vanuit geïnfecteerde planten en wordt, volgens het protocol dat 
uitvoerig beschreven is in Hoofdstuk 3, gezuiverd met behulp van verschillende 
extractie en precipitatie stappen. Het sferische virus bestaat uit 180 identieke mantel 
eiwitten, die assembleren om enkelstrengs RNA. Met behulp van verschillende 
technieken, zoals transmission electron miscroscopy (TEM), UV/Vis spectroscopy en 
fast protein liquid chromatography (FPLC), kunnen de eigenschappen van het virus 
bepaald worden. Bovendien geven deze technieken inzicht in de zuiverheid, vorm, 
grootte en de verhouding RNA/eiwit van het virus.  
 
Een unieke eigenschap van CCMV is dat het kan assembleren en uiteenvallen 
afhankelijk van de pH en ion sterkte van de oplossing. Dit biedt de mogelijkheid om het 
virus te ontleden in de manteleiwitten en het RNA en dus om het genetische materiaal te 
verwijderen. De manteleiwitten kunnen dan onafhankelijk geïsoleerd worden om 
opnieuw te assembleren in een deeltje (een eiwit capside) met een vergelijkbare 
structuur als het oorspronkelijke virus, maar waarin geen RNA opgesloten zit. Het 
assembleren en uiteenvallen van de capside is een reversibel proces: door eenvoudig de 
pH te veranderen, kunnen of de mantel eiwitten afzonderlijk worden verkregen of de 
capside in zijn geheel. Deze studies zijn beschreven in Hoofdstuk 4. 
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Om gedetailleerde informatie te krijgen in de structuren van CCMV en de CCMV 
capside zijn verstrooiingstechnieken, zoals dynamic light scattering (DLS) en small-
angle neutron scattering (SANS) uitgevoerd (Hoofdstuk 5). Met deze technieken 
kunnen onder verschillende condities (bijvoorbeeld wat betreft pH en ion sterkte) en in 
oplossing structurele studies uitgevoerd worden. Dit heeft als grote voordeel dat de 
moleculen in hun natuurlijke omgeving bestudeerd worden. De SANS metingen, die 
zijn uitgevoerd bij de ISIS faciliteit in het Verenigd Koninkrijk, geven informatie over 
de ordening van het RNA en de eiwitten in de verschillende virale assemblages. Door 
het negatief geladen polymeer polystyreensulfonaat (PSS) op te sluiten in het CCMV 
capside werd een nieuw virusdeeltje verkregen, waarvan de structurele eigenschappen 
ook met behulp van SANS konden worden bestudeerd.  
 
De assemblage eigenschappen van de CCMV capside bieden ook de unieke gelegenheid 
om een nanoreactor te construeren. Drie verschillende modeleiwitten, te weten 
myoglobine, dronpa en streptavidine werden ingesloten in de CCMV capside gastheer. 
Deze insluiting werd bewerkstelligd door: de model eiwitten te mengen met de 
afzonderlijke manteleiwitten bij pH 7.5 en vervolgens de pH te verlagen naar pH 5, 
waar de manteleiwitten assembleren tot het capside waarin het modeleiwit ingesloten is. 
De resultaten van dit onderzoek staan beschreven in Hoofdstuk 6. Deze succesvolle 
modelstudies vormden de basis voor de constructie van een werkende virale 
nanoreactor, die uiteindelijk werd verkregen door insluiting van het enzym horseradish 
peroxidase in het CCMV capside (Hoofdstuk 7). Door verdunde statistische incapsulatie 
kon een maximum van één enzym per capside verkregen worden. Met confocale 
microscopie werden de  assemblage eigenschappen en de activiteit van de nanoreactor 
bestudeerd en kon worden vastgesteld of het enzym ingesloten was in het capside of aan 
de buitenkant van de capside geadsorbeerd was.  
 
In Hoofdstuk 8 wordt beschreven op welke manier de buitenkant van CCMV 
gemodificeerd kan worden. Vrije amine groepen van lysine residuen die zich aan de 
buitenkant van CCMV bevinden, werden verbonden met polyethyleenglycol (PEG) 
derivaten. Hoewel de CCMV functionalisatie succesvol verliep, bleek de PEG-CCMV 
hybride architectuur niet stabiel. Om een meer stabiele structuur te creëren werd het 
RNA verwijderd uit de PEG-CCMV, dat vervolgens werd ontleed in de manteleiwitten.  
De PEG gefunctionaliseerde manteleiwitten werden daarna, met behulp van het negatief 
geladen PSS, weer geassembleerd om een stabiel capside te vormen dat gedecoreerd is 
met PEG moleculen. 
 
Het onderzoek dat beschreven is in dit proefschrift laat de eerste fundamentele stappen 
zien die nodig zijn om een nanoreactor te construeren, in dit geval door het incapsuleren 
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van enzymen in het CCMV capside. Op basis van zijn unieke assemblage 
eigenschappen is CCMV gekozen als werkpaard. Dit proefschrift beschouwt niet alleen 
de onderzoeken en experimenten waarin CCMV als platform voor nanotechnologie 
gebruikt wordt, maar ook de gedetailleerde protocollen en procedures om het virus 
zuiver in handen te krijgen. Dergelijke studies zijn van groot belang en dienen als basis 
voor het toekomstig werk in dit onderzoeksgebied. Eenvoudig varieerbare hybride 
systemen zijn beschikbaar door de gecontroleerde integratie van twee verschillende 
synthetische polymeren aan de buitenzijde en in de kern van de CCMV capside. Deze 
modulaire materialen geven een scala aan mogelijkheden op het gebied van 
nanotechnologie en biomedicijnen. 
 
  185   
Resum 
 
 
Els virus són agents infecciosos de mida microscòpica que necessiten la maquinària 
biosintètica d’una cèl.lula hoste per multiplicar-se. En general, estan formats per un àcid 
nucleic, ARN o ADN, envoltat per una càpsida proteica. Existeixen molts tipus de virus, 
i presenten una morfologia molt diversa. A més a més, molts virus poden ser manipulats 
tan genètica com químicament i així introduir una determinada funcionalitat a la 
càpsida. Aquestes propietats fan dels virus estructures molt interessants en el camp de la 
nanotecnologia. Aquesta tesi descriu la recerca duta a terme per construir un 
nanoreactor a partir de l’encapsulació d’un enzim dins la càpsida proteica d’un virus. El 
virus escollit és el cowpea chlorotic mottle virus (CCMV). En el capítol 1 i 2 d’aquesta 
tesi es pot trobar una descripció dels avantatges d’utilitzar partícules víriques en 
nanotecnologia i una ressenya de la recerca realitzada per altres grups d’investigació 
durant els últims anys sobre aquest tema.  
 
El CCMV és un virus  esfèric que infecta plantes. Està format per 180 unitats proteiques 
idèntiques que formen un embolcall al voltant de l’ARN. Aquest virus s’ailla de 
mongeteres infectades i es purifica seguint diferents processos d’extracció i precipitació. 
Un protocol detallat del procediment dut a terme en el laboratori està descrit en el 
capítol 3. Les tècniques més comunes utilitzades per a caracteritzar el virus i determinar 
la seva puresa són espectroscòpia d’ultraviolat i visible, microscopia electrònica i 
cromatografia d’exclusió molecular. 
 
El CCMV té unes propietats peculiars ja que la seva estructura pot ensamblar-se o 
desensemblar-se en funció del pH i de la concentració de sal de la solució. Són aquestes 
propietats les que permeten extreure el material genètic del CCMV i obtenir les unitats 
proteiques pures. Aquestes unitats proteiques es poden reensamblar per formar una 
càpsida proteica de la mateixa mida i forma que el virus, però sense ARN encapsulat. 
Variant les condicions de pH podem, aleshores, formar i trencar aquesta càpsida de 
forma reversible. El procediment pel qual s’ha extret l’ARN del virus i els estudis de 
l’ensamblatge de les unitats proteiques aïllades del virus estan descrits en el capítol 4. 
  
Les diferents estructures que presenta el CCMV i la seva càpsida han estat investigades 
en detall utilitzant SANS (small-angle neutron scattering) i DLS (dynamic light 
scattering), que són tècniques que permeten fer aquests estudis en dissolució. Els 
resultats d’aquest anàlisi, en diferents condicions de pH i de força iònica, es poden 
trobar en el Capítol 5.  
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El potencial de la càpsida del CCMV per acollir enzims en el seu interior i funcionar 
així com a nanoreactor va ser investigat i els resultats estan descrits en el capítol 6 i 7 
d’aquesta tesi. L’encapsulació de l’enzim dins la càpsida del CCMV va ser duta a terme 
utilitzant les propietats d’ensamblatge del virus: l’enzim es va barrejar a pH 7.5 amb les 
unitats proteiques del CCMV que en aquest pH es troben en dissolució (no 
ensamblades). Tot seguit, el pH de la mescla es va abaixar a pH 5 provocant, d’aquesta 
manera, l’ensamblatge de les unitats proteiques resultant en una càpsida  que ha 
incorporat l’enzim en el seu interior. Mitjançant el microscopi confocal de 
fluorescència, l’activitat enzimàtica de l’enzim encapsulat dins la càpsida vírica ha estat 
investigada.  
 
La superfície externa del CCMV ofereix una gran diversitat de grups funcionals. El 
capítol 8 descriu la modificació de la superfície externa del virus amb el polímer sintètic 
polietilè glicol (PEG). El virus va ser funcionalitzat amb PEG amb èxit, però 
l’estructura del virus va resultar ser inestable. Es va obtenir una estructura més estable 
mitjançant l’extracció de l’ARN del complex PEG–CCMV i utilitzant el polianió 
poliestirè sulfonat (PSS) per ensamblar les unitats proteiques víriques funcionalitzades. 
D’aquesta manera es va poder obtenir una càpsida proteica que conté dos polímers 
sintètics, un adherit a la superfície externa i l’altre inclòs en el seu interior. 
 
La feina descrita en aquesta tesi mostra els primers passos per construir un nanoreactor 
format per una càpsida vírica que encapsula un enzim. Però aquesta tesi també descriu 
en detall els procediments duts a terme per obtenir i purificar el CCMV i l’estudi de les 
propietats d’ensamblatge del virus. A més a més, la integració controlada de dos 
polímers sintètics a la superfície externa i a l’interior de la càpsida del CCMV resulta en 
materials híbrids que ofereixen moltes possiblitats noves en el camp de la 
nanotecnologia i la biomedicina. 
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Schematic summary of the processes and species described in this thesis. The blue 
squares indicate the chapter in which the research is described. 
 
Schematische weergave van de processen and virusdeeltjes beschreven in dit 
proefschrift. De blauwe blokjes geven het hoofdstuk aan waarin het desbetreffende 
onderzoek is beschreven. 
 
Resum esquemàtic dels processos i les espècies descrites en aquesta tesi. Els quadres 
blaus indiquen el capítol en el que es descriu la recerca indicada. 
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